#### LETTER OF OFFER

#### THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

This letter of offer ("Letter of Offer") is sent to you as a registered Equity Shareholder / Beneficial Owner (as defined below) of Aurobindo Pharma Limited (hereinafter referred as the "Company") as on the Record Date (as defined below) in accordance with Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended ("Buyback Regulations"). If you require any clarifications about the action to be taken, you should consult your stockbroker or investment consultant or the Manager to the Buyback Offer i.e., Axis Capital Limited, or the Registrar to the Buyback Offer i.e., KFin Technologies Limited. Please refer to the section on "Definitions of Key Terms" on page no. 5 of this Letter of Offer for the definitions of the capitalized terms used herein.



**EXCLUDING TRANSACTION COSTS.** 

#### AUROBINDO PHARMA LIMITED

Corporate Identification Number (CIN): L24239TG1986PLC015190
Registered Office: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Corporate Office: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg

Panmaktha, Ranga Reddy District, Hyderabad - 500 032, Telangana, India Contact Person: Mr B Adi Reddy, Company Secretary and Compliance Officer Tel. No.: +91 40 2373 6370/ 2374 7340; Fax: +91 40 2374 1080/ 2374 6833; Website: www.aurobindo.com;\* Email: info@aurobindo.com

OFFER TO BUYBACK UP TO 51,36,986 (FIFTY ONE LAKH THIRTY SIX THOUSAND NINE HUNDRED AND EIGHTY SIX ONLY) FULLY PAID-UP EQUITY SHARES OF THE COMPANY, HAVING FACE VALUE OF ₹1/- (RUPEE ONE ONLY) EACH ("EQUITY SHARES"), REPRESENTING 0.88% OF THE TOTAL NUMBER OF EQUITY SHARES IN THE PAID-UP SHARE CAPITAL OF THE COMPANY, FROM THE EQUITY SHAREHOLDERS / BENEFICIAL OWNERS OF EQUITY SHARES OF THE COMPANY AS ON TUESDAY, JULY 30, 2024 ("RECORD DATE") ON A PROPORTIONATE BASIS, THROUGH THE "TENDER OFFER" ROUTE AT A PRICE OF ₹1,460/- (RUPEES ONE THOUSAND FOUR HUNDRED AND SIXTY ONLY) PER EQUITY SHARE, PAYABLE IN CASH, FOR AN AGGREGATE AMOUNT UP TO ₹750,00,00,000/- (RUPEES SEVEN HUNDRED AND FIFTY CRORE ONLY)

- 1) The Buyback is in accordance with Article 40(b) of the Articles of Association of the Company and pursuant to Sections 68, 69, 70 and all other applicable provisions, if any, of the Companies Act, and the rules framed thereunder including the Share Capital Rules, the Management Rules, the Listing Regulations to the extent applicable, the Buyback Regulations read with the SEBI Circulars, subject to such other approvals, permissions, consents, exemptions and sanctions, as may be necessary and subject to any modifications and conditions, if any, as may be prescribed by SEBI, Registrar of Companies, Telangana at Hyderabad, NSE, BSE and/ or other authorities, institutions or bodies, as may be necessary and subject to such conditions and modifications as may be prescribed or imposed while granting such approvals, permissions, sanctions and exemptions, which may be agreed by the Board.
- 2) The Buyback Size constitutes 3.84% and 2.67% of the aggregate of the total paid-up equity share capital and free reserves (including securities premium) of the Company as per the audited standalone and consolidated financial statements of the Company as at March 31, 2024, respectively, and is within the statutory limit of 10% of the aggregate of the total paid-up equity share capital and free reserves (including securities premium) of the Company as per the audited standalone and consolidated financial statements of the Company as at March 31, 2024 (i.e., the last audited financial statements available as on the date of Board Meeting recommending the proposal of the Buyback), under the board approval route as per Section 68 and other applicable provisions of the Buyback Regulation 5 and other applicable provisions of the Buyback Regulations.
- 3) The Letter of Offer will be electronically sent to the Equity Shareholders/ Beneficial Owners of Equity Shares as on the Record Date i.e., Tuesday, July 30, 2024, in accordance with the Buyback Regulations and such other circulars or notifications, as may be applicable. Further, in terms of Regulation 9(ii) of the Buyback Regulations, if the Company receives a request from any Eligible Shareholder to dispatch a copy of the Letter of Offer in physical form, the same shall be provided.
- 4) The procedure for tendering shares and settlement is set out in paragraph 20 (*Procedure for Tendering Shares and Settlement*) on page no. 56 of this Letter of Offer. The form of acceptance cum acknowledgement ("**Tender Form**") along with share transfer form ("**Form SH-4**") is enclosed together with this Letter of Offer.
- 5) The procedure for Acceptance is set out in paragraph 19 (*Process and Methodology for the Buyback*) on page no. 50 of this Letter of Offer. The payment of consideration is in cash to the Eligible Shareholders. For mode of payment of consideration to the Eligible Shareholders, please refer to paragraph 20.30 (*Method of Settlement*) on page no. 65 of this Letter of Offer.
- 6) A copy of the Public Announcement is available on the websites of the Company (<a href="www.aurobindo.com">www.aurobindo.com</a>), the Manager to the Buyback (<a href="www.axiscapital.co.in">www.axiscapital.co.in</a>), Registrar to the Buyback (<a href="www.sebi.gov.in">www.sebi.gov.in</a>), NSE (<a href="www.nseindia.com">www.nseindia.com</a>) and BSE (<a href="www.sebi.gov.in">www.axiscapital.co.in</a>), Registrar to the Buyback (<a href="www.axiscapital.co.in">www.axiscapital.co.in</a>), Registrar to the Buyback (<a href="www.axiscapital.co.in">www.axiscapital.co.in</a>),
- 7) Eligible Shareholders are advised to read the Letter of Offer and in particular, refer to paragraph 17 (Details of Statutory Approvals) on page no.48 of this Letter of Offer and paragraph 21 (Note on Taxation) on page no. 68 of this Letter of Offer before tendering their Equity Shares in the Buyback.

# AXIS CAPITAL

#### **Axis Capital Limited**

Address: 1st Floor, Axis House

C-2 Wadia International Centre, P. B. Marg, Worli

Mumbai - 400 025, Maharashtra, India

Tel. no.: +91 22 4325 2183; Fax no.: +91 22 4325 3000

Contact person: Harish Patel/ Simran Gadh

Email: apl.buyback@axiscap.in; Website: www.axiscapital.co.in
SEBI registration no.: INM000012029; Validity period: Permanent

CIN: U51900MH2005PLC157853

# REGISTRAR TO THE BUYBACK

#### **KFin Technologies Limited**

Address: Selenium, Tower- B, Plot No 31 & 32 Gachibowli, Financial District

 $Nanak ramguda, Seriling ampally, \, Hyderabad, \, Telangana -500032$ 

 $\textbf{Tel. no.:} +91\ 40\ 6716\ 2222; \textbf{Fax no.:} +91\ 40\ 6716\ 1563; \textbf{Tollfree no.:} 18003094001$ 

Contact person: M Murali Krishna

Email: aurobindo.buyback@kfintech.com; Website: www.kfintech.com

Investor Grievance mail: einward.ris@kfintech.com

SEBI registration no.: INR000000221; Validity period: Permanent

CIN: L72400TG2017PLC117649

BUYBACK PROGRAMME		
BUYBACK OPENS ON MONDAY, AUGUST 05, 2024		
BUYBACK CLOSES ON	FRIDAY, AUGUST 09, 2024	
LAST DATE OF RECEIPT OF COMPLETED TENDER FORMS AND OTHER SPECIFIED	ON OR BEFORE 5.00 PM (IST) ON FRIDAY, AUGUST 09, 2024	
DOCUMENTS BY THE REGISTRAR TO THE BUYBACK		
BUYBACK ENTITLEMENT		

BUYBACK ENTITLEMENT		
CATEGORY OF ELIGIBLE SHAREHOLDERS RATIO OF BUYBACK ENTITLEMENT*		
RESERVED CATEGORY FOR SMALL SHAREHOLDERS	5 EQUITY SHARES FOR EVERY 41 EQUITY SHARES HELD ON THE RECORD DATE	
GENERAL CATEGORY FOR ALL OTHER ELIGIBLE SHAREHOLDERS	4 EQUITY SHARES FOR EVERY 531 EQUITY SHARES HELD ON THE RECORD DATE	

- \* In addition to the Company's contact details provided above, the investors may reach out to the Investor Service Centre of KFin Technologies Limited for any queries at +91 40 6716 2222 and <a href="mailto:einward.ris@kfintech.com">einward.ris@kfintech.com</a>, details of which are also included at Paragraph 27 of the Letter of Offer.
- # For further information on ratio of Buyback as per the Buyback Entitlement in each category, please refer paragraph 19.6 on page no. 52 of the Letter of Offer.
- ELIGIBLE SHAREHOLDERS CAN ALSO CHECK THEIR ENTITLEMENT ON THE WEBSITE OF THE REGISTRAR TO THE BUYBACK BY FOLLOWING THE STEPS GIVEN BELOW:
- 1) Click on <a href="https://kosmic.kfintech.com/karisma/buybackofferv2.aspx">https://kosmic.kfintech.com/karisma/buybackofferv2.aspx</a>
- 2) Select the name of the Company Aurobindo Pharma Limited  $\,$
- 3) Select holding type "Physical" or "NSDL" or "CDSL" or "PAN"
- 4) Based on the option selected above, enter your "Folio Number" or "NSDL DPID/Client ID" or "CDSL Client ID" or "PAN"
- 5) Click on submit
- 6) Then click on 'View' button
- 7) The entitlement will be provided in the pre-filled 'FORM OF ACCEPTANCE-CUM ACKNOWLEDGEMENT'

# **TABLE OF CONTENTS**

1.	SCHEDULE OF ACTIVITIES	4
2.	DEFINITION OF KEY TERMS	5
3.	DISCLAIMER CLAUSE	9
4.	TEXT OF RESOLUTION PASSED AT THE BOARD MEETING	11
5.	DETAILS OF PUBLIC ANNOUNCEMENT	19
6.	DETAILS OF THE BUYBACK	20
7.	AUTHORITY FOR THE BUYBACK	22
8.	NECESSITY FOR THE BUYBACK	22
9.	MANAGEMENT DISCUSSION AND ANALYSIS OF THE LIKELY IMPACT OF THE BUYBACK ON T	ГНЕ
	COMPANY	23
10.	BASIS OF CALCULATING THE BUYBACK PRICE	30
11.	SOURCES OF FUNDS FOR THE BUYBACK	31
12.	DETAILS OF ESCROW ACCOUNT AND AMOUNT DEPOSITED THEREIN AND FIRM FINANCE	IAL
	ARRANGEMENT	31
13.	CAPITAL STRUCTURE AND SHAREHOLDING PATTERN	32
14.	BRIEF INFORMATION OF THE COMPANY	35
<b>15</b> .	FINANCIAL INFORMATION ABOUT THE COMPANY	43
16.	STOCK MARKET DATA	_
<b>17.</b>	DETAILS OF STATUTORY APPROVALS	48
18.	DETAILS OF THE REGISTRAR TO THE BUYBACK	49
19.	PROCESS AND METHODOLOGY FOR THE BUYBACK	50
20.	PROCEDURE FOR TENDERING SHARES AND SETTLEMENT	56
21.	NOTE ON TAXATION	68
22.	DECLARATION FROM THE BOARD OF DIRECTORS	71
23.	STATUTORY AUDITOR'S REPORT	72
24.	DOCUMENTS FOR INSPECTION	76
25.	DETAILS OF THE COMPLIANCE OFFICER	77
26.	DETAILS OF REMEDIES AVAILABLE TO SHAREHOLDERS/ BENEFICIAL OWNERS	77
27.	DETAILS OF THE INVESTOR SERVICE CENTRE	77
28.	DETAILS OF THE MANAGER TO THE BUYBACK	77
29.	DECLARATION BY THE DIRECTORS	78
TEND	ER FORMS	79

NO OFFER TO SUBSCRIBE/PURCHASE/SELL, OR AN INVITATION TO SUBSCRIBE/PURCHASE/SELL, ANY SECURITIES OF THE COMPANY IN ANY JURISDICTION OR AS A SOLICITATION OR AN INVITATION TO SUBSCRIBE/PURCHASE/SELL ANY SECURITIES INCLUDING THE EQUITY SHARES OF THE COMPANY

- This Letter of Offer together with the Public Announcement has been prepared for the purposes of compliance with applicable Indian laws and regulations. This Letter of Offer has not been filed, registered or approved in any jurisdiction outside India. Accordingly, the information disclosed may not be the same as that which would have been disclosed if this document had been prepared in accordance with the laws and regulations of any jurisdiction outside of India. Except as otherwise required by applicable Indian law, the Company and the Manager to the Buyback are under no obligation to update the information contained herein at any time after the date of this Letter of Offer. This Letter of Offer does not in any way constitute an offer in any form, or an invitation in any form to subscribe/purchase/sell, any securities of the Company in any jurisdiction in which such offer or invitation is not authorized or to any person to whom it is unlawful to make such offer or solicitation and as a consequence, subject the Company or the Manager to the Buyback to any new or additional requirements or registrations;
- The Letter of Offer shall be dispatched through electronic mode to all Eligible Shareholders whose names appeared on the register of members of the Company / register of beneficial owners as downloaded from the Depositories, as of the Record Date. The Company shall provide a copy of the Letter of Offer in physical form in case of receipt of request from any such Eligible Shareholder. However, receipt of the Letter of Offer by any Eligible Shareholder in a jurisdiction in which it would be illegal to make this offer, or where making this offer would require any action to be taken (including, but not restricted to, registration of this Letter of Offer under any local securities laws), shall not be treated by such Eligible Shareholder as an offer being made to them and shall be construed by them as being sent for information purposes only; and
- Potential users of this information are required to inform themselves of any relevant restrictions in their respective jurisdictions. Any Eligible Shareholder who tenders Equity Shares in the Buyback Offer shall be deemed to have declared, represented, warranted and agreed that such Eligible Shareholder is authorized under the provisions of any applicable laws, rules, regulations and statutes to participate in the Buyback.

# 1. SCHEDULE OF ACTIVITIES

A 11	Schedule of activities	
Activity	Date	Day
Date of Board Meeting approving the proposal for the Buyback	July 18, 2024	Thursday
Date of the Public Announcement for the Buyback	July 19, 2024	Friday
Date of publication of the Public Announcement for Buyback	July 22, 2024	Monday
Record Date for determining the Buyback Entitlement and the names of Eligible Shareholders	July 30, 2024	Tuesday
Last date for dispatch of this Letter of Offer	August 01, 2024	Thursday
Buyback Opening Date	August 05, 2024	Monday
Buyback Closing Date	August 09, 2024	Friday
Last date of receipt of completed Tender Form and other specified documents by the Registrar	August 09, 2024	Friday
Last date of verification of Tender Forms by Registrar to the Buyback	August 14, 2024	Wednesday
Last date of providing acceptance/ non-acceptance of tendered Equity Shares to BSE by the Registrar	August 16, 2024	Friday
Last date of completion of settlement of bids by the Clearing Corporation/ BSE	August 19, 2024	Monday
Last date of dispatch of share certificate(s) by the Registrar to the Buyback/ unblocking/ return of unaccepted Equity Shares by BSE to Eligible Shareholders/ Seller Member	August 19, 2024	Monday
Last date for payment of consideration to Eligible Shareholders who participated in the Buyback	August 19, 2024	Monday
Last date of extinguishment of Equity Shares bought back	August 28, 2024	Wednesday

**Note:** Where last dates are mentioned for certain activities, such activities may happen on or before the respective last dates.

# 2. **DEFINITION OF KEY TERMS**

- 2.1 This Letter of Offer uses certain definitions and abbreviations which, unless the context otherwise indicates or implies or specifies otherwise, shall have the meaning as provided below. References to any legislation, act, regulation, rules, guidelines or policies shall be to such legislation, act, regulation, rules, guidelines or policies as amended, supplemented, or re-enacted from time to time and any reference to a statutory provision shall include any subordinate legislation made from time to time under that provision.
- 2.2 The words and expressions used in this Letter of Offer, but not defined herein shall have the meaning ascribed to such terms under the Buyback Regulations, the Companies Act, the Depositories Act, 1996, and the rules and regulations made thereunder.

Term	Description	
Acceptance/ Accept/ or Accepted	Acceptance of Equity Shares tendered by Eligible Shareholders in the Buyback	
Act or Companies Act	The Companies Act, 2013, as amended and rules framed thereunder	
Acquisition Window	The facility for acquisition of Equity Shares through the mechanism provided by BSE in the form of a separate window in accordance with SEBI Circulars	
Additional Equity Shares	Additional Equity Shares tendered by an Eligible Shareholder over and above the Buyback Entitlement of such Eligible Shareholder up to the extent of Equity Shares held by such Eligible Shareholder on the Record Date	
Articles or Articles of Association	Articles of Association of the Company, as amended	
Board or Board of Directors	Board of Directors of the Company, which expression shall include any committee constituted by the Board to exercise its powers, including the powers conferred by the resolution passed by the Board at its meeting held on Thursday, July 18, 2024	
Board Meeting	Meeting of the Board held on Thursday, July 18, 2024 inter alia to approve the Buyback	
BSE	BSE Limited	
Buyback or Buyback Offer or Offer	Offer to buy back up 51,36,986 (Fifty One Lakh Thirty Six Thousand Nine Hundred and Eighty Six only) Equity Shares at a price of ₹ 1,460/- (Rupees One Thousand Four Hundred and Sixty only) per Equity Share, payable in cash, from the Eligible Shareholders, on a proportionate basis through the Tender Offer route as prescribed under the Buyback Regulations read with the SEBI Circulars using the Stock Exchange Mechanism	
Buyback Closing Date	Friday, August 09, 2024, being the last date up to which the tendering of Equity Shares by Eligible Shareholders will be allowed	
Buyback Committee or Committee	The Buyback committee, comprising of K Nityananda Reddy, Vice Chairman & Managing Director, Mettu Madan Mohan Reddy, Whole-time Director and S. Subramanian, Chief Financial Officer, constituted and authorized for the purposes of the Buyback by a resolution passed by the Board at its meeting held on Thursday, July 18, 2024	
Buyback Entitlement or Entitlement	The number of Equity Shares that an Eligible Shareholder is entitled to tender, in the Buyback, based on the number of Equity Shares held by such Eligible Shareholder, on the Record Date and the ratio /	

	percentage of Buyback applicable in the category to which such Eligible Shareholder belongs	
Buyback Opening Date	Monday, August 05, 2024	
Buyback Price or Buyback Offer Price	Price at which Equity Shares will be bought back from the Eligible Shareholders i.e., ₹ 1,460/- (Rupees One Thousand Four Hundred and Sixty only) per Equity Share, payable in cash	
Buyback Period	The period between the date of the Board Meeting to approve the Buyback, i.e., Thursday, July 18, 2024, and the date on which the payment of consideration is made to the Eligible Shareholders who have accepted the Buyback	
Buyback Regulations	SEBI (Buy-Back of Securities) Regulations, 2018, as amended from time to time, including any statutory modification or re-enactments thereof	
Buyback Size	Number of Equity Shares proposed to be bought back, i.e. up to 51,36,986 (Fifty One Lakh Thirty Six Thousand Nine Hundred and Eighty Six only) Equity Shares multiplied by the Buyback Price (i.e., ₹ 1,460/- (Rupees One Thousand Four Hundred and Sixty only) per Equity Share aggregating to an amount up to ₹ 750,00,00,000/- (Rupees Seven Hundred and Fifty Crore only). The Buyback Size excludes Transaction Costs.	
CDSL	Central Depository Services (India) Limited	
CIN	Corporate Identity Number	
Clearing Corporation	on Indian Clearing Corporation Limited	
"Company" or "Our Company" or "we" or "us" or "our"	Aurobindo Pharma Limited	
Company's Broker	Axis Capital Limited	
Company Demat Account	Demat account of the Company designated for the Buyback	
Compliance Officer	Mr B Adi Reddy	
Depositories	Collectively, National Securities Depository Limited and Central Depository Services (India) Limited	
Designated Stock Exchange	BSE	
Director(s)	Director(s) of the Company	
DIN	Director Identification Number	
DP	Depository Participant	
Equity Share(s) or Share(s)	Fully paid-up equity shares of the Company of face value of ₹ 1/- (Rupee One only) each	
Eligible Person(s) or Eligible Shareholder(s)	Equity Shareholders eligible to participate in the Buyback and would mean all Equity Shareholders/ Beneficial Owners of the Equity Shares of the Company on the Record Date, being Tuesday, July 30, 2024, and do not include such Equity Shareholders/ Beneficial Owners of the Equity Shares who are not permitted under the applicable law to tender Equity Shares in the Buyback	
Escrow Account	Escrow account titled "Aurobindo Pharma Limited - Buyback Escrow Account" opened with the Escrow Agent in accordance with Buyback Regulations	
Escrow Agent / Escrow Bank	Axis Bank Limited	

Escrow Agreement	The escrow agreement dated Thursday, July 18, 2024 entered into between the Company, the Escrow Agent, and the Manager to the Buyback	
FATCA	Foreign Account Tax Compliance Act	
FEMA	Foreign Exchange and Management Act, 1999, as amended from time to time, including the regulations, circulars, directions and notifications issued thereunder	
FII(s)	Foreign Institutional Investor(s)	
FPI(s)	Foreign Portfolio Investor(s)	
General Category	Eligible Shareholders other than the Small Shareholders	
IPV	In person verification	
IT Act/ Income Tax Act	The Income Tax Act, 1961, as amended	
Letter of Offer/LOF	This letter of offer dated Thursday, August 01, 2024 containing disclosures in relation to the Buyback as specified in Schedule III of the Buyback Regulations	
Listing Regulations	SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time	
"Manager to the Buyback" or "Manager to the Offer" or "Manager"	Axis Capital Limited	
Management Rules	Companies (Management and Administration) Rules, 2014, as amended	
Memorandum of Association or MOA	Memorandum of Association of the Company, as amended from time to time	
N.A./ NA	Not applicable	
Non-Resident Shareholders	Eligible Shareholders residing outside India including non-resident Indians, foreign nationals, foreign corporate bodies (including erstwhile overseas corporate bodies), FII/ FPI, etc.	
NSDL	National Securities Depository Limited	
NSE	National Stock Exchange of India Limited	
Offer Period or Tendering Period	Period of 5 (five) Working Days from the Buyback Opening Date i.e., Monday, August 05, 2024, to Buyback Closing Date i.e., Friday, August 09, 2024 (both days inclusive)	
OSV	Original seen and verified	
PA or Public Announcement	The public announcement dated Friday, July 19, 2024, made in accordance with the Buyback Regulations, published on Monday, July 22, 2024, in the newspapers set out in paragraph 5 ( <i>Details of Public Announcement</i> ) of this Letter of Offer	
PAN	Permanent Account Number	
Promoter & Promoter Group	The promoter and promoter group of the Company as defined under the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended	
RBI	Reserve Bank of India	
Record Date	The date for the purpose of determining the Buyback Entitlement and the names of the Eligible Shareholders to whom the Letter of Offer (including the Tender Form) will be sent, and who are eligible to participate in the Buyback in accordance with the Buyback	

	Regulations. The Record Date for the Buyback is Tuesday, July 30, 2024	
"Registrar to the Buyback" or "Registrar to the Offer" or "Registrar"	KFin Technologies Limited	
Reserved Category	The Small Shareholders eligible to tender Shares in the Buyback	
ROC	Registrar of Companies, Telangana at Hyderabad	
SEBI	Securities and Exchange Board of India	
SEBI Circulars	SEBI circular no. CIR/CFD/POLICYCELL/1/2015 dated April 13, 2015 and SEBI circular no. CFD/DCR2/CIR/P/2016/131 dated December 09, 2016 and SEBI circular no. SEBI/HO/CFD/DCR-III/CIR/P/2021/615 dated August 13, 2021, and such other circulars or notifications, as may be applicable, including any amendments or statutory modifications for the time being in force	
Seller Member	The stockbroker (who is member of BSE) of an Eligible Shareholder through whom the order for selling the Equity Shares of Eligible Shareholders will be placed in the Acquisition Window	
Small Shareholder	As defined under Regulation 2(i)(n) of the Buyback Regulations and in relation to the Buyback means an Eligible Shareholder who holds Equity Shares of market value of not more than ₹ 2,00,000/- (Rupees Two Lakh only), on the basis of closing price on the recognized stock exchange registering the highest trading volume as on the Record Date	
Share Capital Rules	Companies (Share Capital and Debentures) Rules, 2014, as amended from time to time	
Shareholders or Equity Shareholders or Members or Beneficial Owners	Holders of Equity Shares and includes beneficial owners thereof	
Stock Exchanges	Collectively, BSE and NSE	
Stock Exchange Mechanism	The "Mechanism for acquisition of shares through Stock Exchange" notified by SEBI Circulars	
Tender Form	Form of Acceptance—cum—Acknowledgement to be filled in and sent to the Registrar by the Eligible Shareholder(s) to participate in the Buyback	
Tender Offer	Method of buyback as defined in Regulation 2(i)(q) of the Buyback Regulations	
Transaction Costs	Brokerage costs, fees, turnover charges, applicable taxes such as buyback tax, securities transaction tax, goods and services tax, stamp duty, etc., expenses incurred or to be incurred for the Buyback like filing fees payable to SEBI, advisors/ legal fees, public announcement publication expenses, printing and dispatch expenses and other incidental and related expenses, etc.	
TRS	Transaction Registration Slip generated by the exchange bidding system	
Working Day	Working day as defined in the Buyback Regulations	

# 2.3 Certain conventions, currency of presentation, use of financial information and stock market data

## **Page Numbers and Paragraph Numbers**

Unless otherwise stated, all references to page numbers and paragraph numbers in this Letter of Offer are to page numbers and paragraph numbers of this Letter of Offer.

#### **Currency and Units of Presentation**

All references to "₹", "Rupee(s)" or "Rs." are to Indian Rupees, the official currency of the Republic of India.

#### **Financial and Other Data**

Unless stated or the context requires otherwise, our financial information in this Letter of Offer is derived from our audited standalone and consolidated financial statements for the fiscal year ended on March 31, 2024, March 31, 2023 and March 31, 2022.

Our Company's fiscal year commences on April 1 of each year and ends on March 31 of the next year (referred to herein as "Fiscal", "Fiscal Year" or "FY").

#### **Stock Market Data**

Unless stated or the context requires otherwise, stock market data included in this Letter of Offer is derived from the website of BSE and NSE.

#### 3. DISCLAIMER CLAUSE

- 3.1 As required under the Buyback Regulations, a copy of this Letter of Offer has been submitted to SEBI. It is to be distinctly understood that submission of this Letter of Offer to SEBI should not, in any way be deemed or construed that the same has been cleared or approved by SEBI. SEBI does not take any responsibility either for the financial soundness of the Company to meet the Buyback commitments or for the correctness of the statements made or opinions expressed in the Letter of Offer. The Manager to the Buyback has certified that the disclosures made in the Letter of Offer are generally adequate and are in conformity with the provisions of the Companies Act and Buyback Regulations. This requirement is to facilitate Eligible Shareholders to take an informed decision for tendering their Equity Shares in the Buyback.
- 3.2 It should also be clearly understood that while the Company is primarily responsible for the correctness, adequacy and disclosure of all relevant information in the Letter of Offer, the Manager to the Buyback is expected to exercise due diligence to ensure that the Company discharges its duty adequately in this behalf and towards this purpose, the Manager to the Buyback is furnishing to SEBI a due diligence certificate dated Thursday, August 1, 2024, in accordance with Buyback Regulations which reads as follows:

"We have examined various documents and materials contained in the annexure to this letter, as part of the due-diligence carried out by us in connection with the finalization of the public announcement dated Friday, July 19, 2024 for the Buyback ("Public Announcement") which was published on Monday, July 22, 2024 and the Letter of Offer dated Thursday, August 1, 2024 ("Letter of Offer"). On the basis of such examination and the discussions with the Company, we hereby state that:

• the Public Announcement and the Letter of Offer are in conformity with the documents, materials and papers relevant to the Buyback;

- all the legal requirements connected with the said Buyback including the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended, have been duly complied with;
- the disclosures in the Public Announcement and the Letter of Offer are, to the best of our knowledge, true, fair and adequate in all material respects for the Eligible Shareholders to make a well-informed decision in respect of the Buyback; and
- funds used for Buyback shall be as per the provisions of the Companies Act, 2013, as amended."
- 3.3 The filing of the Letter of Offer with SEBI, does not, however, absolve the Company from any liabilities under the provisions of the Companies Act or from the requirement of obtaining such statutory or other clearances as may be required for the purpose of the proposed Buyback.
- 3.4 The members of the Promoter & Promoter Group/ Board of Directors declare and confirm that no information/ material likely to have a bearing on the decision of Eligible Shareholders has been suppressed/ withheld and/ or incorporated in the manner that would amount to mis-statement/ mis-representation and in the event of it transpiring at any point of time that any information/ material has been suppressed/ withheld and/ or amounts to a mis-statement/ mis-representation, the members of the Promoter & Promoter Group and the Board of Directors and the Company shall be liable for penalty in terms of the provisions of the Companies Act and the Buyback Regulations.
- 3.5 The Board of Directors also declare and confirm that funds borrowed from banks and financial institutions will not be used for the Buyback.

#### 3.6 Disclaimer for persons from the United States of America

The information contained in this Letter of Offer is exclusively intended for persons who are not US Persons as defined in Regulations of the US Securities Act of 1933, as amended, and who are not physically present in the United States of America. This Letter of Offer does not in any way constitute an offer to sell, or an invitation to sell, any securities in the United States of America or in any other jurisdiction in which such offer or invitation is not authorized or to any person to whom it is unlawful to make such offer or solicitation. Potential users of the information contained in this Letter of Offer are requested to inform themselves about, and to observe any such restrictions.

## 3.7 Disclaimer for persons in foreign countries other than the United States of America

This Letter of Offer has not been filed, registered or approved in any jurisdiction outside India. This Letter of Offer does not in any way constitute an offer to sell or an invitation to sell, any securities in any jurisdiction in which such offer or invitation is not authorized or to any person to whom it is unlawful to make such offer or solicitation would subject the Company or the Manager to the Buyback to a new or additional requirements or registration. Potential users of the information contained in this Letter of Offer are requested to inform themselves about and to observe any such restrictions.

# 3.8 Important Notice to All Equity Shareholders

This Letter of Offer has been prepared for the purposes of compliance with the Buyback Regulations. Accordingly, the information disclosed may not be the same as that which would have been disclosed if this document had been prepared in accordance with the laws and regulations of any jurisdiction outside of India. The Company and the Manager to the Buyback are under no obligation to update the information contained herein at any time after the date of this Letter of Offer. The Letter of Offer shall be dispatched to all Shareholders whose names appear on the register of members of the Company, as of the Record Date, as per the Buyback Regulations and such other circulars or notifications, as may be applicable. However, receipt of the Letter of Offer by any Equity Shareholders in a jurisdiction in which it would be illegal to make this Tender Offer, or where making this Tender Offer would require any action to be taken (including, but not restricted to, registration of the Letter of Offer under any local securities laws), shall not be treated by such Shareholders as an offer being made to them. Potential users of the information contained in this Letter of Offer are requested to inform themselves about and to observe any such restrictions. Any Eligible Shareholder who tenders his, her or its Equity Shares in the Buyback shall be deemed to have declared, represented, warranted and agreed that he, she or it is authorized under the provisions of any applicable local laws, rules, regulations and statutes to participate in the Buyback.

# 3.9 Forward Looking Statements

This Letter of Offer contains certain forward-looking statements. These forward-looking statements generally can be identified by words or phrases such as 'aim', 'anticipate', 'believe', 'expect', 'estimate', 'intend', 'objective', 'plan', 'project', 'will', 'will continue', 'will pursue' or other words or phrases of similar import. Similarly, statements that describe our strategies, objectives, plans or goals are also forward-looking statements. All forward-looking statements are subject to risks, uncertainties and assumptions about the Company that could cause actual results to differ materially from those contemplated by the relevant forward-looking statement.

Actual results may differ materially from those suggested by forward-looking statements due to risks or uncertainties associated with expectations relating to, *inter alia*, regulatory changes pertaining to the industries in which the Company operates and its ability to respond to them, the Company's ability to successfully implement its strategy, its growth and expansion, technological changes, exposure to market risks, general economic and political conditions in India or other key markets where it operates which have an impact on its business activities or investments, the monetary and fiscal policies, inflation, deflation, unanticipated turbulence in interest rates, foreign exchange rates, equity prices or other rates or prices, the performance of the financial markets in India and globally, changes in domestic laws, regulations and taxes and changes in competition in the industries in which the Company operates.

#### 4. TEXT OF RESOLUTION PASSED AT THE BOARD MEETING

The Buyback has been authorized and approved by the Board of Directors at their meeting held on Thursday, July 18, 2024. The text of the resolution passed by the Board is as follows:

# Quote

"RESOLVED THAT in accordance with Article 40 (b) of the Articles of Association of Aurobindo Pharma Limited ("Company") and pursuant to the provisions of Sections 68, 69, 70 and all other applicable provisions, if any, of the Companies Act, 2013, as amended (the "Companies Act"), rules framed under the Companies Act, including the Companies (Share Capital and Debentures) Rules, 2014 as amended and the Companies (Management and Administration) Rules, 2014, as amended, to the extent applicable, and in compliance with the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended (the "Buyback Regulations") and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), and including any amendments, statutory modification(s) or re-

enactment(s) for the time being in force, and subject to such other approvals, permissions, consents, exemptions and sanctions, as may be necessary and subject to any modifications and conditions, if any, as may be prescribed or imposed by the Securities and Exchange Board of India ("SEBI"), Registrar of Companies, Telangana at Hyderabad (the "ROC"), BSE Limited ("BSE"), National Stock Exchange of India Limited ("NSE") and/or other authorities institutions or bodies (the "Appropriate Authorities") while granting such approvals, permissions, sanctions and exemptions, which may be agreed to by the board of directors of the Company (the "Board", which expression shall include any committee constituted by the Board to exercise its powers, including the powers conferred by this Board resolution), the Board hereby approves the buyback of up to 51,36,986 (fifty one lakh thirty six thousand nine hundred eighty six only) fully paid-up equity shares of the Company, each having a face value of INR 1/- (Indian Rupee one only) ("Equity Shares"), representing up to 0.88% of the total number of equity shares in the paid-up share capital of the Company as on March 31, 2024 and June 30, 2024, at a price of INR 1,460/- (Indian Rupees fourteen hundred sixty only) per Equity Share ("Buyback Price"), subject to any increase to the Buyback Price as may be approved by the Board or any committee thereof, payable in cash for an aggregate amount up to INR 750,00,00,000/-(Indian Rupees seven hundred fifty crores only) (excluding transaction costs viz. brokerage costs, fees, turnover charges, applicable taxes such as buyback tax, securities transaction tax, goods and services tax, stamp duty, etc., expenses incurred or to be incurred for the Buyback like filing fees payable to the SEBI, advisors/ legal fees, public announcement publication expenses, printing and dispatch expenses and other incidental and related expenses, etc.) ("Buyback Size"), being 3.84% and 2.67% of the aggregate of the fully paid-up equity share capital and free reserves (including securities premium) of the Company as per the latest audited standalone and consolidated financial statements of the Company as at March 31, 2024, respectively (which is within the statutory limits of 10% of the aggregate of the fully paid-up equity share capital and free reserves (including securities premium) of the Company, based on both standalone and consolidated financial statements of the Company, under the Board approval route as per the provisions of the Companies Act and Buyback Regulations), on a proportionate basis through the "tender offer" route as prescribed under the Buyback Regulations, from all of the equity shareholders/ beneficial owners of the Company, including the promoters and members of the promoter group of the Company (as defined under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and to be referred as "Promoter & Promoter Group") who hold Equity Shares as of the record date i.e., Tuesday, July 30, 2024 (the "Record Date" and such buyback the "Buyback").

**RESOLVED FURTHER THAT** the Company shall implement the Buyback using the "Mechanism for acquisition of shares through Stock Exchange pursuant to Tender-Offers under Takeovers, Buy Back and Delisting" notified by the SEBI *vide* circular CIR/CFD/POLICYCELL/1/2015 dated April 13, 2015 read with SEBI circular CFD/DCR2/CIR/P/2016/131 dated December 09, 2016 and SEBI circular SEBI/HO/CFD/DCR-III/CIR/P/2021/615 dated August 13, 2021, including any amendments or statutory modifications for the time being in force ("**SEBI Circulars**").

**RESOLVED FURTHER THAT** the Company shall implement the Buyback out of its securities premium account, free reserves and/ or current surplus and/or cash and cash equivalents and/or internal accruals and/or liquid resources and/or such other sources as may be permitted by law, and the Buyback shall be through tender offer in such manner as may be prescribed under the Companies Act and the Buyback Regulations, and on such terms and conditions as the Board may deem fit.

**RESOLVED FURTHER THAT** in terms of Section 69 of the Companies Act, the Company shall transfer from its free reserves or securities premium account and/ or current surplus and/or cash and cash equivalents and/or internal accruals and/or liquid resources and/or such other sources as may be permitted by law, a sum equal to the nominal value of the Equity Shares bought back through the Buyback, to the capital redemption reserve account

and the details of such transfer shall be disclosed in its subsequent audited financial statements.

**RESOLVED FURTHER THAT** pursuant to Regulation 42 of the Listing Regulations and Regulation 9(i) of the Buyback Regulations, the Record Date for ascertaining the eligibility of the shareholders to participate in the buyback shall be Tuesday, July 30, 2024.

**RESOLVED FURTHER THAT** all equity shareholders/ beneficial owners of the Equity Shares, including Promoter & Promoter Group, who hold Equity Shares as on the Record Date ("Eligible Shareholders"), will be eligible to participate in the Buyback except any shareholders who may be specifically prohibited under the applicable laws by Appropriate Authorities.

**RESOLVED FURTHER THAT** as required by Regulation 6 of the Buyback Regulations, the Company shall buyback Equity Shares from the Eligible Shareholders, on a proportionate basis under the tender offer, provided 15% of the number of Equity Shares which the Company proposes to Buyback or number of Equity Shares entitled as per the shareholding of small shareholders at the Record Date, whichever is higher, shall be reserved for small shareholders, as defined in the Buyback Regulations.

**RESOLVED FURTHER THAT** the Buyback from the Eligible Shareholders who are residents outside India including non-resident Indians, foreign nationals, foreign corporate bodies (including erstwhile overseas corporate bodies), foreign institutional investors / foreign portfolio investors, shall be subject to such approvals, if any and to the extent necessary or required from the concerned authorities including approvals from the Reserve Bank of India under the Foreign Exchange Management Act, 1999 and the rules and regulations framed thereunder, and that such approvals shall be required to be taken by such non-resident shareholders.

**RESOLVED FURTHER THAT** the Buyback would be subject to the condition of maintaining minimum public shareholding requirements as specified in Regulation 38 of the Listing Regulations.

**RESOLVED FURTHER THAT** the Company shall not use borrowed funds, whether secured or unsecured, of any form and nature, from banks and financial institutions for paying the consideration to the equity shareholders who have tendered their Equity Shares in the Buyback.

**RESOLVED FURTHER THAT** the Company shall earmark adequate sources of funds for the purpose of the Buyback, and Mr. K. Nityananda Reddy, Vice Chairman & Managing Director or Mr. M. Madan Mohan Reddy, Whole-time Director of the Company be and are hereby severally authorized to sign and submit a firm financing certificate, and to do all such acts, deeds and things as may be necessary to give effect to the above resolution.

**RESOLVED FURTHER THAT** in terms of Regulation 24(iii) of the Buyback Regulations, Mr B Adi Reddy, Company Secretary and Compliance Officer of the Company, be and is hereby appointed as the Compliance Officer for the Buyback.

**RESOLVED FURTHER THAT** the Company shall maintain a register of securities bought back wherein details of Equity Shares bought back, consideration paid for the Equity Shares bought back, date of cancellation of Equity Shares and date of extinguishing and physically destroying of Equity Shares and such other particulars as may be prescribed, shall be entered and that Mr B Adi Reddy, Company Secretary and Compliance Officer of the Company be and is hereby authorised to authenticate the entries made in the said register.

**RESOLVED FURTHER THAT** as required under the provision to Section 68(6) of the Companies Act and Regulation 8(i)(b) of the Buyback Regulations, the draft of the affidavit for declaration of solvency prepared in the prescribed form along with supporting documents, placed before the meeting be and is hereby approved, and that Mr. K. Nithyananda Reddy, Vice Chairman & Managing Director and Mr. M. Madan Mohan Reddy, Whole-time Director of the Company be and are hereby authorized to finalise and sign the

same, for and on behalf of the Board, and Mr B Adi Reddy, Company Secretary and Compliance Officer of the Company, be and is hereby authorized to file the same with ROC and SEBI and or other concerned authorities, as may be necessary in accordance with applicable law.

**RESOLVED FURTHER THAT** as required by Clause (x) of Schedule I of the Buyback Regulations, the Board hereby confirms that it has made full enquiry into the affairs and prospects of the Company and has formed an opinion that:

- a) immediately following the date of board meeting (i.e., Thursday, July 18, 2024) ("Board Meeting") approving the Buyback, there will be no grounds on which the Company can be found unable to pay its debts;
- b) as regards the Company's prospects for the year immediately following the date of Board Meeting, and having regards to the Board's intention with respect to the management of the Company's business during that year and to the amount and character of the financial resources, which will, in the Board's view, be available to the Company during that year, the Company will be able to meet its liabilities as and when they fall due and will not be rendered insolvent within a period of one year from the date of the Board Meeting; and
- c) in forming its opinion aforesaid, the Board has taken into account the liabilities (including prospective and contingent liabilities) as if the Company were being wound up under the provisions of the Companies Act, or the Insolvency and Bankruptcy Code, 2016, as applicable.

## **RESOLVED FURTHER THAT** the Board hereby confirms that:

- a) all the Equity Shares of the Company are fully paid-up;
- b) the Company shall not issue and allot any Equity Shares or other specified securities (including by way of bonus) or convert any outstanding employee stock options / outstanding instruments into Equity Shares, from the date of the Board Meeting till the expiry of the Buyback period, i.e., the date on which the payment of consideration is made to the shareholders who have accepted the Buyback;
- c) unless otherwise specifically permitted by any relaxation issued by SEBI and / or any other regulatory authority, the Company shall not raise further capital for a period of one year, as prescribed under the provisions of Regulation 24(i)(f) of the Buyback Regulations, from the expiry of the Buyback period, i.e., the date on which the payment of consideration is made to the shareholders who have accepted the Buyback, except in discharge of its subsisting obligations;
- d) the Company, as per the provisions of Section 68(8) of the Companies Act, will not make a further issue of the same kind of shares or other securities including allotment of new shares under Section 62(1)(a) or other specified securities within a period of six months except by way of a bonus issue or in the discharge of subsisting obligations such as conversion of warrants, stock option schemes, sweat equity or conversion of preference shares or debentures into Equity Shares;
- e) the Company shall not withdraw the Buyback after public announcement of the offer to Buyback is made;
- the Company will ensure consequent reduction of its share capital post Buyback and the Equity Shares bought back by the Company will be extinguished and physically destroyed in the manner prescribed under the Buyback Regulations and the Companies Act within the specified timelines;
- g) the Company shall not buyback locked-in Equity Shares and non-transferable Equity Shares until the pendency of the lock-in or till the Equity Shares become transferable;
- h) the consideration for the Buyback shall be paid by the Company only in cash;

- the Company shall not buyback its Equity Shares or other specified securities from any person through negotiated deals whether on or off the stock exchanges or through spot transactions or through any private arrangement in the implementation of Buyback;
- j) there are no defaults (either in the past or subsisting) in the repayment of any deposits (including interest payable thereon), redemption of debentures or preference shares, payment of dividend or repayment of any term loans to any financial institution or banks (including interest payable thereon), as the case may be, and in case of defaults which have ceased to subsist, if any, a period of more than 3 (three) years has lapsed.
- k) in the event of non-fulfilment of the obligations under the Buyback Regulations by the Company, the monies deposited in the Escrow Account / Special Account in full or in part shall be forfeited and distributed pro rata amongst the shareholders who accepted the offer and balance if any shall be utilized for investor protection in accordance with the Buyback Regulations;
- I) that the Company has been in compliance with Sections 92, 123, 127 and 129 of the Companies Act;
- m) the aggregate amount of the Buyback i.e. up to INR 750,00,00,000/-(Indian Rupees seven hundred fifty crores only) does not exceed 10% of the aggregate of the fully paid-up equity share capital and free reserves (including securities premium) of the Company as per the latest audited standalone and consolidated financial statements of the Company as at March 31, 2024;
- n) the number of Equity Shares proposed to be purchased under the Buyback (up to 51,36,986 Equity Shares), does not exceed 25% of the total number of Equity Shares in the paid-up equity share capital of the Company as at March 31, 2024 and June 30, 2024;
- o) the Company has not undertaken a buyback of any of its securities during the period of one year immediately preceding the date of the Board Meeting;
- the Company shall not make any offer of buyback within a period of one year reckoned from the date of expiry of the Buyback period i.e., the date on which the payment of consideration is made to the shareholders who have accepted the Buyback;
- q) the Company shall comply with the statutory and regulatory timelines in respect of the Buyback in such manner as prescribed under the Companies Act and /or the Buyback Regulations and any other applicable laws;
- r) the Buyback shall be completed within a period of one year from the date of passing of Board resolution approving the Buyback;
- s) there is no pendency of any scheme of amalgamation or compromise or arrangement involving the Company pursuant to the provisions of the Companies Act, as on date;
- t) the ratio of the aggregate of secured and unsecured debts owed by the Company shall not be more than twice its paid-up capital and free reserves after the Buyback, based on audited standalone and consolidated financial statements of the Company as on March 31, 2024, as prescribed under the Companies Act and rules made thereunder and Buyback Regulations;
- u) the Company is not buying back its Equity Shares so as to delist its shares or other specified securities from the stock exchanges;
- v) the Company shall not directly or indirectly purchase its Equity Shares through any subsidiary company including its own subsidiary companies, or through any investment company or group of investment companies;
- w) in accordance with Regulation 5(i)(c) and Clause (xii) of Schedule I of the Buyback Regulations, the Company shall not undertake the Buyback unless it has obtained prior consent of its lenders, in case of breach of any covenant with such lenders, and

- accordingly, the Company has obtained the prior consent of its lenders, as necessary, for undertaking the Buyback;
- x) information pertaining to the Company as may be set out in the public announcement, letter of offer, any corrigenda and all offer documents with respect to the Buyback shall be true, fair and adequate information in all material aspects and shall not contain any misleading information; and
- y) per Regulation 24(i)(e) of the Buyback Regulations, the Promoter & Promoter Group, and their associates, shall not deal in the Equity Shares or other specified securities of the Company either through the stock exchanges or off-market transactions (including inter-se transfer of Equity Shares among the Promoter and Promoter Group) from the date of Board resolution approving the Buyback till the closing of the Buyback offer.

**RESOLVED FURTHER THAT** no information / material that is likely to have a bearing on the decision of investors has been suppressed or withheld and /or incorporated in the manner that would amount to a mis-statement or misrepresentation and in the event of it transpiring at any point of time that any information has been suppressed or withheld and / or amounts to a mis-statement or misrepresentation, the Board and the Company shall be liable for penalty in terms of the provisions of the Companies Act and the Buyback Regulations.

**RESOLVED FURTHER THAT** nothing contained herein shall confer any right on any shareholder to offer or any obligation on the Company or the Board to buyback any Equity Shares or impair any power of the Company or the Board to terminate any process in relation to the Buyback, if so permissible by law.

**RESOLVED FURTHER THAT** Mr. K. Nithyananda Reddy, Vice Chairman & Managing Director, Mr. M. Madan Mohan Reddy, Whole-time Director, Mr. S. Subramanian, Chief Financial Officer and Mr. B. Adi Reddy, Company Secretary and Compliance Officer of the Company, be and are hereby severally authorized to file necessary e-forms with the ROC and to do all such acts, deeds and things or incidental for signing and filing of forms, payment of fees, etc. and to do all such other acts, things and deeds, as may be required for the aforesaid purpose or other services as that may be necessary.

**RESOLVED FURTHER THAT** Mr B Adi Reddy, Company Secretary and Compliance Officer of the Company, be and is hereby authorised to represent the Company before the Ministry of Corporate Affairs, SEBI, the stock exchanges, any regulatory/ statutory bodies/ authorities or any other agencies connected with the Buyback and to sign and submit all forms, letters, documents or other papers that may be required.

**RESOLVED FURTHER THAT** any actions taken so far in connection with the Buyback by the officers of the Company be and are hereby ratified, confirmed and approved.

**RESOLVED FURTHER THAT** a copy of the foregoing resolution certified by any Director and/or Company Secretary be forwarded to concerned persons/ authority as may be required."

**RESOLVED THAT** a committee comprising of Mr. K. Nithyananda Reddy, Vice Chairman & Managing Director, Mr. M. Madan Mohan Reddy, Whole-time Director and Mr. S. Subramanian, Chief Financial Officer of the Company be constituted for the purpose of the Buyback ("**Buyback Committee**") and that the Buyback Committee be and is hereby authorized to do all such acts, deeds, matters and things as it may, in its absolute discretion deem necessary, expedient, usual, or proper as the Buyback Committee may consider to be in the best interests of the Company and its shareholders, without any further approval of the Board, including but not limited to the following:

- a) seeking all regulatory approvals required for the Company to implement the Buyback, as applicable;
- b) appointing all intermediaries including but not limited to brokers, registrar, advertising agency, investor service centre, escrow bank, legal advisors, other advisors, depository

participant, printers, consultants or representatives, if any, and settlement of terms of appointment including the remuneration for all such intermediaries / agencies / persons, including by the payment of commission, brokerage, fee, charges etc. and enter into agreements / letters in respect thereof;

- c) opening, operating and closing all necessary accounts, including bank accounts (including Escrow Account and Special Account) and entering into agreements with and to give instructions in connection therewith and / or to delegate the operation of such accounts as required under applicable laws (including the Buyback Regulations), depository accounts (demat account / trading account / buyer broker account) and another account as may be necessary for the Buyback and deciding the authorized signatories for such accounts and for the purpose of payment and authorizing persons to operate the said accounts;
- d) entering into escrow arrangements as may be required by the Buyback Regulations and depositing and / or instructing the deposit of the requisite amount into Escrow Account and finalising the composition / combination of such deposit into Escrow Account in accordance with the provisions of the Buyback Regulations and the escrow arrangement;
- e) increasing the Buyback Price and decreasing the number of Equity Shares proposed to be bought back, such that there is no change in the Buyback Size, till one working day prior to the Record Date, in terms of Regulation 5(via) of the Buyback Regulations;
- f) finalizing the terms and timeline of the Buyback including not limited to the schedule of activities, entitlement ratio, opening date and closing date of the offer period and the timeframe for completing the Buyback and re-affirming declaration of solvency as and when required;
- g) dealing with the stock exchanges (including their clearing corporation), deciding on the appointment of a designated stock exchange, and to sign, execute, and deliver such documents as may be necessary or desirable in connection with implementing the Buyback using the "Mechanism for acquisition of shares through Stock Exchange" notified by SEBI Circulars;
- taking all actions to verify offers and acceptances received, finalize the basis of acceptance, pay the shareholders consideration for shares bought back, extinguishment of the Equity Shares bought back by the Company and filling of necessary documents in relation to the same;
- preparation, finalizing, signing and filing of the public announcement, the letter of offer, all certifications and undertakings and any other document required in relation to the Buyback with the SEBI, ROC, the stock exchanges and other Appropriate Authorities;
- making all applications to the Appropriate Authorities for their requisite approvals including approvals as may be required from the Reserve Bank of India under the Foreign Exchange Management Act, 1999 and the rules and regulations framed there under, if any;
- k) signing, executing and delivering such other documents, deeds and writings and to do all such acts, matters and things as it may, in its absolute discretion deem necessary, expedient or proper, to be in the best interest of the shareholders for the implementation of the Buyback, and to initiate all necessary actions for preparation and issue of various documents and such other undertakings, agreements, papers, documents and correspondence as may be necessary for the implementation of the Buyback to the SEBI, RBI, ROC, stock exchanges, depositories and/or other authorities;
- uploading all required information such as details of the Equity Shares bought back on the website of the Company and filing the same with the stock exchanges as required under applicable law;

- m) affixing the Common Seal of the Company on relevant documents required to be executed for the buyback of shares in accordance with the provisions of the articles of association of the Company;
- settling and resolving any queries raised by the SEBI, stock exchanges, ROC and any other authorities whatsoever in connection to any matter incidental to and ancillary of the Buyback;
- o) authorising/ appointing persons to represent the Company, if required, before the ROC, SEBI, stock exchanges, or any other authority in connection with the Buyback and to sign and submit all forms, letters, documents or other papers that may be required;
- p) creating and maintaining requisite statutory registers and records as required under the Companies Act and to furnish appropriate returns to the Appropriate Authorities;
- q) obtaining all necessary certificates and reports from statutory auditors and other third parties as required under applicable law;
- r) giving such directions as may be necessary or desirable and settling any questions or difficulties whatsoever that may arise in relation to the Buyback;
- s) to settle and resolve any queries or difficulties raised by SEBI, stock exchanges, ROC and any other authorities whatsoever in connection to any matter incidental to and ancillary to the Buyback;
- t) to give any information, explanation, declarations and confirmations in relation to the public announcement and any other advertisements, as may be required by the relevant authorities including SEBI;
- u) earmarking and making arrangements for adequate sources of funds for the purpose of the Buyback;
- v) closing the Buyback and completing all the required formalities as specified under the Companies Act, Buyback Regulations and the Listing Regulations and other applicable laws;
- w) to finalize and execute necessary certifications, confirmations, undertakings etc. that may be required to be provided on behalf of the Board in regard to the Buyback;
- x) to finalize, sign, execute and submit necessary documents, deeds, affidavits, undertakings, certifications, agreements, forms, returns, applications, letters, etc., seek approval(s) and to represent the Company with the SEBI, stock exchanges, ROC, National Securities Depository Limited, Central Depository Services (India) Limited and any other regulatory authority in connection with the Buyback;
- y) to incur such other expenses as may be necessary with regard to the Buyback including fees to be paid to SEBI / other regulatory authorities, registrar's fees, fees for demat escrow agent and other intermediaries, fee for any consultants / advisers that may be hired, publication expenses, postage expenses, transaction costs viz. brokerage, applicable taxes such as securities transaction tax, goods and services tax, stamp duty, etc. and such other expenses that may be necessary or incidental in this regard.
- z) drafting, making alterations to, additions to, deletions to, variations to, amendments or corrections to and issuing and filing with appropriate statutory/other authorities, the public announcement, the letter of offer and all other documents, resolutions, advertisements, confirmations, intimations and declarations, and the certificate for extinguishment and physical destruction of shares certificates (if any), and other documents required in connection with the Buyback and causing the declaration of solvency and supporting affidavit to be executed in accordance with applicable law and such alterations, additions, omissions, variations, amendments or corrections will be deemed to have been approved by the Board; and
- aa) doing such other acts, deeds, matters, or things, and executing such documents, forms, letters, confirmations, and taking all steps as may be necessary to sign, submit and file

all necessary forms, letters, applications, e-forms and other documents as they may in their absolute discretion, deem necessary, expedient, usual or proper or are necessary, expedient, usual or proper with regard to the implementation in connection with or in furtherance of the Buyback.

**RESOLVED FURTHER THAT** the quorum for any meeting of the Buyback Committee for implementing the Buyback shall be any two members and Buyback Committee may regulate its own proceedings and meet as often as required, to discharge its functions.

**RESOLVED FURTHER THAT** subject to the relevant provisions of the Companies Act, the Buyback Committee is permitted to pass any resolution by circulation and the resolution passed by circulation shall have the same effect and force as if the resolutions have been passed in the meeting of the Buyback Committee.

**RESOLVED FURTHER THAT** the Buyback Committee shall have the power and authority to delegate all or any of the authorities conferred upon it to any officer(s) and/or representatives of the Company, in order to give effect to the aforesaid resolutions and to revoke and substitute such delegation / sub-delegation of authority from time to time.

**RESOLVED FURTHER THAT** all acts, deeds, matters and things done by the Buyback Committee for the purpose shall have the same effect as if done by the Board.

**RESOLVED FURTHER THAT** for the purpose of giving effect to this resolution, the Board and the Buyback Committee be and are hereby severally authorized to accept and make any alteration(s), modification(s) to the terms and conditions as they may deem necessary, concerning any aspect of the Buyback, in accordance with the statutory requirements or any conditions laid down by any regulatory or other authority while giving its approval as well as to give such directions as may be necessary or desirable, to settle any questions, difficulties or doubts that may arise and generally, to do all such acts, deeds, matters and things as it may, in its absolute discretion deem necessary, expedient, usual or proper in relation to or in connection with or for matters consequential to the Buyback without seeking any further consent or otherwise to the end and intent that they shall be deemed to have given their approval thereto expressly by the authority of this resolution."

**RESOLVED FURTHER THAT** the Buyback Committee shall stand dissolved on the date of completion of Buyback process.

**RESOLVED FURTHER THAT** a copy of the foregoing resolution certified by any Director and/or Company Secretary be forwarded to concerned persons/ authority as may be required

# Unquote

#### 5. DETAILS OF PUBLIC ANNOUNCEMENT

In accordance with Regulation 7(i) of the Buyback Regulations, the Company has made a Public Announcement for the Buyback dated Friday, July 19, 2024, which was published on Monday, July 22, 2024 in the newspapers mentioned below, which is within 2 (two) Working Days from the date of the Board Meeting approving the Buyback, i.e., Thursday, July 18, 2024:

Publication	Language	Editions
Financial Express	English	All editions
Jansatta	Hindi	All editions
Nava Telangana	Telugu*	Hyderabad edition

<sup>\*</sup> Telugu being the regional language where the registered office of the Company is located.

The Company will publish further notices or corrigenda, if any relating to the Public Announcement, in the abovementioned newspapers. A copy of the Public Announcement is available on the websites of the Company at (www.aurobindo.com), the Manager to the

Buyback (<u>www.axiscapital.co.in</u>), Registrar to the Buyback (<u>www.kfintech.com</u>), SEBI (<u>www.sebi.gov.in</u>), NSE (<u>www.nseindia.com</u>) and BSE (<u>www.bseindia.com</u>).

#### 6. DETAILS OF THE BUYBACK

- 6.1 At the Board Meeting held on Thursday, July 18, 2024, the Board, subject to such approvals of regulatory and/or statutory authorities as may be required under applicable laws, has approved the buyback of up to 51,36,986 (Fifty One Lakh Thirty Six Thousand Nine Hundred and Eighty Six only) Equity Shares, representing approximately 0.88% of the total number of Equity Shares in the paid-up share capital of the Company, at a price of ₹1,460/- (Rupees One Thousand Four Hundred and Sixty only) per Equity Share, subject to any increase to the Buyback Price as may be approved by the Board or the Buyback Committee, payable in cash, for an aggregate amount up to ₹750,00,00,000/- (Rupees Seven Hundred and Fifty Crore only), excluding Transaction Costs, from all of the equity shareholders/ beneficial owners of the Company, including the members of the Promoter & Promoter Group, who hold Equity Shares as of the Record Date on a proportionate basis through the "Tender Offer" route in accordance with the provisions of the Buyback Regulations, Companies Act, rules framed thereunder including the Share Capital Rules and Management Rules, and the Listing Regulations, to the extent applicable, and the SEBI Circulars.
- The Buyback Size constitutes 3.84% and 2.67% of the aggregate of the total paid-up equity share capital and free reserves (including securities premium) of the Company as per the audited standalone and consolidated financial statements of the Company as at March 31, 2024, respectively, and is within the statutory limit of 10% of the aggregate of the total paid-up equity share capital and free reserves (including securities premium) of the Company as per the audited standalone and consolidated financial statements of the Company as at March 31, 2024 (i.e., the last audited financial statements available as on the date of Board Meeting recommending the proposal of the Buyback), under the board approval route as per Section 68 and other applicable provisions of the Companies Act and Regulation 5 and other applicable provisions of the Buyback Regulations. Further, since the Equity Shares proposed to be bought back represents approximately 0.88% of the total number of Equity Shares in the paid-up share capital of the Company as of March 31, 2024 and June 30, 2024, the same is within the 25% limit as per the provisions of the Companies Act and Regulation 4(i) of the Buyback Regulations.
- 6.3 The Buyback is in accordance with Article 40(b) of the Articles of Association of the Company and Sections 68, 69, 70 and all other applicable provisions, if any, of the Companies Act, and rules framed thereunder, including the Share Capital Rules, the Management Rules, the Listing Regulations to the extent applicable, Buyback Regulations read with SEBI Circulars, subject to such other approvals, permissions, consents, exemptions and sanctions, as may be necessary and subject to any modifications and conditions, if any, as may be prescribed by SEBI, ROC, BSE, NSE and/ or other authorities, institutions or bodies, as may be necessary and subject to such conditions and modifications as may be prescribed or imposed while granting such approvals, permissions, sanctions and exemptions, which may be agreed by the Board.
- The Equity Shares are listed on BSE and NSE. The Buyback shall be undertaken on a proportionate basis (subject to reservation for Small Shareholders) from all the equity shareholders/ beneficial owners of the Company, including the members of the Promoter & Promoter Group, who hold Equity Shares as on the Record Date through the Tender Offer process prescribed under Regulation 4(iv)(a) of the Buyback Regulations and shall be implemented using the Stock Exchange Mechanism as specified in the SEBI Circulars. In this regard, the Company will request BSE to provide the Acquisition Window for facilitating tendering of Equity Shares under the Buyback and, for the purposes of this Buyback, BSE will be the Designated Stock Exchange.

- 6.5 The funds for implementation of the proposed Buyback will be sourced out of the free reserves of the Company and/ or such other sources as may be permitted by Buyback Regulations or the Companies Act. Funds borrowed from banks and financial institutions, if any, will not be used for the Buyback.
- 6.6 The Company shall transfer from its free reserves and/ or such other sources as may be permitted by law, a sum equal to the nominal value of the Equity Shares bought back through the Buyback to the capital redemption reserve account and the details of such transfer shall be disclosed in its subsequent audited financial statements.
- 6.7 The Buyback from the Eligible Shareholders who are Non-Resident Shareholders, shall be subject to such approvals, if any, and to the extent necessary or required from the concerned authorities including approvals from the RBI under the FEMA, and that such approvals shall be required to be taken by such Non-Resident Shareholders.
- 6.8 The aggregate shareholding of the members of the Promoter & Promoter Group and persons in control of the Company as on the date of the Public Announcement and this Letter of Offer is as follows:

Sr. No.	Name	Category	Number of Equity Shares held	% shareholding
1.	Venkata Ramprasad Reddy	Promoter	1,80,00,000	3.07
	Penaka			
2.	K Nityananda Reddy	Promoter	2,53,59,572	4.33
	Total (A)		4,33,59,572	7.40
3.	M Sivakumaran	Promoter Group	1,44,91,360	2.47
4.	Rajeshwari Kambham	Promoter Group	18,25,500	0.31
5.	Suneela Rani Penaka	Promoter Group	1,30,000	0.02
6.	Prasada Reddy Kambham	Promoter Group	3,01,156	0.05
7.	K Suryaprakash Reddy	Promoter Group	7,380	0.00
8.	M Sumanth Kumar Reddy	Promoter Group	16,00,000	0.27
9.	Kirthi Reddy Kambam	Promoter Group	2,02,50,000	3.46
10.	Kambam Spoorthi	Promoter Group	70,00,000	1.19
11.	Penaka Neha Reddy	Promoter Group	Nil	Nil
12.	Trident Chemphar Limited	Promoter Group	7,89,537	0.13
13.	Axis Clinicals Limited	Promoter Group	6,58,000	0.11
14.	RPR Sons Advisors Private	Promoter Group	19,63,76,250	33.51
	Limited, Suneela Rani			
	Penaka (joint holding)			
15.	Axis Clinicals Limited,	Promoter Group	1,67,26,716	2.85
	Trident Chemphar Limited,			
	RPR Sons Advisors Private			
	Limited (joint holding)			
	Total (B)		26,01,55,899	44.40
	Total (A+B)		30,35,15,471	51.80

- 6.9 In terms of the Buyback Regulations, under Tender Offer route, the members of the Promoter & Promoter Group and persons in control of the Company have the option to participate in the Buyback. In this regard, the members of the Promoter & Promoter Group vide their letters dated Friday, July 19, 2024, have expressed their intention to participate in the Buyback. For further details, please refer to Paragraph 9.7 of this Letter of Offer.
- 6.10 The Buyback will not result in any benefit to Promoter & Promoter Group or any directors of the Company except to the extent of the cash consideration received by them from the Company pursuant to their respective participation in the Buyback in their capacity as equity shareholders of the Company, and the change in their shareholding as per the

response received in the Buyback, as a result of the extinguishment of Equity Shares, which will lead to reduction in the equity share capital of the Company post Buyback. Any change in voting rights of the Promoter & Promoter Group of the Company pursuant to completion of Buyback will not result in any change in control over the Company.

- 6.11 Pursuant to the proposed Buyback and depending on the response to the Buyback, the aggregate voting rights in the Company of the members of the Promoter & Promoter Group and persons in control of the Company may change from the existing shareholding of the total equity capital and voting rights of the Company. Assuming response to the Buyback is to the extent of 100% (full acceptance) from all the Eligible Shareholders up to their Entitlement, the aggregate shareholding of the members of the Promoter & Promoter Group and the persons in control of the Company, post Buyback may increase to 51.86% of the post Buyback equity share capital of the Company. For further details, please refer to paragraph 13.6 of this Letter of Offer.
- 6.12 The Buyback would be subject to the condition of maintaining minimum public shareholding requirements as specified in Regulation 38 of the Listing Regulations.
- 6.13 Participation in the Buyback by Eligible Shareholders will trigger buyback tax in India and such tax is to be discharged by the Company. This may trigger capital gains taxation in the hands of the Eligible Shareholders in their country of residence, if outside India. The transaction of Buyback would also be chargeable to securities transaction tax in India. However, in view of the particularized nature of tax consequences, Eligible Shareholders are advised to consult their own legal, financial and tax advisors prior to participating in the Buyback. In terms of the Buyback Regulations, under the Tender Offer route, the Promoter and Promoter Group have the option to participate in the Buyback.

#### 7. AUTHORITY FOR THE BUYBACK

The Buyback is being undertaking by the Company in accordance with Article 40(b) of the Articles of Association of the Company and Sections 68, 69, 70 and all other applicable provisions, if any, of the Companies Act, and rules framed thereunder, including the Share Capital Rules, the Management Rules, the Listing Regulations to the extent applicable, Buyback Regulations read with SEBI Circulars, subject to such other approvals, permissions, consents, exemptions and sanctions, as may be necessary and subject to any modifications and conditions, if any, as may be prescribed by SEBI, ROC, BSE, NSE, and/ or other authorities, institutions or bodies, as may be necessary and subject to such conditions and modifications as may be prescribed or imposed while granting such approvals, permissions, sanctions and exemptions, which may be agreed by the Board.

# 8. NECESSITY FOR THE BUYBACK

The Buyback is being undertaken, *inter-alia*, for the following reasons:

- 8.1 The Buyback will help the Company to reward its shareholders and enhance the overall return to shareholders;
- 8.2 The Buyback is expected to improve earnings per share and other key ratios such as return on net worth and return on assets over a period of time; and
- 8.3 The Buyback, which is being implemented through the Tender Offer route as prescribed under the Buyback Regulations, would involve allocation of number of Equity Shares as per their entitlement or 15% of the number of Equity Shares to be bought back, whichever is higher, reserved for Small Shareholders. The Company believes that this reservation for

Small Shareholders would benefit a large number of public shareholders, who would get classified as "Small Shareholders" as per Regulation 2(i)(n) of the Buyback Regulations.

# 9. MANAGEMENT DISCUSSION AND ANALYSIS OF THE LIKELY IMPACT OF THE BUYBACK ON THE COMPANY

- 9.1 We believe that the Buyback is not likely to cause any impact on the profitability or earnings of the Company, except to the extent of reduction in the amount available for investment, which the Company could have been otherwise deployed towards generating investment income. Assuming there is full participation in the Buyback, the funds deployed by the Company towards the Buyback (excluding Transaction Costs) would be up to ₹ 750,00,00,000/- (Rupees Seven Hundred and Fifty Crore only). This shall impact the investment income earned by the Company, on account of reduced amount of funds available for investments. With a likely reduction in the equity share capital base, the Buyback will likely improve the return on net worth or return on equity ratio.
- 9.2 We believe that the Buyback will not in any manner impair the ability of the Company to pursue growth opportunities or meet its cash requirements for business operations. The Buyback is being undertaken, *inter alia*, for helping the Company to reward the Eligible Shareholders broadly in proportion to their shareholding, thereby, enhancing the overall return to the Equity Shareholders.
- 9.3 The Buyback will not result in a change in control or otherwise affect the existing management structure of the Company.
- 9.4 The aggregate shareholding of the members of the Promoter & Promoter Group and person in control of the Company as on the date of the Public Announcement and this Letter of Offer is as follows:

Sr.			Number of Equity	%
No.	Name	Category	Shares held	shareholding
1.	Venkata Ramprasad Reddy	Promoter	1,80,00,000	3.07
	Penaka			
2.	K Nityananda Reddy	Promoter	2,53,59,572	4.33
	Total (A)		4,33,59,572	7.40
3.	M Sivakumaran	Promoter Group	1,44,91,360	2.47
4.	Rajeshwari Kambham	Promoter Group	18,25,500	0.31
5.	Suneela Rani Penaka	Promoter Group	1,30,000	0.02
6.	Prasada Reddy Kambham	Promoter Group	3,01,156	0.05
7.	K Suryaprakash Reddy	Promoter Group	7,380	0.00
8.	M Sumanth Kumar Reddy	Promoter Group	16,00,000	0.27
9.	Kirthi Reddy Kambam	Promoter Group	2,02,50,000	3.46
10.	Kambam Spoorthi	Promoter Group	70,00,000	1.19
11.	Penaka Neha Reddy	Promoter Group	Nil	Nil
12.	Trident Chemphar Limited	Promoter Group	7,89,537	0.13
13.	Axis Clinicals Limited	Promoter Group	6,58,000	0.11
14.	RPR Sons Advisors Private	Promoter Group	19,63,76,250	33.51
	Limited, Suneela Rani			
	Penaka (joint holding)			
15.	Axis Clinicals Limited,	Promoter Group	1,67,26,716	2.85
	Trident Chemphar Limited,			
	RPR Sons Advisors Private			
	Limited (joint holding)			
	Total (B)		26,01,55,899	44.40
	Total (A+B)		30,35,15,471	51.80

9.5 The aggregate shareholding of the director(s)/ trustee(s) of the companies/ trusts forming part of the Promoter & Promoter Group in the Company:

Sr No	Name of Company/ Trust forming part of the Promoter & Promoter Group	Name of the Director/ Trustee	No. of Equity Shares	% shareholding
1.	Axis Clinicals Limited	Sannareddy Sadananda Reddy	2,00,000	0.03
		Jayachandra Reddy Atluri	30,680	0.01
2.	Trident Chemphar Limited	Sannareddy Sadananda Reddy	2,00,000	0.03
3.	RPR Sons Advisors Private Limited	Venkata Ramprasad Reddy Penaka	1,80,00,000	3.07
		Suneela Rani Penaka	1,30,000	0.02

9.6 aggregate shareholding of the directors and key managerial personnel of the Company (other than members of the Promoter & Promoter Group) in the Company:

Sr. No.	Name	Number of Equity Shares held	% shareholding
1.	S. Subramanian	7,126	Negligible
2.	Mettu Madan Mohan Reddy	2,010	Negligible
	Total	9,136	Negligible

9.7 Intention of members of the Promoter & Promoter Group and persons in control of the Company to participate in the Buyback:

In terms of the Buyback Regulations, under Tender Offer route, the members of the Promoter & Promoter Group and persons in control of the Company have the option to participate in the Buyback. In this regard, the members of the Promoter & Promoter Group *vide* their letters dated July 19, 2024, have expressed their intention to participate in the Buyback and tender up to the number of Equity Shares set out in the table below, or such lower number of Equity Shares as permitted under the applicable law:

			Maximum number
Sr. No.	Name	Number of Equity Shares held	of Equity Shares intended to be
			tendered up to
1.	Venkata Ramprasad Reddy Penaka	1,80,00,000	3,60,000
2.	K Nityananda Reddy	2,53,59,572	5,07,192
3.	M Sivakumaran	1,44,91,360	2,89,828
4.	Rajeshwari Kambham	18,25,500	36,510
5.	Suneela Rani Penaka	1,30,000	2,600
6.	Prasada Reddy Kambham	3,01,156	6,024
7.	K Suryaprakash Reddy	7,380	148
8.	M Sumanth Kumar Reddy	16,00,000	32,000
9.	Kirthi Reddy Kambam	2,02,50,000	4,05,000
10.	Kambam Spoorthi	70,00,000	1,40,000
11.	Penaka Neha Reddy	Nil	Nil
12.	Trident Chemphar Limited	7,89,537	15,791

	Limited, RPR Sons Advisors Private Limited (joint holding)		
15.	Axis Clinicals Limited, Trident Chemphar	1,67,26,716	3,34,535
	Suneela Rani Penaka (joint holding)		
14.	RPR Sons Advisors Private Limited,	19,63,76,250	39,27,525
13.	Axis Clinicals Limited	6,58,000	13,160

9.8 The entire shareholding of the members of the Promoter & Promoter Group is in dematerialised form. The details of the date and price of acquisition of the Equity Shares proposed to be tendered in the Buyback by the members of the Promoter & Promoter Group and persons in control of the Company who intend to participate in the Buyback are set out below:

# 9.8.1 Venkata Ramprasad Reddy Penaka

Sr. No.	Date of Acquisition	Nature of transaction	Face Value (in ₹)	Number of Equity Shares acquired	Issue price/ transfer price per Equity Share (in ₹)
1	July 22, 2015 <sup>(1)</sup>	Bonus issue in the ratio of 1:1	1	3,60,000	Nil

**Note**: (1) Received a total of 90,00,000 equity shares pursuant to the bonus issuance.

# 9.8.2 K Nityananda Reddy

Sr. No.	Date of Acquisition	Nature of transaction	Face Value (in ₹)	Number of Equity Shares acquired	Issue price/ transfer price per Equity Share (in ₹)
1	July 22, 2015 <sup>(1)</sup>	Bonus issue in the ratio of 1:1	1	5,07,192	Nil

**Note**: (1) Received a total of 1,37,62,350 equity shares pursuant to the bonus issuance.

# 9.8.3 M Sivakumaran

Sr. No.	Date of Acquisition	Nature of transaction	Face Value (in ₹)	Number of Equity Shares acquired	Issue price/ transfer price per Equity Share (in ₹)
1	July 22, 2015 <sup>(1)</sup>	Bonus issue in the ratio of 1:1	1	2,89,828	Nil

**Note**: (1) Received a total of 73,45,680 equity shares pursuant to the bonus issuance.

## 9.8.4 Rajeshwari Kambham

Sr. No.	Date of Acquisition	Nature of transaction	Face Value (in ₹)	Number of Equity Shares acquired	Issue price/ transfer price per Equity Share (in ₹)
1	July 22, 2015 <sup>(1)</sup>	Bonus issue in the ratio of 1:1	1	36,510	Nil

**Note**: (1) Received a total of 8,87,750 equity shares pursuant to the bonus issuance.

## 9.8.5 Suneela Rani Penaka

Sr. No.	Date of Acquisition	Nature of transaction	Face Value (in ₹)	Number of Equity Shares acquired	Issue price/ transfer price per Equity Share (in ₹)
1	September 30, 2021 <sup>(1)</sup>	Gift from member of Promoter & Promoter Group	1	2,600	Nil

**Note**: (1) Received a total of Received a total of 1,30,000 equity shares from Penaka Neha Reddy, a member of the Promoter & Promoter Group.

# 9.8.6 **Prasada Reddy Kambham**

Sr		Nature of transaction	Face Value (in ₹)	Number of Equity Shares acquired	Issue price/ transfer price per Equity Share (in ₹)
1	July 22, 2015 <sup>(1)</sup>	Bonus issue in the ratio of 1:1	1	6,024	Nil

**Note**: (1) Received a total of 2,00,578 equity shares pursuant to the bonus issuance.

# 9.8.7 K Suryaprakash Reddy

Sr. No.	Date of Acquisition	Nature of transaction	Face Value (in ₹)	Number of Equity Shares acquired	Issue price/ transfer price per Equity Share (in ₹)
1	July 22, 2015 <sup>(1)</sup>	Bonus issue in the ratio of 1:1	1	148	Nil

**Note**: (1) Received a total of 3,690 equity shares pursuant to the bonus issuance.

# 9.8.8 M Sumanth Kumar Reddy

Sr. No.	Date of Acquisition	Nature of transaction	Face Value (in ₹)	Number of Equity Shares acquired	Issue price/ transfer price per Equity Share (in ₹)
1	July 22, 2015 <sup>(1)</sup>	Bonus issue in the ratio of 1:1	1	32,000	Nil

**Note**: (1) Received a total of 8,00,000 equity shares pursuant to the bonus issuance.

# 9.8.9 Kirthi Reddy Kambam

Sr. No.	Date of Acquisition	Nature of transaction	Face Value (in ₹)	Number of Equity Shares acquired	Issue price/ transfer price per Equity Share (in ₹)
1	July 22, 2015 <sup>(1)</sup>	Bonus issue in the ratio of 1:1	1	4,05,000	Nil

Note: (1) Received a total of 1,03,50,000 equity shares pursuant to the bonus issuance

#### 9.8.10 Kambam Spoorthi

Sr. No.	Date of Acquisition	Nature of transaction	Face Value (in ₹)	Number of Equity Shares acquired	Issue price/ transfer price per Equity Share (in ₹)
1	July 22, 2015 <sup>(1)</sup>	Bonus issue in the ratio of 1:1	1	1,40,000	Nil

**Note**: (1) Received a total of 38,00,000 equity shares pursuant to the bonus issuance.

## 9.8.11 Trident Chemphar Limited

Sr. No.	Date of Acquisition	Nature of transaction	Face Value (in ₹)	Number of Equity Shares acquired	Issue price/ transfer price per Equity Share (in ₹)
1	March 18, 2020 <sup>(1)</sup>	Market purchase	1	15,791	392.82

**Note**: (1) Acquired a total of 1,30,000 equity shares through market purchase at a weighted average price of  $\stackrel{?}{\stackrel{?}{\sim}}$  392.82/-.

#### 9.8.12 Axis Clinicals Limited

Sr. No.	Date of Acquisition	Nature of Value (in ₹)		Number of Equity Shares acquired	Issue price/ transfer price per Equity Share (in ₹)
1	July 22, 2015 <sup>(1)</sup>	Bonus issue in the ratio of 1:1	1	13,160	Bonus issue

**Note**: (1) Received a total of 26,18,745 equity shares pursuant to the bonus issuance.

# 9.8.13 RPR Sons Advisors Private Limited, Suneela Rani Penaka (Joint holding)

Sr. No.	Date of Acquisition	Nature of transaction	Face Value (in ₹)	Number of Equity Shares acquired	Issue price/ transfer price per Equity Share (in ₹)
1	January 19, 2017 <sup>(1)</sup>	Contribution by partners through an off-market transfer	1	39,27,525	12.12

**Note**: (1) 19,63,76,250 Equity Shares of the Company were contributed by Suneela Rani Penaka a member of the Promoter & Promoter Group, at a weighted average price of ₹ 12.12/- per equity share.

# 9.8.14 Axis Clinicals Limited, Trident Chemphar Limited, RPR Sons Advisors Private Limited (Joint holding)

Sr. No.	Date of Acquisition	Nature of transaction	Face Value (in ₹)	Number of Equity Shares acquired	Issue price/ transfer price per Equity Share (in ₹)
1	March 30, 2017 <sup>(1)</sup>	Contribution by partners through an off-market transfer	1	3,34,535	32.64

**Note**: (1) 45,79,490 equity shares of the Company were contributed by Axis Clinicals Limited and 1,21,47,226 Equity Shares of the Company were contributed by Trident Chemphar Limited both members of the Promoter & Promoter Group, at a weighted average price of ₹ 32.64/- per equity share.

9.9 No Equity Shares or other specified securities in the Company were either purchased or sold by (a) the members of the Promoter & Promoter Group and persons who are in control of the Company; (b) the director(s)/ trustee(s) of the companies/ trusts forming part of the Promoter & Promoter Group in the Company; (c) directors and key managerial personnel of the Company, during the 6 (Six) months preceding the date of the Board Meeting, and during the 12 (Twelve) months preceding the date of the Public Announcement, except as follows:

Name	Aggregate no. of Equity Shares allotted / transferred	Nature of transaction	Maximum price per Equity Share (₹)*	Date of maximum price	Minimum price per Equity Share (₹)*	Date of minimum price
Kirthi Reddy Kambam	2,00,000	Sale	1,284.80	June 7, 2024	1,267.00	June 7, 2024
Sannareddy Sadananda	5,000	Sale	927.00	Septembe r 29, 2023	927.00	September 29, 2023
Reddy	7,000	Sale	1,053.00	November 22, 2023	1,033.65	November 22, 2023
	3,000	Sale	1,040.50	December 4, 2023	1,040.50	December 4, 2023
	10,000	Sale	1,080.00	December 20, 2023	1,066.00	December 20, 2023
	5,000	Sale	1,091.50	December 28, 2023	1,088.00	December 28, 2023
	5,000	Sale	1,071.00	March 27, 2024	1,071.00	March 27, 2024
	5,000	Sale	1,089.00	March 28, 2024	1,089.00	March 28, 2024
	10,000	Sale	1,260.00	June 5, 2024	1,248.40	June 5, 2024
	20,000	Sale	1,210.00	June 28, 2024	1,200.00	June 28, 2024
Jayachandra Reddy Atluri	500	Sale	1,261.45	June 11, 2024	1,261.25	June 11, 2024
Venkata Krishna	40	Purchase	1,038.20	December 14, 2023	1,038.20	December 14, 2023
Anjaneya Prasad	40	Sale	1,084.55	December 29, 2023	1,084.50	December 29, 2023
Marthy	90	Purchase	1,025.00	February 12, 2024	1,025.00	February 12, 2024
	90	Sale	1,125.00	April 4, 2024	1,125.00	April 4, 2024

<sup>\*</sup> Excluding transaction costs such as brokerage, STT etc.

- 9.10 The Buyback will not result in any benefit to the members of the Promoter & Promoter Group, persons in control of the Company or any Director except to the extent of the cash consideration received by them from the Company pursuant to their respective participation in the Buyback in their capacity as Equity Shareholders of the Company, and the change in their shareholding as per the response received in the Buyback, as a result of the extinguishment of Equity Shares which will lead to reduction in the equity share capital of the Company post Buyback.
- 9.11 Assuming the response to the Buyback is to the extent of 100% (full acceptance) from all the Eligible Shareholders up to their Entitlement including the members of the Promoter &

Promoter Group, the aggregate shareholding and the voting rights of the members of the Promoter & Promoter Group, may increase to 51.86% post Buyback from the current pre Buyback shareholding of 51.80%, and the aggregate shareholding of the public Shareholders in the Company may decrease to 48.14% post Buyback from the current pre Buyback shareholding of 48.20%. The members of the Promoter & Promoter Group are already in control over the Company and therefore any further increase in the voting rights of the members of the Promoter & Promoter Group will not result in any change in control of the Company.

- 9.12 Consequent to the Buyback and based on the number of Equity Shares bought back from the Non-Resident Shareholders, Indian financial institutions, banks, mutual funds and the public including other bodies corporate, the shareholding of the members of the Promoter & Promoter Group would undergo a change. Please refer to paragraph 13.6 for further details.
- 9.13 The debt-equity ratio post Buyback on standalone as well as consolidated basis will be compliant with the permissible limit of 2:1 prescribed under Section 68(2)(d) of Companies Act and Regulation 4(ii) of the Buyback Regulations, even if the response to the Buyback is to the extent of 100% (full acceptance) from all the Eligible Shareholders.
- 9.14 The Company shall not issue and allot any Equity Shares or other specified securities (including by way of bonus) from the date of the Board Meeting till the expiry of the Buyback Period, i.e., the date on which the payment of consideration is made to the Eligible Shareholders who have accepted the Buyback.
- 9.15 The Company has outstanding facilities with its lenders. In accordance with Regulation 5(i)(c) and Clause (xii) of Schedule I of the Buyback Regulations, the Company shall not undertake the Buyback unless it has obtained prior consent of its lenders, in case of breach of any covenant with such lenders. The Company confirms that it has obtained the prior consent of its lenders, as necessary, for undertaking the Buyback.
- 9.16 Unless otherwise specifically permitted by any relaxation issued by SEBI and/ or any other regulatory authority, the Company shall not raise further capital for a period of 1 (one) year, as prescribed under the provisions of Regulation 24(i)(f) of the Buyback Regulations, from the expiry of the Buyback Period, i.e., the date on which the payment of consideration is made to the Eligible Shareholders who have accepted the Buyback, except in discharge of its subsisting obligations. Further, the Company shall not issue and allot any Equity Shares or other specified securities (including by way of bonus) from the date of the Board Meeting till the expiry of the Buyback Period, i.e., the date on which the payment of consideration is made to the Shareholders who have accepted the Buyback. The Company, as per the provisions of Section 68(8) of the Companies Act, will not make a further issue of the same kind of shares or other securities including allotment of new shares under Section 62(1)(a) of the Companies Act or other specified securities within a period of 6 (six) months except by way of a bonus issue or in the discharge of subsisting obligations such as conversion of warrants, stock option schemes, sweat equity or conversion of preference shares or debentures into equity shares.
- 9.17 As per Regulation 24(i)(e) of the Buyback Regulations, the members of the Promoter & Promoter Group, and their associates, shall not deal in the Equity Shares or other specified securities of the Company either through the Stock Exchanges or off-market transactions (including by way of inter-se transfer of Equity Shares among the members of the Promoter & Promoter Group) from the date of the Board Meeting till the closing of the Buyback.
- 9.18 Salient financial parameters consequent to the Buyback based on standalone and consolidated audited financial statement of the Company for the financial year ended March 31, 2024 are set forth below:

Parameter	Stand	alone	Cons	olidated
	Pre-Buyback	Post	Pre-	Post Buyback <sup>(1)</sup>
		Buyback <sup>(1)</sup>	Buyback	Биураск -
Networth (in ₹ Million)	1,95,390.9	1,87,890.9	2,80,910.6	2,73,410.6
Return on Net worth (%)	10.0%	10.4%	11.3%	11.6%
Basic Earnings per share (₹)	32.43 <sup>(2)</sup>	32.72	54.16	54.63
Book value per share (₹)	333.47	323.50	479.42	470.75
Price/ Earnings Ratio	32.6	32.4	20.1	19.9
Total Debt/Equity Ratio	0.14	0.15	0.22	0.23

#### Note:

- (1) Assuming full acceptance.
- (2) Basic earnings per share (3) from continuing operations has been considered.

The key ratios have been computed as below:

Key Ratios	Basis			
Basic Earnings per	Profit after tax / Weighted average number of equity shares			
share	outstanding			
Book value per share	Net worth / Total number of outstanding shares			
Total Debt-Equity Ratio	Total Debt <sup>(1)</sup> / Net worth			
_	Calculated as closing market price of the Equity Shares on NSE			
Price / Earning ratio	as on March 28, 2024 divided by earnings per share for the			
	period ended March 31, 2024			
Net Worth	Paid-up equity share capital + security premium + general			
	reserve + retained earnings of the Company			

#### Note:

(1) Total Debt = Current Borrowings + Non-Current Borrowings + Current Portion of Noncurrent borrowings

# 10. BASIS OF CALCULATING THE BUYBACK PRICE

- 10.1 The Equity Shares are proposed to be bought back at a price ₹ 1,460/- (Rupees One Thousand Four Hundred and Sixty only) per Equity Share.
- 10.2 The Buyback Price has been arrived at after considering various factors including, but not limited to the trends in the volume weighted average prices and the closing price of the Equity Shares at the Stock Exchanges.
- 10.3 The Buyback Price represents:
  - 10.3.1 premium of 22.98% and 22.04% over the volume weighted average market price of the Equity Share on BSE and NSE, respectively, during the 3 (three) months preceding Sunday, July 14, 2024, being the date of intimation to the Stock Exchanges for the Board Meeting to consider the proposal of the Buyback ("Intimation Date").
  - 10.3.2 premium of 17.44% and 13.84% over the volume weighted average market price of the Equity Share on BSE and NSE, respectively, during the 2 (two) weeks preceding the Intimation Date.
  - 10.3.3 premium of 10.02% and 10.04%% over the closing price of the Equity Share on BSE and NSE, respectively, as on the trading day immediately preceding the Intimation Date, i.e., Friday, July 12, 2024.

- 10.3.4 premium of 9.16% and 9.25% over the closing price of the Equity Share on BSE and NSE, respectively, as on Thursday, July 18, 2024, being the date of the Board Meeting.
- The closing market price of the Equity Shares on the trading day immediately preceding the Intimation Date, i.e., Friday, July 12, 2024, was ₹ 1,327.05/- and ₹ 1,326.85/- and as on the date of the Board Meeting was ₹ 1,337.50/- and ₹ 1,336.40/- on BSE and NSE, respectively.
- 10.5 For trends in the market price of the Equity Shares, please refer to paragraph 16 (*Stock Market Data*) of this Letter of Offer. For details of salient financial parameters, both pre-Buyback and post-Buyback, based on the audited standalone and consolidated financial statements of the Company for the financial year ended March 31, 2024, please refer to paragraph 9.18 of this Letter of Offer.

### 11. SOURCES OF FUNDS FOR THE BUYBACK

The maximum amount required for Buyback will not exceed ₹ 750,00,00,000/- (Rupees Seven Hundred and Fifty Crore only) (excluding Transaction Costs). The Buyback Size constitutes 3.84% and 2.67% of the aggregate of the total paid-up share capital and free reserves (including securities premium), as per the audited standalone and consolidated financial statements of the Company as at March 31, 2024, respectively, which is within the statutory limit of 10% of the total paid-up equity capital and free reserves (including securities premium) of the Company as at March 31, 2024 and June 30, 2024 is in compliance with the Buyback Regulations and the Companies Act.

- 11.1 The funds for the implementation of the proposed Buyback will be sourced out of the free reserves (retained earnings) of the Company and/ or such other sources as may be permitted by Buyback Regulations or the Companies Act. Funds borrowed from banks and financial institutions, if any, will not be used for the Buyback.
- 11.2 The Company shall transfer from its free reserves and/ or such other sources as may be permitted by law, a sum equal to the nominal value of the Equity Shares bought back through the Buyback to the capital redemption reserve account and the details of such transfer shall be disclosed in its subsequent audited financial statements.

# 12. DETAILS OF ESCROW ACCOUNT AND AMOUNT DEPOSITED THEREIN AND FIRM FINANCIAL ARRANGEMENT

- 12.1 In accordance with Regulation 9(xi) of the Buyback Regulations, an escrow agreement has been entered into amongst the Company, Manager to the Buyback and the Escrow Agent on Thursday, July 18, 2024.
- In accordance with the Buyback Regulations and pursuant to the Escrow Agreement, an Escrow Account in the name and style "Aurobindo Pharma Limited Buyback Escrow Account" bearing account number 921020045210550 has been opened with the Escrow Agent, namely, Axis Bank Limited, having its registered office at Axis Bank Limited, Yes Bank House, Trishul, 3rd Floor, Opposite Samartheshwar Temple, Law Garden, Ellis Bridge, Ahmedabad 380 006, Gujarat, acting through its branch situated at 6-3-879/B, First Floor, G. Pullareddy Building, Greenlands, Begumpet Road, Hyderabad -500016. The Company has deposited an amount of ₹ 90,00,00,000/- (Rupees Ninety Crore only) in the Escrow Account in cash i.e., an amount equivalent to the aggregate of 25% of ₹ 100 Crore and 10% of the Buyback Size beyond ₹ 100 Crore, by way of security for fulfilment of its obligations under the Buyback, in compliance with the provisions under Regulation 9(xi) of the Buyback Regulations. In accordance with the Buyback Regulations, the Manager to the Buyback has been empowered to operate the Escrow Account.

- 12.3 The Company has adequate and firm financial resources to fulfil the obligations under the Buyback. G Pavan Kumar Reddy (Membership No. 229495), partner at G P M & Associates, Chartered Accountants (Firm Registration No. 015343S) having its office at Flat No. B-207, B-Block, Galaxy Apartments, Survey No. 74, Kondapur Village, Serilingampally Mandal, Hyderabad 500 084, has certified through its certificate dated Friday, July 19, 2024 ("Certificate") that the Company has firm and adequate financial arrangements for meeting its obligations arising out of the Buyback.
- 12.4 Based on the Certificate, the Manager to the Buyback confirms that it is satisfied that firm arrangements for fulfilling the obligations under the Buyback are in place and that the Company has the ability to implement the Buyback in accordance with the Buyback Regulations.

#### 13. CAPITAL STRUCTURE AND SHAREHOLDING PATTERN

13.1 The present capital structure of the Company as on date of this Letter of Offer is as follows:

Parameters		Pre-Buyback
Authorised Share Capital		
4,54,29,93,820 Equity Shares of ₹ 1/- each		₹ 4,54,29,93,820
2,12,10,000 preference shares of ₹ 100/- each		₹ 2,12,10,00,000
	Total	₹ 6,66,39,93,820
Issued, Subscribed and Fully Paid-Up Share Capital		
58,59,38,609 Equity Shares of ₹ 1/- each		₹ 58,59,38,609
	Total	₹ 58,59,38,609

13.2 Assuming full acceptance in the Buyback of 51,36,986 Equity Shares, the capital structure post Buyback would be as follows:

Parameters		Post-Buyback <sup>(1)</sup>
Authorised Share Capital		
4,54,29,93,820 Equity Shares of ₹ 1/- each		₹ 4,54,29,93,820
2,12,10,000 preference shares of ₹ 100/- each		₹ 2,12,10,00,000
	Total	₹ 6,66,39,93,820
Issued, Subscribed and Fully Paid-Up Share Capital		
58,08,01,623 Equity Shares of ₹ 1/- each		₹ 58,08,01,623
	Total	₹ 58,08,01,623

**Note**: (1) Post-Buyback issued, subscribed and paid-up capital may differ depending upon the actual number of Equity Shares bought back.

- 13.3 As on the date of this Letter of Offer, the Equity Shares are fully paid up and there are no partly paid-up equity shares.
- 13.4 As on the date of this Letter of Offer, there are no convertible debentures or preference shares or any other convertible instruments of the Company.
- 13.5 The Company has not undertaken any buyback programmes in the last 3 (three) years.
- 13.6 The shareholding pattern of the Company before the Buyback (i.e., as on the Record Date), and after the Buyback (assuming full acceptance of 51,36,986 Equity Shares in the Buyback), is as follows:

Category of Shareholder	No. of Equity Shares pre- Buyback	% to the existing equity share capital	No. of Equity Shares post Buyback <sup>(1)</sup>	% to the Post Buyback equity share capital
Promoter & Promoter Group and persons acting in concert (A)	30,35,15,471	51.80	30,12,29,025	51.86
Shareholding of non- promoters (B)	28,24,23,138	48.20		
Foreign Investors (OCBs/ FIIs/ NRIs/ Non-residents/ Non-domestic companies)	10,17,78,928	17.37	27,95,72,598	48.14
Indian Financial Institutions/ Banks/ Mutual Funds/ Government Companies	14,14,24,962	24.14		
Others (Individuals, Bodies Corporate, Employees, etc.)	3,92,19,248	6.69		
Total (A+B)	58,59,38,609	100.00	58,08,01,623	100.00

**Note**: (1) Assuming the full Acceptance of 51,36,986 Equity Shares in the Buyback in accordance with the Buyback Entitlement for all Eligible Shareholders. However, the post-Buyback shareholding pattern may differ depending upon the actual number of Equity Shares bought back.

- 13.7 The aggregate shareholding in the Company of (a) the members of the Promoter & Promoter Group and persons in control of the Company; (b) the director(s)/ trustee(s) of the companies/ trusts forming part of the Promoter & Promoter Group; and (c) the directors (other than members of the Promoter & Promoter Group) and key managerial personnel, as on the date of the Public Announcement, is as follows:
  - 13.7.1 Aggregate shareholding of the members of the Promoter & Promoter Group and persons in control of the Company in the Company:

Sr. No.	Name	Category	Number of Equity Shares held	% shareholding
1.	Venkata Ramprasad Reddy Penaka	Promoter	1,80,00,000	3.07
2.	K Nityananda Reddy	Promoter	2,53,59,572	4.33
	Total (A)		4,33,59,572	7.40
3.	M Sivakumaran	Promoter Group	1,44,91,360	2.47
4.	Rajeshwari Kambham	Promoter Group	18,25,500	0.31
5.	Suneela Rani Penaka	Promoter Group	1,30,000	0.02
6.	Prasada Reddy Kambham	Promoter Group	3,01,156	0.05
7.	K Suryaprakash Reddy	Promoter Group	7,380	0.00
8.	M Sumanth Kumar Reddy	Promoter Group	16,00,000	0.27
9.	Kirthi Reddy Kambam	Promoter Group	2,02,50,000	3.46
10.	Kambam Spoorthi	Promoter Group	70,00,000	1.19
11.	Penaka Neha Reddy	Promoter Group	Nil	Nil
12.	Trident Chemphar Limited	Promoter Group	7,89,537	0.13
13.	Axis Clinicals Limited	Promoter Group	6,58,000	0.11
14.	RPR Sons Advisors Private Limited, Suneela Rani Penaka (joint holding)	Promoter Group	19,63,76,250	33.51

15.	Axis	Clinicals	Limited,	Promoter Group	1,67,26,716	2.85
	Triden	t Chemphar	Limited,			
	RPR S	ons Advisor	s Private			
	Limited	d (joint holdi	ng)			
		То	tal (B)	26,01,55,899	44.40	
	•	Tota	al (A+B)	30,35,15,471	51.80	

13.7.2 Aggregate shareholding of the director(s)/ trustee(s) of the companies/ trusts forming part of the Promoter & Promoter Group in the Company:

Sr No	Name of Company/ Trust forming part of the Promoter & Promoter Group	Name of the Director/ Trustee	No. of Equity Shares	% shareholding
1.	Axis Clinicals Limited	Sannareddy Sadananda Reddy	2,00,000	0.03
		Jayachandra Reddy Atluri	30,680	0.01
2.	Trident Chemphar Limited	Sannareddy Sadananda Reddy	2,00,000	0.03
3.	RPR Sons Advisors Private Limited	Venkata Ramprasad Reddy Penaka	1,80,00,000	3.07
		Suneela Rani Penaka	1,30,000	0.02

13.7.3 Aggregate shareholding of the directors (other than the members of the Promoter & Promoter Group) and key managerial personnel of the Company in the Company:

Sr. No.	Name	Number of Equity Shares held	% shareholding	
1.	S. Subramanian	7,126	Negligible	
2.	Mettu Madan Mohan Reddy	2,010	Negligible	
	Total	9,136	Negligible	

13.8 No Equity Shares or other specified securities in the Company were either purchased or sold by (a) the members of the Promoter & Promoter Group and persons who are in control of the Company; (b) the director(s)/ trustee(s) of the companies/ trusts forming part of the Promoter & Promoter Group in the Company; (c) directors and key managerial personnel of the Company, during the 6 (Six) months preceding the date of the Board Meeting, and during the 12 (Twelve) months preceding the date of the Public Announcement, except as follows:

Name	Aggregate no. of Equity Shares allotted / transferred	Nature of transaction	Maximum price per Equity Share (₹)*	Date of maximum price	Minimum price per Equity Share (₹)	Date of minimum price
Kirthi Reddy	2,00,000	Sale	1,284.80	June 7,	1,267.00	June 7,
Kambam				2024		2024
Sannareddy	5,000	Sale	927.00	Septembe	927.00	September
Sadananda				r 29, 2023		29, 2023
Reddy	7,000	Sale	1,053.00	November	1,033.65	November
				22, 2023		22, 2023

	3,000	Sale	1,040.50	December	1,040.50	December
				4, 2023		4, 2023
	10,000	Sale	1,080.00	December	1,066.00	December
				20, 2023		20, 2023
	5,000	Sale	1,091.50	December	1,088.00	December
				28, 2023		28, 2023
	5,000	Sale	1,071.00	March 27,	1,071.00	March 27,
				2024		2024
	5,000	Sale	1,089.00	March 28,	1,089.00	March 28,
				2024		2024
	10,000	Sale	1,260.00	June 5,	1,248.40	June 5,
				2024		2024
	20,000	Sale	1,210.00	June 28,	1,200.00	June 28,
				2024		2024
Jayachandra	500	Sale	1,261.45	June 11,	1,261.25	June 11,
Reddy Atluri				2024		2024
Venkata	40	Purchase	1,038.20	December	1,038.20	December
Krishna				14, 2023		14, 2023
Anjaneya	40	Sale	1,084.55	December	1,084.50	December
Prasad				29, 2023		29, 2023
Marthy	90	Purchase	1,025.00	February	1,025.00	February
				12, 2024		12, 2024
	90	Sale	1,125.00	April 4,	1,125.00	April 4,
				2024		2024

<sup>\*</sup> Excluding transaction costs such as brokerage, STT etc.

- 13.9 Assuming response to the Buyback is to the extent of 100% (full acceptance) from all the Eligible Shareholders up to their Entitlement including all members of the Promoter & Promoter Group who have expressed their intention to participate, the aggregate shareholding of the members of the Promoter & Promoter Group, post Buyback may increase to 51.86% from 51.80%.
- 13.10 There is no ongoing scheme of amalgamation or compromise or arrangement pursuant to the provisions of the Companies Act, as on date.

#### 14. BRIEF INFORMATION OF THE COMPANY

- 14.1 The Company was incorporated on December 26, 1986 as a private limited company under the provisions of the Companies Act, 1956 and converted into a public limited company with effect from April 30, 1992. The registered office of the Company is presently situated at Plot No. 2, Maithrivihar, Behind Maitrivanam, Ameerpet, Hyderabad 500 038.
- 14.2 The Equity Shares were listed at BSE (scrip code: 524804) on April 06, 1995, and NSE (symbol: AUROPHARMA) on July 19, 2000. The ISIN of the Equity Shares is INE406A01037.
- 14.3 The paid-up equity share capital of the Company for the year ended March 31, 2024 was ₹ 58,59,38,609 and total free reserves for the year ended March 31, 2024 was ₹ 1,94,805.0 million, on a standalone basis and ₹ 2,80,324.7 million on a consolidated basis.

## 14.4 History and Growth of Business:

The Company manufactures and markets generic formulations, specialty formulations (branded drugs) and Active Pharmaceutical Ingredients (API) and has emerged as one of the prominent players in the global pharmaceutical landscape. The Company's corporate office is situated in Hyderabad and it has 29 manufacturing facilities for its API and formulations business.

#### 14.5 Financial Growth:

For the financial years ended March 31, 2024, March 31, 2023 (based on the financial statements presented in the financial year ended on March 31, 2024 restating the March 31, 2023 numbers) and March 31, 2022, the Company recorded, on a standalone basis, total income of ₹ 1,12,617.0 million, ₹ 89,009.2 million and ₹ 1,19,581.3 million, respectively. The net profit after tax for the financial years ended March 31, 2024, March 31, 2023 (based on the financial statements presented in the financial year ended on March 31, 2024 restating the March 31, 2023 numbers) and March 31, 2022 was ₹ 19,541.4 million, ₹ 12,271.1 million and ₹ 14,547.1 million, respectively. For the financial years ended March 31, 2024, March 31, 2023 and March 31, 2022, the Company recorded, on a consolidated basis, total income of ₹ 2,95,592.5 million, ₹ 2,51,459.7 million and ₹ 2,37,758.4 million respectively. The net profit after tax (attributable to owners of the Company before other comprehensive income) on a consolidated basis for the financial years ended March 31, 2024, March 31, 2023 and March 31, 2022 was ₹ 31,729.7 million, ₹ 19,275.0 million and ₹ 26,481.5 million, respectively. For further details on financial information about the Company for the financial years ended March 31, 2024, March 31, 2023 and March 31, 2022, please refer to paragraph 15 (Financial Information about the Company) of this Letter of Offer.

# 14.6 Following is the equity share capital history of the Company since inception:

Date of allotment	No. of Equity Shares	Face Value per Equity Share (₹)	Issue Price per Equity Share (₹)	Nature of Consideration	Cumulative no. of Equity Shares	Cumulative equity share capital (₹)	Nature of Issue
December 26, 1986	20	100.00	100.00	Cash	20	2,000	Subscription to MOA
November 25, 1987	9,980	100.00	100.00	Cash	10,000	10,00,000	Preferential issue to promoters
March 30, 1989	7,000	100.00	100.00	Cash	17,000	17,00,000	Preferential issue to promoters
March 31, 1990	5,750	100.00	100.00	Cash	22,750	22,75,000	Preferential issue to promoters
November 18, 1991	1,250	100.00	100.00	Cash	24,000	24,00,000	Preferential issue to promoters
March 30, 1992	5,500	100.00	100.00	Cash	29,500	29,50,000	Preferential issue to promoters
April 30, 1992	2,65,500	10.00	-	Stock split	2,95,000	29,50,000	Stock split of ₹ 100/- to ₹ 10/-
May 04, 1992	2,95,000	10.00	-	NA	5,90,000	59,00,000	Bonus issue in the ratio of 1:1
December 31, 1992	15,000	10.00	10.00	Cash	6,05,000	60,50,000	Preferential issue to promoters
March 31, 1993	9,050	10.00	25.00	Cash	6,14,050	61,40,500	Preferential issue to promoters
June 08, 1993	12,28,100	10.00	-	NA	18,42,150	1,84,21,500	Bonus issue in the ratio of 2:1
September 30, 1993	7,000	10.00	30.00	Cash	18,49,150	1,84,91,500	Preferential issue to promoters
October 30, 1993	850	10.00	30.00	Cash	18,50,000	1,85,00,000	Preferential issue to promoters
April 26, 1994	72,500	10.00	30.00	Cash	19,22,500	1,92,25,000	Preferential issue to promoters
April 27, 1994	12,25,000	10.00	150.00	Cash	31,47,500	3,14,75,000	Preferential issue to non-promoters
April 30, 1994	2,500	10.00	30.00	Cash	31,50,000	3,15,00,000	Preferential issue to a director
November 02, 1994	11,02,500	10.00	-	NA	42,52,500	4,25,25,000	Bonus issue in the ratio of 7:20

Date of allotment	No. of Equity Shares	Face Value per Equity Share (₹)	Issue Price per Equity Share (₹)	Nature of Consideration	Cumulative no. of Equity Shares	Cumulative equity share capital (₹)	Nature of Issue
March 27, 1995	4,72,500	10.00	-	Other than Cash	47,25,000	4,72,50,000	Allotment to the shareholders of Chaitanya Organics Private Limited pursuant to a scheme of amalgamation
November 27, 1998	47,25,000	10.00	-	NA	94,50,000	9,45,00,000	Bonus issue in the ratio of 1:1
September 10, 1999	5,51,000	10.00	490.00	Cash	1,00,01,000	10,00,10,000	Preferential issue to non-promoters
April 07, 2000	1,00,01,000	10.00	-	NA	2,00,02,000	20,00,20,000	Bonus issue in the ratio of 1:1
July 05, 2001	1,98,000	10.00	-	Other than Cash	2,02,00,000	20,20,00,000	Allotment to shareholders of Sri Chakra Remedies Limited pursuant to a scheme of amalgamation
March 20, 2002	4,00,000	10.00	226.00	Cash	2,06,00,000	20,60,00,000	Preferential issue to promoters
March 27, 2002	70,000	10.00	226.00	Cash	2,06,70,000	20,67,00,000	Preferential issue to promoters
April 12, 2002	5,30,000	10.00	226.00	Cash	2,12,00,000	21,20,00,000	Preferential issue to promoters
April 14, 2002	10,00,000	10.00	226.00	Cash	2,22,00,000	22,20,00,000	Preferential issue to non-promoters
September 27, 2002	10,50,000	10.00	226.00	Cash	2,32,50,000	23,25,00,000	Preferential issue to non-promoters
September 04, 2003	9,50,000	10.00	226.00	Cash	2,42,00,000	24,20,00,000	Preferential issue to promoters
October 31, 2003	2,42,00,000	5.00	-	NA	4,84,00,000	24,20,00,000	Stock split of ₹ 10/- to ₹ 5/-
February 18, 2004	23,70,000	5.00	375.00	Cash	5,07,70,000	25,38,50,000	Preferential issue to non-promoters
July 15, 2005	10,00,000	5.00	375.00	Cash	5,17,70,000	25,88,50,000	Preferential issue to promoters
August 02, 2005	15,00,000	5.00	375.00	Cash	5,32,70,000	26,63,50,000	Preferential issue to promoters
July 31, 2006	24,661	5.00	362.60	Cash	5,32,94,661	26,64,73,305	Conversion of stock options
December 15, 2006	53,976	5.00	362.60	Cash	5,33,48,637	26,67,43,185	Conversion of stock options
July 11, 2007	3,74,046	5.00	522.04	Cash	5,37,22,683	26,86,13,415	Conversion of foreign currency convertible bonds ("FCCB")
July 31, 2007	16,638	5.00	362.60	Cash	5,37,39,321	26,86,96,605	Conversion of stock options
December 10, 2007	25,947	5.00	362.60	Cash	5,37,65,268	26,88,26,340	Conversion of stock options
November 04, 2009	83,121	5.00	522.04	Cash	5,38,48,389	26,92,41,945	Conversion of FCCB
December 15, 2009	1,50,030	5.00	362.60	Cash	5,39,98,419	26,99,92,095	Conversion of stock options
January 06, 2010	11,42,920	5.00	522.04	Cash	5,51,41,339	27,57,06,695	Conversion of FCCB
February 01, 2010	50,869	5.00	522.04	Cash	5,51,92,208	27,59,61,040	Conversion of FCCB

Date of allotment	No. of Equity Shares	Face Value per Equity Share (₹)	Issue Price per Equity Share (₹)	Nature of Consideration	Cumulative no. of Equity Shares	Cumulative equity share capital (₹)	Nature of Issue
February 24, 2010	1,33,491	5.00	522.04	Cash	5,53,25,699	27,66,28,495	Conversion of FCCB
March 12, 2010	4,03,138	5.00	522.04	Cash	5,57,28,837	27,86,44,185	Conversion of FCCB
April 20, 2010	3,32,485	5.00	522.04	Cash	5,60,61,322	28,03,06,610	Conversion of FCCB
May 18, 2010	2,25,592	5.00	522.04	Cash	5,62,86,914	28,14,34,570	Conversion of FCCB
June 08, 2010	1,66,243	5.00	522.04	Cash	5,64,53,157	28,22,65,785	Conversion of FCCB
July 19, 2010	27,007	5.00	362.60	Cash	5,64,80,164	28,24,00,820	Conversion of stock options
July 27, 2010	14,54,625	5.00	522.04	Cash	5,79,34,789	28,96,73,945	Conversion of FCCB
August 02, 2010	2,86,769	5.00	522.04	Cash	5,82,21,558	29,11,07,790	Conversion of FCCB
December 30, 2010	2,700	5.00	362.60	Cash	5,82,24,258	29,11,21,290	Conversion of stock options
February 11, 2011	23,28,97,032	1.00	-	NA	29,11,21,290	29,11,21,290	Stock split of ₹ 5/- to ₹ 1/-
January 09, 2013	90,000	1.00	91.60	Cash	29,12,11,290	29,12,11,290	Conversion of stock options
January 09, 2014	1,27,500	1.00	91.60	Cash	29,13,38,790	29,13,38,790	Conversion of stock options
March 10, 2014	68,231	1.00	187.40	Cash	29,14,07,021	29,14,07,021	Conversion of stock options
March 10, 2014	50,000	1.00	200.70	Cash	29,14,57,021	29,14,57,021	Conversion of stock options
October 07, 2014	7,700	1.00	187.40	Cash	29,14,64,721	29,14,64,721	Conversion of stock options
January 17, 2015	3,31,200	1.00	91.60	Cash	29,17,95,921	29,17,95,921	Conversion of stock options
March 12, 2015	1,08,354	1.00	187.40	Cash	29,19,04,275	29,19,04,275	Conversion of stock options
March 12, 2015	3,000	1.00	161.30	Cash	29,19,07,275	29,19,07,275	Conversion of stock options
March 12, 2015	75,000	1.00	200.70	Cash	29,19,82,275	29,19,82,275	Conversion of stock options
July 22, 2015	29,19,82,275	1.00	-	NA	58,39,64,550	58,39,64,550	Bonus issue in the ratio of 1:1
January 19, 2016	8,55,000	1.00	45.80	Cash	58,48,19,550	58,48,19,550	Conversion of stock options
March 09, 2016	3,50,036	1.00	93.70	Cash	58,51,69,586	58,51,69,586	Conversion of stock options
March 09, 2017	6,97,823	1.00	93.70	Cash	58,58,67,409	58,58,67,409	Conversion of stock options
March 30, 2017	15,000	1.00	80.65	Cash	58,58,82,409	58,58,82,409	Conversion of stock options
March 28, 2018	17,200	1.00	93.70	Cash	58,58,99,609	58,58,99,609	Conversion of stock options
March 28, 2018	8,000	1.00	80.65	Cash	58,59,07,609	58,59,07,609	Conversion of stock options
March 27, 2019	8,000	1.00	80.65	Cash	58,59,15,609	58,59,15,609	Conversion of stock options
August 07, 2019	23,000	1.00	80.65	Cash	58,59,38,609	58,59,38,609	Conversion of stock options

# 14.7 The details of the Board of Directors of the Company as on the date of Public Announcement is as follows:

Name, Occupation,	Designation	Qualifications	Date of	Other Directorships
Age and DIN	<b>3</b>	•	Appointment/	
			re-	
			appointment	
Mangalam	Chairman &	Science graduate from	April 01, 2024	1. Ambuja Cements
Ramasubramanian	Independent Director	University of Madras		Limited
Kumar				2. Bank of India
Occupation: Retired				3. Aurobindo Pharma
from LIC				USA Inc
Age: 62 years				4. Cholamandalam
<b>DIN</b> : 03628755				Investment and
				Finance Company
I/ Nitrananada Daddu	Vice Chairman 0	Destavaduata in Caianaa	December 20	Limited
K Nityananda Reddy Occupation:	Vice Chairman & Managing Director	Postgraduate in Science	December 26, 1986	Raidurgam     Developers Limited
Industrialist	ivialiaging Director		1900	2. APL Healthcare
Age: 66 years				Limited
<b>DIN</b> : 01284195				3. Pattancheru
<b>5.11.</b> 0120 1133				Envirotech Ltd.
				4. Apitoria Pharma
				Private Limited
				5. Aurobindo Pharma
				Foundation
				6. Aurobindo
				Antibiotics Private
				Limited
				7. Lyfius Pharma
				Private Limited
				8. Qule Pharma
				Private Limited
				9. All Pharma
				(Shanghai) Trading Co Ltd, China
Mettu Madan Mohan	Whole-time Director	Postgraduate in Science	Santambar 19	·
Reddy	Whole-time birector	r ostgraddate in science	2006	Specialities Limited
Occupation:			2000	2. Pravesha Industries
Industrialist				Private Limited
Age: 64 years				3. Aurozest Private
<b>DIN</b> : 01284266				Limited
				4. Eugia Sez Private
				Limited
				5. Curateq Biologics
				Private Limited
				6. Eugia Steriles
				Private Limited
				7. Auro Vaccines
				Private Limited
				8. Theranym Biologics
				Private Limited
				9. Aurobindo Pharma
				USA Inc

Name, Occupation,	Designation	Qualifications	Date of	Other Directorships
Age and DIN			Appointment/	
			re-	
			appointment	
Venkata Ramprasad Reddy Penaka Occupation: Industrialist Age: 66 years DIN: 01284132	Non-executive Director	Postgraduate in Commerce	December 26, 1986	<ol> <li>Penaka Pharma (India) Private Limited</li> <li>RPR Sons Advisors Private Limited</li> <li>Aurovida Farmaceuticos SA Mexico</li> <li>Aurobindo Pharma USA Inc</li> </ol>
Penaka Sarath	Non-executive	Graduate in Business	Sentember 27	
Chandra Reddy Occupation: Industrialist Age: 39 years DIN: 01628013	Director	Administration	2007	<ol> <li>FVN Chemphal FVI. Ltd</li> <li>STEPS Therapeutics Co. Ltd., Thailand,</li> <li>Shreas Industries Limited</li> <li>Aurobindo Pharma Foundation</li> <li>ALV Shamshabad Private Limited</li> </ol>
Savita Mahajan	Independent Director	Degree in Economics		
Occupation: Retired from private service Age: 65 years DIN: 06492679		from Delhi University and MBA from IIM, Ahmedabad	2017	Finance Corporation Limited 2. Bhagirath Resurgence Private Limited
				<ol> <li>Gemini Edibles &amp; Fats India Limited</li> <li>Avanse Financial Services Limited</li> </ol>
Girish Paman Vanvari Occupation: Consultant/ Professional Age: 52 years DIN: 07376482	Independent Director		November 05, 2020	Limited 2. Tarsons Products Limited 3. Rategain Travel Technologies Limited 4. Kolte-Patil Developers Limited 5. Himadri Speciality Chemical Limited 6. Blue Jet Healthcare Limited
Santanu Mukherjee Occupation: Retired from banking sector Age: 67 years DIN: 07716452	Independent Director	B.Sc. Honors (Chemistry and Mathematics) from Presidency College under Kolkata University and CAIIB from the Indian Institute of Bankers.	February 09, 2023	<ol> <li>NACL Industries Limited</li> <li>Suven Life Sciences Limited</li> <li>Rainbow Children's Medicare Limited</li> <li>Bandhan Bank Limited</li> </ol>

Name, Occupation,	Designation	Qualifications	Date of	Other Directorships
Age and DIN			Appointment/ re-	
			appointment	
				<ul> <li>Muthoot Housing Finance Company Limited</li> <li>Sumedha Fiscal Services Ltd</li> <li>Rainbow Speciality Hospitals Private Limited</li> </ul>
Dr. Satakarni Makkapati Occupation: Private Service Age: 43 years DIN: 09377266	Non-executive Director	Masters' in business administration (MBA) from the IMD Business School at Lausanne (Switzerland), Doctor of Philosophy (PhD) in faculty of Physical Sciences and Engineering from the Russell Group at the University of Manchester (UK) and a bachelor's degree in chemical engineering	November 09, 2023	<ol> <li>Theranym Biologics         Private Limited</li> <li>Apitoria Pharma         Private Limited</li> <li>Auro Peptides         Limited</li> <li>Auro Vaccines         Private Limited</li> </ol>
Dr. (Mrs.) Deepali Pant Joshi Occupation: Retired from RBI Age: 66 years DIN: 07139051	Independent Director	Master's degree in arts, Law graduate from the University of Lucknow and also completed the Harvard University Harvard Asia Centre Post-doctoral work in Finance and Economics (on secondment from the RBI)	February 10, 2024	<ol> <li>TVS Motor Company Limited</li> <li>Ambadi Enterprises Limited</li> <li>Coromandel International Limited</li> <li>Pahal Financial Services Private Limited</li> <li>Kan And More Private Limited</li> <li>Satya Microcapital Limited</li> <li>TVS Motors (Singapore) Pte Ltd.</li> </ol>

14.8 The details of changes in Board of Directors during the last 3 (three) years preceding the date of the Public Announcement are as under:

Sr No	Name	Appointment/ Re- appointment/ Resignation/ Cessation	Effective Date	Reason
1.	Mangalam Ramasubramanian Kumar	Appointment	April 01, 2024	Appointment as an Independent Director of the Company not liable to retire by rotation, for a period of 3 (three) consecutive years.
2.	K. Ragunathan	Cessation	April 01, 2024	Ceased to be Independent Director upon completion of his second term.

Sr No	Name	Appointment/ Re- appointment/ Resignation/	Effective Date	Reason
110		Cessation		
3.	Dr. Avnit Bimal Singh	Resignation	February 11, 2024	Resigned as Independent Director.
4.	Deepali Pant Joshi	Appointment	February 10, 2024	Appointment as an Independent Director of the Company not liable to retire by rotation, for a period of 2 (two) consecutive years.
5.	Satakarni Makkapati	Appointment	November 09, 2023	Appointment as a non-executive and non-independent Director of the Company, liable to retire by rotation.
6.	Sarath Chandra Reddy Penaka	Re-appointment	August 25, 2023	Retired by rotation and, being eligible, was re-appointed as non-executive director liable to retire by rotation.
7.	M. Sivakumaran	Resignation	August 25, 2023	Resigned as director and whole-time director.
8.	Santanu Mukherjee	Appointment	February 9, 2023	Appointment as an Independent Director of the Company for a period of 2 (two) consecutive years.
9.	Sarath Chandra Reddy Penaka	Cessation	November 12, 2022	Ceased to be a whole-time director and continues as non-executive director.
10.	Girish Paman Vanvari	Re-appointment	November 05, 2022	Reappointment as an Independent Director of the Company for a second term of 5 (five) consecutive years.
11.	K. Nithyananda Reddy	Re-appointment	August 02, 2022	Retired by rotation and, being eligible, was re-appointed as director liable to retire by rotation.
12.	Mettu Madan Mohan Reddy	Re-appointment	August 02, 2022	Retired by rotation and, being eligible, was re-appointed as director liable to retire by rotation.
13.	Sarath Chandra Reddy Penaka	Re-appointment	June 01, 2022	Re-appointment as whole-time director of the Company for a period of 3 (three) consecutive years.
14.	N. Govindarajan	Resignation	January 01, 2022	Resigned as director and Managing Director.
15.	K. Nityananda Reddy	Re-appointment	January 01, 2022	Redesignated as Vice Chairman & Managing Director.
16.	Sarath Chandra Reddy Penaka	Re-appointment	August 26, 2021	Retired by rotation and being eligible, was re-appointed as director liable to retire by rotation.
17.	M. Sivakumaran	Re-appointment	August 26, 2021	Retired by rotation and being eligible, was re-appointed as director liable to retire by rotation.

14.9 The Buyback will not result in any benefit to the members of the Promoter & Promoter Group, persons in control of the Company or any Directors of the Company except to the extent of the cash consideration received by them from the Company pursuant to their respective participation in the Buyback in their capacity as Equity Shareholders of the Company, and the change in their shareholding as per the response received in the Buyback, as a result of the extinguishment of Equity Shares which will lead to reduction in the equity share capital of the Company post Buyback.

14.10 No action has been taken by SEBI in the past against the members of the Promoter & Promoter Group or Directors of the Company, except as set out below:

Pursuant to SEBI's adjudication order dated September 23, 2019 (bearing reference no. Order/MC/VS/2019-20/4550-4556), certain members of the Promoter & Promoter Group of the Company (namely, Trident Chemphar Limited, Venkata Ramprasad Reddy Penaka, Suneela Rani Penaka and Prasada Reddy Kambham, together the "Concerned Promoters") had settled certain alleged non-compliances of the SEBI (Prohibition of Insider Trading) Regulations, 1992 and SEBI (Prohibition of Insider Trading) Regulations, 2015, pursuant to SEBI's settlement order dated May 6, 2020 (bearing reference no. SO/EFD-2/SD/346/MAY/2020) and in accordance with the SEBI (Settlement Proceedings) Regulations, 2018, as amended. However, vide an email dated October 23, 2020, SEBI informed the Concerned Promoters that there were some calculation errors in the settlement amounts (on account of the component of disgorgement (along with interest) being inadvertently omitted from the settlement terms) and asked the Concerned Promoters to make good the balance amounts. In this regard, the Concerned Promoters filed a writ petition before Hon'ble High Court of Telangana, at Hyderabad. The Hon'ble High Court vide its order dated November 18, 2020 had granted interim relief to the Concerned Promoters by way of suspension of the SEBI direction dated October 23, 2020, subject to deposit of ₹ 1.75 Crore with SEBI. Accordingly, the said amount was deposited by the Concerned Promoters and the matter is presently pending for disposal before Hon'ble High Court of Telangana, at Hyderabad.

#### 15. FINANCIAL INFORMATION ABOUT THE COMPANY

15.1 The brief audited financial information of the Company as extracted from the audited standalone results for the financial years ended March 31, 2024, March 31, 2023 (based on the financial statements presented in the financial year ended on March 31, 2024 restating the March 31, 2023 numbers) and March 31, 2022 are provided below:

(Amount in ₹ Million)

Particulars	Audited				
	For the year	For the year	For the year		
	ended on March	ended on March	ended on March		
	31, 2024 <sup>1</sup>	31, 2023 <sup>1</sup>	31, 2022		
Revenue from operations	1,06,456.4	84,570.0	1,12,871.4		
Other Income	6,160.6	4,439.2	6,709.9		
Total Income	1,12,617.0	89,009.2	1,19,581.3		
Total Expenses (excluding Interest, Depreciation & Amortisation, Tax)	84,216.0	69,520.9	98,137.4		
Interest	1,826.0	745.8	169.4		
Depreciation & Amortisation	2,545.8	2,432.6	4,152.6		
Profit Before Exceptional Items and Tax	24,029.2	16,309.9	17,121.9		
Exceptional Items	-	-	747.1		
Profit Before Tax	24,029.2	16,309.9	16,374.8		
Tax Expenses (including Deferred Tax)	5,028.2	3,888.2	1,827.7		
Net Profit After Tax from continuing operations and before share of profit of Joint Ventures	19,001.0	12,421.7	14,547.1		
Share of profit of Joint Ventures (Net of tax)	-	-	-		
Net Profit After Tax from continuing operations	19,001.0	12,421.7	14,547.1		
Net Profit from discontinued operations (Net of tax) <sup>2</sup>	540.4	-150.6	-		

Particulars	Audited			
	For the year ended on March 31, 2024 <sup>1</sup>	For the year ended on March 31, 2023 <sup>1</sup>	For the year ended on March 31, 2022	
Net Profit for the year including non- controlling interest	19,541.4	12,271.1	14,547.1	
Net Profit attributable to Owners of the Company	19,541.4	12,271.1	14,547.1	

#### Notes

- (1) The composite scheme of amalgamation under Sections 230-232 and other applicable provisions of the Companies Act, 2013 for amalgamation of Mviyes Pharma Ventures Private limited ("Mviyes") and Auronext Pharma Private limited ("Auronext") (together referred to as "Amalgamating Companies") with the Company ("the Scheme") was sanctioned by Hon'ble National Company law Tribunal (NCLT) Hyderabad bench vide order dated April 29, 2024. The Scheme has become effective on May 17, 2024 upon filing of the certified copy of the orders passed by NCLT with the relevant Registrar of Companies. In terms of the Scheme, all the assets, liabilities, reserves and surplus of the Amalgamating Companies have been transferred to and vested in the Company. The amalgamation has been accounted under the 'pooling of interests' method in accordance with Appendix C of Indian Accounting Standard ('Ind AS') 103 'Business Combinations' at the carrying value of the assets and liabilities of the Amalgamating Companies as included in the financial statements of the respective Amalgamating Company. Accordingly, FY2022-23 financials have been restated to give effect of the amalgamation from the beginning of the year.
- (2) The Board of Directors of the Company at its meeting held on February 9, 2023 and April 1, 2023 approved the transfer of certain Active Pharmaceutical Ingredients (API) business units to its wholly owned subsidiary, Apitoria Pharma Private Limited (formerly known as Auro Pharma India Private limited) on a going concern basis by way of slump sale, subject to receipt of requisite regulatory approvals. Consequent to receipt of such approvals, the Company transferred the aforementioned API units to Apitoria Pharma Private Limited with effect from October 1, 2023. Accordingly, disclosures as required under Indian Accounting Standard (Ind AS) 105 "Non-Current Assets Held for Sale and Discontinued Operations", in the standalone financial results for FY2023-2024 and FY2022-2023 have been suitably presented.

(Amount in ₹ Million)

	Audited				
Particulars	As at	As at	As at		
	March 31, 2024	March 31, 2023	March 31, 2022		
Equity Share capital	585.9	585.9	585.9		
Other Equity	1,94,805.0	1,77,917.1	1,69,957.7		
Net Worth	1,95,390.9	1,78,503.0	1,70,543.6		
Debt, excluding working capital loans	-	-	-		
Total Debt	28,178.4	41,425.7	18,186.2		
- Secured loans	14,319.9	19,227.8	2,887.5		
- Unsecured loans	13,858.5	22,197.9	15,298.7		

(Amount in ₹, except certain ratios)

	Audited				
Key Ratios	For the year ended on March 31, 2024	For the year ended on March 31, 2023	For the year ended on March 31, 2022		
Basic and Diluted earnings per share from Continuing operations	32.43	21.20	24.83		
Basic and Diluted earnings per share from Total operations	33.35	20.94	24.83		
Book value per share	333.47	304.64	291.06		
Total Debt / Equity Ratio	0.14	0.23	0.11		
Return on Net Worth (%)	10.0%	6.9%	8.5%		

The key ratios have been computed as below:

Key Ratios	Basis
Basic Earnings per share	PAT / weighted average number of equity shares outstanding

Diluted Earnings per share	PAT / weighted average number of equity shares
Diluted Larinings per share	outstanding
Book value per share	Net worth / Total number of outstanding shares
Total Debt-Equity Ratio	Total Debt <sup>1</sup> / Net worth
Return on Net Worth excluding	Profit After Tax (PAT) / Net worth
revaluation reserves (%)	
Not Worth	Paid-up equity share capital + security premium +
Net Worth	general reserve + retained earnings of the Company

#### Notes:

- (1) Total Debt = Current Borrowings + Non-Current Borrowings + Current Portion of Non-current borrowings
- 15.2 The brief audited financial information of the Company as extracted from the audited consolidated results for the financial years ended March 31, 2024, March 31, 2023 and March 31, 2022 are provided below:

(Amount in ₹ Million)

Particulars	Audited				
	For the year	For the year	For the year		
	ended on March	ended on March	ended on March		
	31, 2024	31, 2023	31, 2022		
Revenue from operations	2,90,018.7	2,48,553.8	2,34,554.9		
Other Income	5,573.8	2,905.9	3,203.5		
Total Income	2,95,592.5	2,51,459.7	2,37,758.4		
Total Expenses (excluding Interest, Depreciation & Amortisation, Tax)	2,31,588.7	2,11,367.4	1,90,687.2		
Interest	2,897.1	1,404.8	486.4		
Depreciation & Amortisation	15,216.6	12,445.8	11,265.2		
Profit Before Exceptional Items and Tax	45,890.1	26,241.7	35,319.6		
Exceptional Items	1,918.6	-	1,279.7		
Profit Before Tax	43,971.5	26,241.7	34,039.9		
Tax Expenses (including Deferred Tax)	12,110.2	6,848.5	7,256.3		
Net Profit After Tax before share of profit of Joint Ventures	31,861.3	19,393.2	26,783.6		
Share of profit of Joint Ventures (Net of tax)	-171.6	-116.7	-312.5		
Net Profit After Tax from continuing operations	31,689.7	19,276.5	26,471.1		
Net Profit from discontinued operations (Net of tax)	-	-	-		
Net Profit for the year including non- controlling interest	31,689.7	19,276.5	26,471.1		
Net Profit attributable to Owners of the Company	31,729.7	19,275.0	26,481.5		

(Amount in ₹ Million)

			Annount in Aminion,			
	Audited					
Particulars	As at	As at	As at			
	March 31, 2024	March 31, 2023	March 31, 2022			
Equity Share capital	585.9	585.9	585.9			
Other Equity	2,80,324.7	2,51,414.5	2,37,500.4			
Net Worth	2,80,910.6	2,52,000.4	2,38,086.3			
Debt, excluding working capital loans	22,371.0	6,968.0	5,078.1			
Total Debt	63,152.2	48,615.2	23,727.7			
- Secured loans	39,683.7	25,573.7	5,436.9			
- Unsecured loans	23,468.5	23,041.5	18,290.8			

(Amount in ₹, except certain ratios)

	Audited					
Key Ratios	For the year ended on	For the year ended on	For the year ended on			
	March 31, 2024	March 31, 2023	March 31, 2022			
Basic earnings per share	54.16	32.90	45.19			
Diluted earnings per share	54.16	32.90	45.19			
Book value per share	479.42	430.08	406.33			
Total Debt / Equity Ratio	0.22	0.19	0.10			
Return on Net Worth (%)	11.3%	7.6%	11.1%			

The key ratios have been computed as below:

Key Ratios	Basis
Basic Earnings per share	PAT / weighted average number of equity shares outstanding
Diluted Earnings per share	PAT / weighted average number of equity shares outstanding
Book value per share	Net worth / Total number of outstanding shares
Total Debt-Equity Ratio	Total Debt <sup>1</sup> / Net worth
Return on Net Worth excluding revaluation reserves (%)	Profit After Tax (PAT) / Net worth
Net Worth	Paid-up equity share capital + security premium + general reserve + retained earnings of the Company

#### Notes

- (1) Total Debt = Current Borrowings + Non-Current Borrowings + Current Portion of Non-current borrowings
- 15.3 The Company shall comply with the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended, wherever and if applicable. The Company hereby declares that it has complied with and will comply with Sections 68, 69 and 70 and other applicable provisions of the Companies Act, as may be applicable to the Buyback.

#### 16. STOCK MARKET DATA

- 16.1 The Shares of the Company are listed on BSE and NSE. The Equity Shares are currently traded under the scrip code 524804 at BSE and trading code AUROPHARMA at NSE.
- 16.2 The high, low and average market prices in preceding 3 (three) financial years and the monthly high, low and average market prices for the 6 (six) months preceding the date of the Public Announcement, and the corresponding volumes on BSE and NSE are given below:

#### BSE:

	DJL.							
Period	High# (₹)	Date of High	Number of Equity Shares traded on that date	- ,	Date of Low	Number of Equity Shares on that date	Average Price* (₹)	Total volume traded of Equity Shares in the period (number of Equity Shares)
			Pr	eceding 3 (	three) Years			
April 1, 2023 to March 31, 2024	1,177.00	January 30, 2024	32,287	517.00	April 03, 2023	40,86,8	873.07	22,75,90,27
April 1, 2022 to March 31, 2023	714.60	April 06, 2022	48,04,9	397.30	February 03, 2023	38,25,7	518.54	22,67,35,56
April 1, 2021 to March 31, 2022	1,063.75	May 11, 2021	13,11,71	584.20	March 07, 2022	18,02,44	789.74	34,41,27,57

Period	High <sup>#</sup> (₹)	Date of High	Number of Equity Shares traded on that date	Low <sup>#</sup> (₹)	Date of Low	Number of Equity Shares on that date	Average Price* (₹)	Total volume traded of Equity Shares in the period (number of Equity Shares)
			Pr	eceding 6	(six) months			
June 1, 2024 to June 30, 2024	1,292.15	June 07, 2024	13,26,32	1,109.30	June 04, 2024	3,84,63	1234.59	65,09,32
May 1, 2024 to May 31, 2024	1,245.60	May 24, 2024	5,44,59	1,097.50	May 07, 2024	2,44,07	1178.74	1,11,53,29
April 1, 2024 to April 30, 2024	1,175.60	April 30, 2024	4,48,67	1,066.05	April 15, 2024	9,07,81	1111.787	1,15,99,84
March 1, 2024 to March 31, 2024	1,113.85	March 04, 2024	10,84,42	985.00	March 13, 2024	3,85,03	1042.39	81,00,67
February 1, 2024 to February 29, 2024	1,153.75	February 01, 2024	25,56,59	959.05	February 14, 2024	25,95,12	1030.32	3,82,54,53
January 1, 2024 to January 31, 2024	1,177.00	January 30, 2024	3,22,87	1,062.00	January 18, 2024	8,27,42	1124.89	4,44,85,21

## NSE:

Period	High# (₹)	Date of High	Number of Equity Shares traded on that date	Low <sup>#</sup> (₹)	Date of Low	Number of Equity Shares on that date	Average Price* (₹)	Total volume traded of Equity Shares in the period (number of Equity Shares)
	Preceding 3 (three) Years							
April 1, 2023 to March 31, 2024	1,177.10	January 30, 2024	13,17,033	516.45	April 03, 2023	20,11,656	873.18	53,40,71,445
April 1, 2022 to March 31, 2023	714.70	April 06, 2022	10,74,896	397.20	February 03, 2023	14,62,669	518.59	42,44,22,934
April 1, 2021 to March 31, 2022	1,063.90	May 11, 2021	26,69,450	584.25	March 07, 2022	20,48,437	789.74	64,60,69,441
			Pred	eding 6 (size	x) months			
June 1, 2024 to June 30, 2024	1,292.10	June 07, 2024	18,79,997	1,109.45	June 04, 2024	14,34,945	1,234.50	3,09,28,582
May 1, 2024 to May 31, 2024	1,245.70	May 24, 2024	12,20,847	1,097.10	May 07, 2024	16,76,642	1,178.86	3,43,61,027
April 1, 2024 to April 30, 2024	1,175.80	April 30, 2024	24,42,943	1,069.30	April 16, 2024	17,00,783	1,112.03	3,45,70,688
March 1, 2024 to March 31, 2024	1,114.00	March 04, 2024	38,93,794	984.30	March 15, 2024	20,84,432	1,042.65	3,62,49,186
February 1, 2024 to February 29, 2024	1,155.05	February 01, 2024	1,06,93,504	958.50	February 14, 2024	67,14,469	1,030.09	8,15,04,225

Source: www.bseindia.com
\*Arithmetical average of closing prices; "High and low are based on high and low of daily high and daily low prices respectively.

Period	High <sup>#</sup> (₹)	Date of	Number of	Low <sup>#</sup> (₹)	Date of	Number of	Average	Total volume traded
		High	Equity Shares		Low	Equity Shares	Price* (₹)	of Equity Shares in
			traded on that			on that date		the period (number
			date					of Equity Shares)
January 1,	1,177.10	January 30,	13,17,033	1,061.40	January 18,	37,51,754	1,1125.12	5,02,09,720
2024 to		2024			2024			
January 31,								
2024								

Source: www.nseindia.com

16.3 The notice of the Board Meeting convened to consider the proposal of the Buyback was given to BSE and NSE on Sunday, July 14, 2024, i.e. the Intimation Date. The Board, at its meeting held on Thursday, July 18, 2024, approved the proposal for the Buyback at ₹ 1,460/- (Rupees One Thousand Four Hundred and Sixty only) per Equity Share and the intimation was sent to BSE and NSE on the same day. The closing market price of the Equity Shares on BSE and NSE during this period, are summarized below:

Event	Date	BSE (₹)	NSE (₹)
1 (one) trading day prior to the Intimation	July 12, 2024	1,327.05	1,326.85
Date			
1 (one) trading day post the Intimation	July 15, 2014	1,371.70	1,374.85
Date			
1 (one) trading day prior to the Board	July 16, 2024	1,371.70	1,371.05
Meeting			
Date of the Board Meeting	July 18, 2024	1,337.50	1,336.40
1 (one) trading day post the Board	July 19, 2024	1,330.95	1,330.80
Meeting			
Date of Public Announcement	July 19, 2024	1,330.95	1,330.80
Date of publication of the Public	July 22, 2024	1,344.65	1,344.55
Announcement			
1 (one) trading day post the publication of	July 23, 2024	1,357.40	1,357.75
the Public Announcement			

Source: www.bseindia.com and www.nseindia.com

#### 17. DETAILS OF STATUTORY APPROVALS

- 17.1 The Board, at its meeting held on Thursday, July 18, 2024, approved the proposal for the Buyback. The Buyback will be subject to such necessary approvals as may be required under the applicable laws including from SEBI and/ or BSE or NSE, and the Buyback from Non-Resident Shareholders, erstwhile overseas corporate bodies and other applicable categories will be subject to such approvals of the RBI, if any, under FEMA and/or such other applicable rules and regulations in force for the time being.
- 17.2 The Buyback from each Eligible Shareholder is subject to all statutory consents and approvals as may be required by such Eligible Shareholder under applicable laws and regulations. The Eligible Shareholder shall be solely responsible for obtaining all such statutory consents and approvals (including, without limitation the approval from the RBI, if any) as may be required by them in order to sell their Equity Shares to the Company pursuant to the Buyback. An Eligible Shareholder would be required to provide copies of all such consents and approvals obtained by them to the Registrar to the Buyback. The Buyback of Equity Shares from Non-Resident Shareholders will be subject to approvals, if any, of the appropriate authorities, including RBI under FEMA, as applicable. It is the obligation of such Non-Resident Shareholders, to obtain such approvals and submit such approvals along with the Tender Form, so as to enable them to tender Equity Shares in the Buyback and for the Company to purchase such Equity Shares, tendered. The Company will

<sup>\*</sup>Arithmetical average of closing prices; #High and low are based on high and low of daily high and daily low prices respectively

have the right to make payment to the Eligible Shareholders in respect of whom no prior RBI approval is required and not accept Equity Shares from the Eligible Shareholders in respect of whom prior RBI approval is required in the event copies of such approvals are not submitted.

- 17.3 By participating in the Buyback, the Non-Resident Shareholders give the Company the authority to make, sign, execute, deliver, acknowledge and perform all applications to file regulatory reporting(s), if required, and such Non-Resident Shareholders undertake to provide assistance to the Company for such regulatory reporting, if required by the Company
- 17.4 As of date, there is no other statutory or regulatory approval required to implement the Buyback, other than that indicated above. If any statutory or regulatory approval becomes applicable subsequently, the Buyback Offer will be subject to such statutory or regulatory approval(s). In the event of any delay in receipt of any statutory / regulatory approvals, changes to the proposed timetable of the Buyback Offer, if any, shall be intimated to the Stock Exchanges.

#### 18. DETAILS OF THE REGISTRAR TO THE BUYBACK

18.1 Eligible Shareholders who wish to tender their Equity Shares in the Buyback can send the Tender Form by registered post/ speed post or hand deliver the same, along with the TRS generated by the exchange bidding system along with all relevant documents by superscribing the envelope as "Aurobindo Pharma Limited Buyback Offer 2024", to the Registrar to the Buyback at its office set out below, so that the same are received on or before the Buyback Closing Date i.e., Friday, August 09, 2024 by 5:00 pm (IST).



KFin Technologies Limited

**Address**: Selenium, Tower- B, Plot No 31 & 32 Gachibowli, Financial District Nanakramguda, Serilingampally, Hyderabad, Telangana - 500032

**Tel. no.**: +91 40 6716 2222; Fax no.: +91 40 6716 1563;

Contact person: M Murali Krishna Toll Free number: 18003094001

Email: aurobindo.buyback@kfintech.com

Website: www.kfintech.com

Investor Grievance mail: <a href="mailto:einward.ris@kfintech.com">einward.ris@kfintech.com</a>

SEBI Registration Number: INR000000221

Validity: Permanent

CIN: L72400TG2017PLC117649

- 18.2 In case of any query, the Shareholders may contact the Registrar to the Buyback, from Monday to Friday between 10:00 am (IST) to 5:00 pm (IST) on all working days except public holidays at the above-mentioned address.
- 18.3 For the Eligible Shareholders holding Equity Shares in dematerialised form, the Tender Form and TRS are not required to be submitted to the Company, Manager or the Registrar. After the confirmation of lien marked in demat account of the Eligible Shareholders to the Clearing Corporation and a valid bid in the exchange bidding system, the bid for buyback shall be deemed to have been accepted for Eligible Shareholders holding the Equity Shares in dematerialised form.

ELIGIBLE SHAREHOLDERS ARE REQUESTED TO NOTE THAT THE TENDER FORM, TRS AND OTHER RELEVANT DOCUMENTS SHOULD NOT BE SENT TO THE COMPANY OR TO THE MANAGER TO THE BUYBACK.

ELIGIBLE SHAREHOLDERS ARE ADVISED TO ENSURE THAT THE TENDER FORM, TRS AND OTHER RELEVANT DOCUMENTS ARE COMPLETE IN ALL RESPECTS. OTHERWISE, THE SAME ARE LIABLE TO BE REJECTED.

#### 19. PROCESS AND METHODOLOGY FOR THE BUYBACK

- 19.1 The Company proposes to Buyback up to 51,36,986 (Fifty One Lakh Thirty Six Thousand Nine Hundred and Eighty Six only) Equity Shares, representing 0.88% of the total number of Equity Shares in the paid-up share capital of the Company as of March 31, 2024 and June 30, 2024, from the Eligible Shareholders, on a proportionate basis, through the Tender Offer route, at a price of ₹ 1,460/- (Rupees One Thousand Four Hundred and Sixty only) per Equity Share, payable in cash for an aggregate amount up to ₹ 750,00,00,000/- (Rupees Seven Hundred and Fifty Crore only), which constitutes 3.84% and 2.67% of the aggregate of the total paid-up equity share capital and free reserves (including securities premium) of the Company as per the audited standalone and consolidated financial statements of the Company as at March 31, 2024, respectively, and is within the statutory limit of 10% of the aggregate of the total paid-up equity share capital and free reserves (including securities premium) of the Company as per the audited standalone and consolidated financial statements of the Company as at March 31, 2024 (i.e., the last audited financial statements available as on the date of Board Meeting recommending the proposal of the Buyback), under the Board approval route as per Section 68 and other applicable provisions of the Companies Act and Regulation 5 and other applicable provisions of the Buyback Regulations. Further, since the Equity Shares proposed to be bought back represents approximately 0.88% of the total number of Equity Shares in the paid-up share capital of the Company as of March 31, 2024 and June 30, 2024, the same is within the 25% limit as per the provisions of the Companies Act and Regulation 4(i) of the Buyback Regulations. The Buyback is in accordance with Article 40(b) of the Articles of Association of the Company and Sections 68, 69, 70 and all other applicable provisions, if any, of the Companies Act, and rules framed thereunder, including the Share Capital Rules, the Management Rules, the Listing Regulations to the extent applicable, Buyback Regulations read with SEBI Circulars, subject to such other approvals, permissions, consents, exemptions and sanctions, as may be necessary and subject to any modifications and conditions, if any, as may be prescribed by SEBI, ROC, NSE, BSE and/ or other authorities, institutions or bodies, as may be necessary and subject to such conditions and modifications as may be prescribed or imposed while granting such approvals, permissions, sanctions and exemptions, which may be agreed by the Board.
- 19.2 The Company expresses no opinion as to whether Eligible Shareholders should participate in the Buyback and, accordingly, Eligible Shareholders may take their own decision after consulting their own advisors, as they may deem fit, regarding their participation in the Buyback.
- 19.3 The aggregate shareholding of the members of the Promoter & Promoter Group as on the date of the Public Announcement and the date of this Letter of Offer is 30,35,15,471 Equity Shares, which represents 51.80% of the existing equity share capital of the Company. In terms of the Buyback Regulations, under the Tender Offer route, the members of the Promoter & Promoter Group and persons in control of the Company have the option to participate in the Buyback. In this regard, the members of the Promoter & Promoter Group vide their letters dated Friday, July 19, 2024, have expressed their intention to participate in the Buyback and tender up to the number of Equity Shares set out in the table below, or such lower number of Equity Shares as permitted under the applicable law:

Sr. No.	Name	Number of Equity Shares held	Maximum number of Equity Shares intended to be tendered up to	
1.	Venkata Ramprasad Reddy Penaka	1,80,00,000	3,60,000	
2.	K Nityananda Reddy	2,53,59,572	5,07,192	
3.	M Sivakumaran	1,44,91,360	2,89,828	
4.	Rajeshwari Kambham	18,25,500	36,510	
5.	Suneela Rani Penaka	1,30,000	2,600	
6.	Prasada Reddy Kambham	3,01,156	6,024	
7.	K Suryaprakash Reddy	7,380	148	
8.	M Sumanth Kumar Reddy	16,00,000	32,000	
9.	Kirthi Reddy Kambam	2,02,50,000	4,05,000	
10.	Kambam Spoorthi	70,00,000	1,40,000	
11.	Penaka Neha Reddy	Nil	Nil	
12.	Trident Chemphar Limited	7,89,537	15,791	
13.	Axis Clinicals Limited	6,58,000	13,160	
14.	RPR Sons Advisors Private Limited, Suneela Rani Penaka (joint holding)	19,63,76,250	39,27,525	
15.	Axis Clinicals Limited, Trident Chemphar Limited, RPR Sons Advisors Private Limited (joint holding)	1,67,26,716	3,34,535	
	Total	30,35,15,471	60,70,313	

19.4 Assuming the response to the Buyback is to the extent of 100% (full acceptance) from all the Eligible Shareholders up to their Entitlement including the members of the Promoter & Promoter Group, the aggregate shareholding and the voting rights of the members of the Promoter & Promoter Group, may increase to 51.86% post Buyback from the current pre Buyback shareholding of 51.80%, and the aggregate shareholding of the public Shareholders in the Company may decrease to 48.14% post Buyback from the current pre Buyback shareholding of 48.20%.

#### 19.5 Record Date and Ratio of Buyback as per the Buyback Entitlement of each category

- 19.5.1 As required under the Buyback Regulations, the Board has fixed Tuesday, July 30, 2024 as the Record Date for the purpose of determining the Entitlement and the names of the Eligible Shareholders, who are eligible to participate in the Buyback.
- 19.5.2 The Equity Shares proposed to be bought back by the Company shall be divided into two categories:
  - (i) Reserved category for Small Shareholders ("Reserved Category"); and
  - (ii) General category for other Eligible Shareholders ("General Category").
- Shareholder" is a shareholder of the Company who holds Equity Shares whose market value, on the basis of the closing price of the Equity Shares on BSE and NSE having the highest trading volume as on the Record Date, is not more than ₹ 2,00,000/- (Rupees Two Lakh only). As on the Record Date, the closing price on NSE, having the highest trading volume, was ₹ 1,399.45/- per Equity Share. Accordingly, all Eligible Shareholders holding not more than 142 Equity Shares as on the Record Date are classified as 'Small Shareholders' for the purpose of the Buyback.

- 19.5.4 Based on the above definition, there are 2,17,964 Small Shareholders with aggregate shareholding of 63,17,241 Equity Shares, as on the Record Date, which constitutes 1.08% of the outstanding number of Equity Shares of the Company and 122.98% of the maximum number of Equity Shares which are proposed to be bought back as part of this Buyback. 57,96,21,368 Equity Shares were held by the other Eligible Shareholders in the General Category as on the Record Date.
- 19.5.5 In accordance with Regulation 6 of the Buyback Regulations, the reservation for the Small Shareholders, will be higher of:
  - (i) 15% of the number of Equity Shares which the Company proposes to Buyback i.e., 15% of 51,36,986 Equity Shares which works out to 7,70,548 Equity Shares; or
  - (ii) The number of Equity Shares to which the Small Shareholders are entitled, as per their shareholding as on Record Date i.e., [(63,17,241 / 58,59,38,609) X 51,36,986] which works out to 55,384 Equity Shares.

All the outstanding Equity Shares have been taken into account for computing the Entitlement.

19.5.6 Based on the above analysis and in accordance with Regulation 6 of the Buyback Regulations, 7,70,548 Equity Shares have been reserved for the Small Shareholders ("Reserved Category") and accordingly, the General Category for all other Eligible Shareholders shall consist of 43,66,438 Equity Shares ("General Category").

#### 19.6 Category wise Entitlement Ratio of Buyback

Based on the above, the Entitlement ratio of Buyback for both categories is decided as below:

Category	ategory Indicative Entitlement Ratio of Buyback*				
Pasamuad Catagory	5 Equity Shares out of every 41 Equity Shares held on the Record				
Reserved Category	Date				
Conoral Catagory	4 Equity Shares out of every 531 Equity Shares held on the Record				
General Category	Date				

<sup>\*</sup>The above Ratio of Buyback is approximate and providing indicative Buyback Entitlement. Any computation of entitled Equity Shares using the above Ratio of Buyback may provide a slightly different number due to rounding-off. The actual Buyback Entitlement for Reserved Category for Small Shareholders is 12.1975400336951% and General Category for all other Eligible Shareholders is 0.753325919481975%.

#### 19.7 Illustration of Entitlement Ratio

- 19.7.1 For Small Shareholders Eligible Shareholder holding 1000 Equity Shares will receive an entitlement of 121 Equity Shares (12.1975400336951% of 1000 Equity shares held on the Record Date). The Company will accept 100% Equity Shares who have validly tendered their Equity Shares to the extent of their Buyback Entitlement or the number of Equity Shares tendered by them, whichever is less. Additional equity shares will be accepted based on proportionate basis as described in Paragraph 19 on page no. 50 of this Letter of Offer.
- 19.7.2 For General Shareholders Eligible Shareholder holding 1000 Equity Shares will receive an entitlement of 7 Equity shares (0.753325919481975% of 1000 Equity shares held on the Record Date). The Company will accept 100% Equity Shares who have validly tendered their Equity Shares to the extent of their Buyback Entitlement or the number of Equity Shares tendered by them, whichever is less.

Additional equity shares will be accepted based on proportionate basis as described in Paragraph 19 on page no. 50 of this Letter of Offer.

#### 19.8 Fractional Entitlements

If the Entitlement under Buyback, after applying the above mentioned ratios to the Equity Shares held on Record Date, is not a round number (i.e., not in the multiple of 1 Equity Share) then the fractional Entitlement shall be ignored for computation of Buyback Entitlement to tender Equity Shares in the Buyback Offer, for both categories of Eligible Shareholders.

On account of ignoring the fractional Entitlement, those Small Shareholders who hold 8 or less Equity Shares as on Record Date, will be dispatched a Tender Form with zero Entitlement. Such Small Shareholders are entitled to tender Additional Equity Shares as part of the Buyback Offer and will be given preference in the acceptance of one Equity Share, if such Small Shareholders have tendered Additional Equity Shares.

#### 19.9 Basis of Acceptance of Equity Shares validly tendered in the Reserved Category

Subject to the provisions contained in this Letter of Offer, the Company will accept the Equity Shares tendered in the Buyback by the Small Shareholders in the Reserved Category in the following order of priority:

- 19.9.1 Acceptance of 100% Equity Shares from Small Shareholders in the Reserved Category who have validly tendered their Equity Shares, to the extent of their Buyback Entitlement, or the number of Equity Shares tendered by them, whichever is less.
- 19.9.2 Post the Acceptance as described in paragraph 19.9.1 above, in case, there are any Equity Shares left to be bought back from the Small Shareholders in the Reserved Category, the Small Shareholders who were entitled to tender zero Equity Shares (on account of fractional Entitlement), and have tendered Additional Equity Shares as part of the Buyback, shall be given preference and one Equity Share each from the Additional Equity Shares tendered by these Small Shareholders shall be bought back in the Reserved Category.
- 19.9.3 Post the Acceptance as described in paragraphs 19.9.1 and 19.9.2 above, in case, there are any validly tendered unaccepted Equity Shares in the Reserved Category ("Reserved Category Additional Shares") and Equity Shares left to be bought back in Reserved Category, the Reserved Category Additional Shares shall be accepted in a proportionate manner and the Acceptances shall be made in accordance with the Buyback Regulations, i.e., valid Acceptances per Eligible Shareholder shall be equal to the Reserved Category Additional Shares validly tendered by the Eligible Shareholder divided by the total Reserved Category Additional Shares and multiplied by the total number of Equity Shares remaining to be bought back in Reserved Category. For the purpose of this calculation, the Reserved Category Additional Shares taken into account for such Small Shareholders, from whom one Equity Share has been Accepted in accordance with paragraph 19.9.2 above, shall be reduced by one.
- 19.9.4 Adjustment for fractional results in case of proportionate Acceptance, as described in paragraph 19.9.3 above, will be made as follows:
  - (i) For any Small Shareholder, if the number of Additional Equity Shares to be Accepted, calculated on a proportionate basis is not in the multiple of 1 (one) and the fractional Acceptance is greater than or equal to 0.50

(point five zero), then the fraction would be rounded off to the next higher integer.

(ii) For any Small Shareholder, if the number of Additional Equity Shares to be Accepted, calculated on a proportionate basis is not in the multiple of 1 (one) and the fractional Acceptance is less than 0.50 (point five zero), then the fraction shall be ignored.

In case of any practical issues, resulting out of rounding-off of Equity Shares or otherwise, the Buyback Committee or any person(s) authorized by the Buyback Committee will have the authority to decide such final allocation with respect to such rounding-off or any excess of Equity Shares or any shortage of Equity Shares after allocation of Equity Shares as set out in the process described in paragraph 19 of this Letter of Offer.

#### 19.10 Basis of Acceptance of Equity Shares validly tendered in the General Category

Subject to the provisions contained in this Letter of Offer, the Company will Accept the Equity Shares tendered in the Buyback Offer by Eligible Shareholders (other than Small Shareholders) in the General Category in the following order of priority:

- 19.10.1 Acceptance of 100% Equity Shares from Eligible Shareholders in the General Category who have validly tendered their Equity Shares, to the extent of their Buyback Entitlement, or the number of Shares tendered by them, whichever is less.
- 19.10.2 Post the Acceptance as described in paragraph 19.10.1 above, in case, there are any validly tendered unaccepted Equity Shares in the General Category ("General Category Additional Shares") and Equity Shares left to be bought back in General Category, the General Category Additional Shares shall be accepted in a proportionate manner and the Acceptances shall be made in accordance with the Buyback Regulations, i.e., valid Acceptances per Eligible Shareholder shall be equal to the General Category Additional Shares validly tendered by the Eligible Shareholder divided by the total General Category Additional Shares and multiplied by the total number of Shares remaining to be bought back in General Category.
- 19.10.3 Adjustment for fractional results in case of proportionate Acceptance, as described in paragraph 19.10.2 above, will be made as follows:
  - (i) For any Eligible Shareholder, if the number of Additional Equity Shares to be Accepted, calculated on a proportionate basis is not in the multiple of 1 (one) and the fractional Acceptance is greater than or equal to 0.50 (point five zero), then the fraction would be rounded off to the next higher integer.
  - (ii) For any Eligible Shareholder, if the number of Additional Equity Shares to be Accepted, calculated on a proportionate basis is not in the multiple of 1 (one) and the fractional Acceptance is less than 0.50 (point five zero), then the fraction shall be ignored.

In case of any practical issues, resulting out of rounding-off of Equity Shares or otherwise, the Buyback Committee or any person(s) authorized by the Buyback Committee will have the authority to decide such final allocation with respect to such rounding-off or any excess of Equity Shares or any shortage of Equity Shares after allocation of Equity Shares as set out in the process described in paragraph 19 of this Letter of Offer.

#### 19.11 Basis of Acceptance of Equity Shares between the two categories

- 19.11.1 After Acceptances of Equity Shares, as mentioned in paragraphs 19.9 and 19.10 above, in case, there are any Equity Shares left to be bought back in one category ("Partially Filled Category") and there are additional unaccepted validly tendered Equity Shares ("Further Additional Shares") in the second category ("Over Tendered Category"), then the Further Additional Shares in the Over Tendered Category shall be Accepted in a proportionate manner i.e., valid Acceptances per Eligible Shareholder shall be equal to Further Additional Shares validly tendered by the Eligible Shareholder in the Over Tendered Category divided by the total Further Additional Shares in the Over Tendered Category and multiplied by the total Shares left to be bought back in the Partially Filled Category.
- 19.11.2 If the Partially Filled Category is the General Category and the Over Tendered Category is the Reserved Category, then any Small Shareholder who has received a Tender Form with zero Buyback Entitlement and who has tendered Additional Equity Shares shall be eligible for priority Acceptance of one Equity Share before Acceptance in paragraph 19.11.1 out of the Equity Shares left to be bought back in the Partially Filled Category provided no Acceptance could take place from such Shareholder in accordance with paragraph 19.9 of this Letter of Offer.
- 19.11.3 Adjustment for fraction results in case of proportionate Acceptance, as defined in paragraphs 19.11.1 and 19.11.2 above:
  - (i) For any Eligible Shareholder, if the number of Further Additional Shares to be Accepted, calculated on a proportionate basis is not in the multiple of 1 (one) and the fractional Acceptance is greater than or equal to 0.50 (point five zero), then the fraction would be rounded off to the next higher integer.
  - (ii) For any Eligible Shareholder, if the number of Further Additional Shares to be Accepted, calculated on a proportionate basis is not in the multiple of 1 (one) and the fractional Acceptance is less than 0.50 (point five zero), then the fraction shall be ignored.

In case of any practical issues, resulting out of rounding-off of Equity Shares or otherwise, the Buyback Committee or any person(s) authorized by the Buyback Committee will have the authority to decide such final allocation with respect to such rounding-off or any excess of Equity Shares or any shortage of Equity Shares after allocation of Equity Shares as set out in the process described in paragraph 19 of this Letter of Offer.

#### 19.12 For avoidance of doubt, it is clarified that, in accordance with the clauses above:

- 19.12.1 Equity Shares Accepted under the Buyback from each Eligible Shareholder, shall be lower of the following:
  - (i) the number of Equity Shares tendered by the respective Eligible Shareholder; and
  - (ii) the number of Equity Shares held by the respective Eligible Shareholder, as on the Record Date.
- 19.12.2 Equity Shares tendered by any Eligible Shareholder over and above the number of Equity Shares held by such Eligible Shareholder as on the Record Date shall not be considered for the purpose of Acceptance.

19.12.3 In case of any practical issues, resulting out of rounding-off of Equity Shares or otherwise, any person(s) authorized by the Board will have the authority to decide such final allocation with respect to such rounding-off or any excess of Equity Shares or any shortage of Equity Shares after allocation of Equity Shares as set out in the process described in paragraph 19 of this Letter of Offer.

#### 19.13 Clubbing of Entitlement

In accordance with Regulation 9(ix) of the Buyback Regulations, in order to ensure that the same Eligible Shareholders with multiple demat accounts/ folios do not receive a higher Entitlement under the Small Shareholder category, the Company proposes to club together the Equity Shares held by such Eligible Shareholders with a common PAN for determining the category (Small Shareholder or General) and Entitlement under the Buyback. In case of joint shareholding, the Company will club together the Equity Shares held in cases where the sequence of the PANs of the joint Shareholders is identical and where the PANs of all joint Shareholders are not available, the Company will check the sequence of the names of the joint holders and club together the Equity Shares held in such cases where the name of joint Shareholders is identical. In case of Eligible Shareholders holding Equity Shares in physical form, where the sequence of PANs is identical and where the PANs of all joint Shareholders are not available, the Company will check the sequence of the names of the joint holders and club together the Equity Shares held in such cases where the sequence of the PANs and name of joint Shareholders are identical. The shareholding of institutional investors like mutual funds, pension funds/trusts and insurance companies etc., with common PAN will not be clubbed together for determining the category and will be considered separately, where these Equity Shares are held for different schemes and have a different demat account nomenclature based on information prepared by the Registrar to the Buyback as per the Shareholder records received from the Depositories. Further, the Equity Shares held under the category of "clearing members" or "corporate body margin account" or "corporate body -broker" as per the beneficial position data as on the Record Date, with common PAN, are not proposed to be clubbed together for determining their Entitlement and will be considered separately, where these Equity Shares are assumed to be held on behalf of clients.

#### 20. PROCEDURE FOR TENDERING SHARES AND SETTLEMENT

- 20.1 The Buyback is open to all Eligible Shareholders holding Equity Shares either in physical and/or in dematerialized form as on Record Date.
- 20.2 The Company proposes to effect the Buyback through the Tender Offer route through Stock Exchange Mechanism, on a proportionate basis. The Letter of Offer and Tender Form, outlining the terms of the Buyback as well as the detailed disclosures as specified in the Buyback Regulations, will be e-mailed to Eligible Shareholders. The Eligible Shareholders who have registered their email IDs with the Depositories/ the Company, shall be dispatched the Letter of Offer through electronic means.
- 20.3 In case an Eligible Shareholder requests for a copy of this Letter of Offer in physical form, the same shall be provided by the Company. In case of non-receipt of Letter of Offer and the Tender Form, please follow the procedure as mentioned in paragraph 20.28 of this Letter of Offer.
- 20.4 The Company will not accept any Equity Shares tendered for Buyback which are under any restraint order of the court/ any other competent authority for transfer/ sale and/ or title in respect of which is otherwise under dispute or where loss of share certificates has been notified to the Company and the duplicate share certificates have not been issued either due to such request being under process as per the provisions of law or otherwise. The Company shall comply with Regulation 24(v) of the Buyback Regulations which states that the Company shall not buyback locked-in Equity Shares and non-transferable Equity Shares

till the pendency of the lock-in or till such Equity Shares become transferable. The Company shall also not accept the Equity Shares offered for Buyback where the title to such Equity Shares is under dispute or otherwise not clear.

20.5 Eligible Shareholders will have to transfer the Equity Shares from the same demat account in which they were holding the Equity Shares as on the Record Date and in case of multiple demat accounts, Eligible Shareholders are required to tender the applications separately from each demat account. In case of any changes in the demat account in which the Equity Shares were held as on Record Date, such Eligible Shareholders should provide sufficient proof of the same to the Registrar to the Buyback and such tendered Equity Shares may be accepted subject to appropriate verification and validation by the Registrar to the Buyback. The Board or Buyback Committee authorized by the Board will have the authority to decide such final allocation in case of non-receipt of sufficient proof by such Eligible Shareholder.

For the Clearing Corporation to make a payout of more than ₹ 50,00,00,000 (Rupees Fifty Crore only), a Legal Entity Identifier (LEI) number of the Eligible Shareholder will have to be provided. Accordingly, an Eligible Shareholder who is tendering shares of value more than ₹ 50,00,00,000 (Rupees Fifty Crore only) will have to provide LEI number with the relevant supporting documents such as the LEI registration certificate to the Registrar through email at aurobindo.buyback@kfintech.com latest by 5:00 p.m. (IST) on the Buyback Closing Date.

- 20.6 As elaborated under paragraphs 19.6 and 19.7 above, the Equity Shares proposed to be bought as a part of the Buyback are divided into two categories: (a) Reserved Category for Small Shareholders and (b) the General Category for all other Eligible Shareholders. The Buyback Entitlement of Eligible Shareholders in each category shall be calculated accordingly.
- 20.7 Post Acceptance of the Equity Shares tendered on the basis of Buyback Entitlement, Equity Shares left to be bought as a part of the Buyback, if any, in one category shall first be accepted, in proportion to the Equity Shares tendered, over and above their Buyback Entitlement, by Eligible Shareholders in that category, and thereafter, from Eligible Shareholders who have tendered over and above their Buyback Entitlement, in the other category.
- 20.8 All purchases pursuant to the Buyback will be paid for in ₹, including to holders of Equity Shares who are resident outside India. Payment of consideration to Eligible Shareholders shall be made within 5 (Five) Working Days of the Buyback Closing Date as required under the Buyback Regulations. Accordingly, the Registrar to the Buyback will process the bids under the Buyback as promptly as practicable after the Buyback Closing Date, and the Company expects to start making payments for accepted bids as promptly as practicable and within 5 (Five) Working Days after the Buyback Closing Date.
- 20.9 The participation of Eligible Shareholders in the Buyback is voluntary. Eligible Shareholders holding Equity Shares of the Company may choose to participate, in full or in part, and get cash in lieu of shares to be accepted under the Buyback or they may choose not to participate and enjoy a resultant increase in their percentage shareholding, post-Buyback, without additional investment. Eligible Shareholders holding Equity Shares of the Company may also accept a part of their Entitlement. Eligible Shareholders holding Equity Shares of the Company also have the option of tendering Additional Equity Shares (over and above their Entitlement) and participate in the shortfall created due to non-participation of some other Eligible Shareholders, if any. If the Buyback Entitlement for any Eligible Shareholder is not a round number, the fractional entitlement shall be ignored for computation of entitlement to tender Equity Shares in the Buyback. The Acceptance of any Equity Shares tendered in excess of the Buyback Entitlement by the Eligible Shareholder shall be in terms of the procedure outlined herein. In case any Eligible Shareholder or any person claiming to be an Eligible Shareholder cannot participate in the Buyback Offer for any reason, the

Company, the Manager and Registrar to the Buyback and their officers shall not be liable in any manner for such non-participation.

- 20.10 The maximum number of Equity Shares that can be tendered under the Buyback by any Eligible Shareholder cannot exceed the number of Equity Shares held by the Eligible Shareholder as on the Record Date. In case the Eligible Shareholder holds Equity Shares through multiple demat accounts, the tender through a demat account cannot exceed the number of Equity Shares held in that demat account.
- 20.11 The Company shall accept all the Equity Shares validly tendered for the Buyback by Eligible Shareholders, on the basis of their Buyback Entitlement as on the Record Date.
- 20.12 The Buyback shall be implemented using the "Mechanism for acquisition of shares through Stock Exchange" as specified by the SEBI Circulars and following the procedure prescribed in the Companies Act, the Share Capital Rules and the Buyback Regulations and as may be determined by the Board (including the Buyback Committee authorized to complete the formalities of the Buyback) and on such terms and conditions as may be permitted by law from time to time.
- 20.13 For implementation of the Buyback, the Company has appointed Axis Capital Limited as the registered broker to the Company ("Company's Broker") to facilitate the process of tendering of Equity Shares through the Stock Exchange Mechanism for the Buyback and through whom the purchases and settlements on account of the Buyback would be made by the Company. The contact details of the Company's Broker are as follows:



#### **AXIS CAPITAL LIMITED**

1<sup>st</sup> Floor, Axis House, C-2 Wadia International Centre, P. B. Marg, Worli, Mumbai - 400 025 **Tel:** +91 22 4325 2183; **Fax:** +91 22 4325 3000

> Contact Person: Amrish Parmar Email: apl.buyback@axiscap.in SEBI Registration Number: INZ000189931

- 20.14 BSE will be the Designated Stock Exchange for the purpose of this Buyback. The Company will request BSE to provide the separate acquisition window ("Acquisition Window") to facilitate placing of sell orders by Eligible Shareholders who wish to tender Equity Shares in the Buyback. The details of the Acquisition Window will be specified by BSE from time to time.
- 20.15 During the tendering period, the order for selling the Equity Shares will be placed in the Acquisition Window by Eligible Shareholders through their respective stock broker(s) ("Seller Member(s)") during normal trading hours of the secondary market. The Seller Member can enter orders for Equity Shares held in dematerialized form and physical form. In the tendering process, the Company's Broker may also process the orders received from the Eligible Shareholders.
- 20.16 In the event the Seller Member(s) of any Eligible Shareholder is not registered with BSE as a trading member/ stock broker, then that Eligible Shareholder can approach any BSE registered stock broker and can register themselves by using quick unique client code ("UCC") facility through the BSE registered stock broker (after submitting all details as may be required by such BSE registered stock broker in compliance with applicable law). In case the Eligible Shareholders are unable to register using UCC facility through any other BSE registered broker, Eligible Shareholders may approach Company's Broker i.e., Axis Capital

Limited to place their bids, subject to completion of KYC requirements as required by the Company's Broker.

20.17 Eligible Shareholders approaching a stockbroker registered with the BSE (with whom they do not have an account) may have to submit the requisite documents as may be required. The requirement of documents and procedures may vary from broker to broker, and may inter alia include:

### In case of Eligible Seller being an individual

If Eligible Seller is registered with KYC Registration Agency ("KRA"): Forms required:

- Central Know Your Client (CKYC) form including FATCA, IPV, OSV if applicable
- Know Your Client (KYC) form documents required (all documents self-attested):
  - Bank details (cancelled cheque)
- Demat details only if Equity Shares are in dematerialised form (demat master/ latest demat statement)

#### If Eligible Seller is not registered with KRA: Forms required:

- CKYC form including FATCA, IPV, OSV if applicable
- KRA form
- KYC form documents required (all documents self-attested):
  - PAN card copy
  - Address proof
  - Bank details (cancelled cheque)
- Demat details only if Equity Shares are in dematerialised form (demat master/ latest demat statement)

It may be noted that other than submission of above forms and documents in person verification may be required.

### In case of Eligible Seller is HUF:

If Eligible Seller is registered with KRA: Forms required:

- CKYC form of karta including FATCA, IPV, OSV if applicable
- KYC form documents required (all documents self-attested):
  - Bank details (cancelled cheque)
- Demat details only if Equity Shares are in dematerialised form (demat master/ latest demat statement)

#### If Eligible Seller is not registered with KRA: Forms required:

- CKYC form of karta including FATCA, IPV, OSV if applicable
- KRA form
- KYC form documents required (all documents self-attested):
  - PAN card copy of HUF & karta
  - Address proof of HUF & karta
  - HUF declaration
  - Bank details (cancelled cheque)
- Demat details only if Equity Shares are in dematerialised form (demat master/ latest demat statement)

It may be noted that other than submission of above forms and documents in person verification may be required.

#### In case of Eligible Seller other than Individual and HUF:

If Eligible Seller is KRA registered: Form required

- KYC form documents required (all documents certified true copy)
  - Bank details (cancelled cheque)
- Demat details only if Equity Shares are in dematerialised form (demat master /latest

- demat statement)
- FATCA, IPV, OSV if applicable
- Latest list of directors/authorised signatories/partners/trustees
- Latest shareholding pattern
- Board resolution
- Details of ultimate beneficial owner along with PAN card and address proof
- Last 2 (two) years financial statements

#### If Eligible Seller is not KRA registered: Forms required:

- KRA form
- KYC form documents required (all documents certified true copy):
  - PAN card copy of company/ firm/trust
  - Address proof of company/ firm/trust
  - Bank details (cancelled cheque)
- Demat details only if Equity Shares are in dematerialised form (demat master /latest demat statement)
- FATCA, IPV, OSV if applicable
- Latest list of directors/authorised signatories/partners/trustees
- PAN card copies & address proof of Directors/authorised signatories/partners/trustees
- Latest shareholding pattern
- Board resolution/partnership declaration
- Details of ultimate beneficial owner along with PAN card and address proof
- Last 2 (two) years financial statements
- MOA/Partnership deed /trust deed

It may be noted that above mentioned list of documents is an indicative list. The requirement of documents and procedures may vary from broker to broker.

- 20.18 <u>All Eligible Shareholders, through their respective Seller Member/ stock broker(s), will be eligible and responsible to place orders in the Acquisition Window.</u>
- 20.19 During the Tendering Period, the order for selling the Equity Shares will be placed in the Acquisition Window by Eligible Shareholders through their respective Seller Member(s) during normal trading hours of the secondary market. The Seller Member can enter orders for Equity Shares held in dematerialized form and physical form.
- 20.20 The Buyback from the Eligible Shareholders who are residents outside India including foreign corporate bodies (including erstwhile overseas corporate bodies), foreign portfolio investors, non-resident Indians, members of foreign nationality, if any, shall be subject to the Foreign Exchange Management Act, 1999 and rules and regulations framed thereunder, if any, Income Tax Act, 1961 and rules and regulations framed thereunder, as applicable, and also subject to the receipt / provision by such Eligible Shareholders of such approvals, if and to the extent necessary or required from concerned authorities including, but not limited to, approvals from the RBI under the Foreign Exchange Management Act, 1999 and rules and regulations framed thereunder, if any.
- 20.21 The reporting requirements for non-resident shareholders under RBI, Foreign Exchange Management Act, 1999, as amended and any other rules, regulations, guidelines, for remittance of funds, shall be made by the Eligible Shareholders and/ or the Eligible Shareholder's Broker through which the Eligible Shareholder places the bid.
- 20.22 Modification/ cancellation of orders and multiple bids from a single Eligible Shareholder will be allowed during the Tendering Period of the Buyback. Multiple bids made by a single

- Eligible Shareholder for selling Equity Shares shall be clubbed and considered as "one bid" for the purposes of acceptance.
- 20.23 The cumulative quantity tendered shall be made available on the website of BSE (<a href="www.bseindia.com">www.bseindia.com</a>) (throughout the trading session and will be updated at specific intervals during the Tendering Period.
- 20.24 All documents sent by the Eligible Shareholders will be at their own risk. Eligible Shareholders are advised to safeguard adequately their interests in this regard. Eligible Shareholders shall also provide all relevant documents, which are necessary to ensure transferability of the Equity Shares in respect of the Tender Form to be sent. Such documents may include (but not be limited to):
  - 20.24.1 Duly attested power of attorney, if any person other than the Eligible Shareholder has signed the Tender Form;
  - 20.24.2 Duly attested death certificate and succession certificate/legal heirship certificate, in case any Eligible Shareholder has expired; and
  - 20.24.3 In case of companies, the necessary certified corporate authorizations (including board and/or general meeting resolutions).

## 20.25 Procedure to be followed by Eligible Shareholders holding Equity Shares in dematerialized form:

- 20.25.1 Eligible Shareholders who desire to tender their Equity Shares held by them in dematerialized form under the Buyback would have to do so through their respective Seller Member by indicating to the concerned Seller Member, the details of Equity Shares they intend to tender under the Buyback.
- 20.25.2 The Seller Member(s) would be required to place an order/ bid on behalf of the Eligible Shareholders who wish to tender Equity Shares in the Buyback using the Acquisition Window of BSE.
- 20.25.3 The details of the settlement number under which the lien will be marked on the Equity Shares tendered for the Buyback will be provided in a separate circular to be issued by BSE or the Clearing Corporation.
- 20.25.4 The lien shall be marked by the Seller Member in the demat account of the Eligible Shareholder for the shares tendered in Tender Offer. Details of shares marked as lien in the demat account of the Eligible Shareholder shall be provided by the Depositories to BSE Clearing Limited and Indian Clearing Corporation Limited ("Clearing Corporation"). In case, the Shareholders demat account is held with one Depository and clearing member pool and Clearing Corporation Account is held with other Depository, shares shall be blocked in the shareholders demat account at source Depository during the tendering period. Inter Depository Tender Offer ("IDT") instructions shall be initiated by the shareholders at source Depository to clearing member/ Clearing Corporation account at target Depository. Source Depository shall block the shareholder's securities (i.e., transfers from free balance to blocked balance) and send IDT message to target Depository for confirming creation of lien. Details of shares blocked in the shareholders demat account shall be provided by the target Depository to the Clearing Corporation.
- 20.25.5 For custodian participant orders for Equity Shares in dematerialised form, early pay-in is mandatory prior to confirmation of order by custodian. The custodian

shall either confirm or reject the orders not later than the closing of trading hours on the last day of the Tendering Period. Thereafter, all unconfirmed orders shall be deemed to be rejected. For all confirmed custodian participant orders, order modification by the concerned Seller Member shall revoke the custodian confirmation and the revised order shall be sent to the custodian again for confirmation.

- 20.25.6 Upon placing the bid, the Seller Member(s) shall provide a Transaction Registration Slip ("TRS") generated by the exchange bidding system to the Eligible Shareholder on whose behalf the bid has been placed. The TRS will contain the details of the order submitted like bid ID number, application number, DP ID, client ID, number of Equity Shares tendered etc. In case of non-receipt of the completed tender form and other documents, but lien marked on Equity Shares and a valid bid in the exchange bidding system, the bid by such Eligible Shareholder shall be deemed to have been submitted.
- 20.25.7 IT IS CLARIFIED THAT IN CASE OF EQUITY SHARES IN DEMATAREALISED FORM, SUBMISSION OF THE TENDER FORM AND TRS IS NOT MANDATORY. After the receipt of the Equity Shares in dematerialised form by the Clearing Corporation and a valid bid in the exchange bidding system, the Buyback shall be deemed to have been accepted, for Eligible Shareholders holding Equity Shares in dematerialised form.
- 20.25.8 The Eligible Shareholders will have to ensure that they keep the Depository participant ("**DP**") account active and unblocked to receive credit in case of return of Equity Shares due to rejection or due to prorated Buyback decided by the Company. Further, Eligible Shareholders will have to ensure that they keep the bank account attached with the DP account active and updated to receive credit remittance due to acceptance of Buyback of shares by the Company.

#### 20.26 Procedure to be followed by Eligible Shareholders holding Equity Shares in physical form

In accordance with SEBI's circular dated July 31, 2020 (circular no. SEBI/HO/CFD/CMD1/CIR/ P/2020/144), shareholders holding Equity Shares in physical form are allowed to tender such shares in a buyback undertaken through the Tender Offer route. However, such tendering shall be as per the provisions of the Buyback Regulations. Nevertheless, Eligible Shareholders holding Equity Shares in physical form are urged to have their Equity Shares dematerialized so as to be able to freely transfer them and participate in corporate actions in a convenient and effective manner. The procedure for tendering equity shares in physical form is as below:

20.26.1 Eligible Shareholders who are holding Equity Shares in physical form and intend to participate in the Buyback will be required to approach their respective Seller Member along with the complete set of documents for verification procedures to be carried out before placement of the bid. Such documents will include the (a) Tender Form duly signed by all Eligible Shareholders (in case shares are in joint names, in the same order in which they hold the shares), (b) original share certificate(s), (c) valid share transfer form(s)/ Form SH-4 duly filled and signed by the transferors (i.e., by all registered Shareholders in the same order and as per the specimen signatures registered with the Company) and duly witnessed at the appropriate place authorizing the transfer in favour of the Company, (d) selfattested copy of PAN card(s) of all Eligible Shareholders, (e) any other relevant documents such as power of attorney, corporate authorization (including board resolution/ specimen signature), notarized copy of death certificate and succession certificate or probated will, if the original shareholder is deceased, etc., as applicable. In addition, if the address of the Eligible Shareholder has

undergone a change from the address registered in the register of members of the Company, the Eligible Shareholder would be required to submit a selfattested copy of address proof consisting of any one of the following documents: valid Aadhar card, voter identity card or passport.

- 20.26.2 Based on documents mentioned in paragraph 20.26.1 above, the concerned Seller Member shall place an order/ bid on behalf of the Eligible Shareholders holding Equity Shares in physical form who wish to tender Equity Shares in the Buyback, using the Acquisition Window of BSE. Upon placing the bid, the Seller Member shall provide a TRS generated by the exchange bidding system to the Eligible Shareholder. TRS will contain the details of order submitted like folio number, certificate number, distinctive number, number of Equity Shares tendered etc.
- 20.26.3 Any Seller Member/ Eligible Shareholder who places a bid for Equity Shares in physical form, is required to deliver the original share certificate(s) and documents (as mentioned above) along with TRS generated by exchange bidding system upon placing of bid, either by registered post, speed post or courier or hand delivery to the Registrar to the Buyback i.e., KFin Technologies Limited (at the address mentioned on cover page) on or before the Buyback Closing Date i.e., Friday, August 09, 2024 by 5:00 pm (IST). The envelope should be super scribed as "Aurobindo Pharma Limited Buyback 2024". One copy of the TRS will be retained by Registrar to the Buyback and it will provide acknowledgement of the same to the Seller Member.
- 20.26.4 The Eligible Shareholders holding Equity Shares in physical form should note that Equity Shares in physical form will not be accepted unless the complete set of documents are submitted. Acceptance of the Equity Shares in physical form for Buyback by the Company shall be subject to verification as per the Buyback Regulations and any further directions issued in this regard. The Registrar to the Buyback will verify such bids based on the documents submitted on a daily basis and till such verification, BSE shall display such bids as 'unconfirmed physical bids'. Once Registrar to the Buyback confirms the bids, they will be treated as 'confirmed bids'.
- 20.26.5 In case any Eligible Shareholder has submitted Equity Shares in physical form for dematerialization, such Eligible Shareholders should ensure that the process of getting the Equity Shares dematerialized is completed well in time so that they can participate in the Buyback before the closure of the tendering period of the Buyback.
- 20.26.6 All documents as mentioned above shall be enclosed with the valid Tender Form, failing which the Equity Shares tendered will be liable for rejection. The Equity Shares shall be liable for rejection on the following grounds amongst others: (i) If there is any other company's equity share certificate(s) enclosed with the Tender Form instead of the Equity Share certificate(s) of the Company; (ii) If the transmission of Equity Shares is not completed, and the Equity Shares are not in the name of the Eligible Shareholders; (iii) If the Eligible Shareholders tender Equity Shares but the Registrar to the Buyback does not receive the Equity Share certificate(s); (iv) In case the signature on the Tender Form and Form SH-4 does not match as per the specimen signature recorded with Company/ Registrar of the Company.
- 20.26.7 An unregistered shareholder holding Equity Shares in physical form may also tender their Equity Shares in the Buyback by submitting the duly executed transfer deed for transfer of shares, purchased prior to the Record Date, in their

name, along with the offer form, copy of their PAN card and of the person from whom they have purchased shares and other relevant documents as required for transfer, if any.

- 20.27 For Equity Shares held by Eligible Shareholders, being Non-Resident Shareholders of Equity Shares (Read with paragraph 17 "Details of Statutory Approvals"):
  - 20.27.1 Eligible Shareholders, being Non-Resident Shareholders of Equity Shares (excluding FIIs) shall also enclose a copy of the permission received by them from RBI, if applicable, to acquire the Equity Shares held by them.
  - 20.27.2 Eligible Shareholders who are FIIs/FPIs should also enclose a copy of their SEBI registration certificate.
  - 20.27.3 In case the Equity Shares are held on repatriation basis, the Non-Resident Shareholder shall obtain and enclose a letter from its authorised dealer / bank confirming that at the time of acquiring such Equity Shares, payment for the same was made by the Non-Resident Shareholder from the appropriate account (e.g., NRE a/c.) as specified by RBI in its approval. In case the Non-Resident Shareholder is not in a position to produce the said certificate, the Equity Shares would be deemed to have been acquired on non-repatriation basis and in that case the Non-Resident Shareholder shall submit a consent letter addressed to the Company, allowing the Company to make the payment on a non-repatriation basis in respect of the valid Equity Shares accepted under the Buyback.
  - 20.27.4 If any of the above stated documents (as applicable) are not enclosed along with the Tender Form, the Equity Shares tendered under the Buyback are liable to be rejected.

THE NON RECEIPT OF THIS LETTER OF OFFER BY, OR ACCIDENTAL OMMISSION TO DISPATCH THE LETTER OF OFFER TO ANY PERSON WHO IS ELIGIBLE TO RECEIVE THE SAME TO PARTICIPATE IN THE BUYBACK, SHALL NOT INVALIDATE THE BUYBACK OFFER IN ANY WAY. PLEASE NOTE THAT THE COMPANY SHALL ACCEPT EQUITY SHARES VALIDLY TENDERED FOR THE BUYBACK OFFER ON THE BASIS OF THEIR HOLDING AND ENTITLEMENT AS APPEARING IN THE RECORDS OF THE COMPANY AS ON THE RECORD DATE.

- 20.28 In case of non-receipt of the Letter of Offer and the Tender Form:
  - 20.28.1 In case the Eligible Shareholders hold Equity Shares in dematerialized form: If any Eligible Shareholder who is holding Equity Shares in dematerialized form and has been sent the Letter of Offer through electronic means wishes to obtain a physical copy of the Letter of Offer, they may send a request in writing to the Company or Registrar at the address or email ID mentioned at the cover page of the Letter of Offer stating name, address, number of Equity Shares held on Record Date, client ID number, DP name/ ID, beneficiary account number. Upon receipt of such request, a physical copy of the Letter of Offer shall be provided to such Eligible Shareholder. An Eligible Shareholder may participate in the Buyback by downloading the Tender Form from the websites of the Company (www.aurobindo.com), the Manager to the Buyback (www.axiscapital.co.in), Registrar to the Buyback (www.kfintech.com), SEBI (www.sebi.gov.in), NSE (www.nseindia.com) and BSE (www.bseindia.com) or by providing his/her/its application in writing on a plain paper, signed by all Eligible Shareholders (in case of joint holding), stating name and address of the Eligible Shareholder(s), number of Equity Shares held as on the Record Date, Client ID number, DP name, DP ID,

beneficiary account number and number of Equity Shares tendered for the Buyback.

20.28.2 In case the Eligible Shareholders hold in physical form: An Eligible Shareholder may participate in the Buyback by providing his/her/its application in writing on a plain paper signed by all Eligible Shareholders (in case of joint holding) stating name, address, folio number, number of Equity Shares held, Equity Share certificate number, number of Equity Shares tendered for the Buyback and the distinctive numbers thereof, enclosing the original Equity Share certificate(s), copy of Eligible Shareholder's PAN card(s) and executed share transfer form in favour of the Company. An Eligible Shareholder may participate in the Buyback by downloading the Tender Form from the websites of the Company (www.aurobindo.com), the Manager to the Buyback (www.axiscapital.co.in), Registrar to the Buyback (www.kfintech.com), SEBI (www.sebi.gov.in), NSE (www.nseindia.com) and BSE (www.bseindia.com), and must ensure that the Tender Form, along with the TRS and requisite documents, reach the Registrar to the Buyback on or before the Buyback Closing Date i.e., Friday, August 09, 2024 by 5:00 pm (IST). If the signature(s) of the Eligible Shareholders provided in the plain paper application differs from the specimen signature(s) recorded with the registrar of the Company or are not in the same order (although attested), such Tender Forms are liable to be rejected under this Buyback.

Please note that Eligible Shareholder(s) who intend to participate in the Buyback will be required to approach their respective Seller Member (along with the complete set of documents for verification procedures in case of Equity Shares held in physical form) and have to ensure that their bid is entered by their respective Seller Member in the electronic platform to be made available by BSE before the Buyback Closing Date.

The Company shall accept Equity Shares validly tendered by the Eligible Shareholder(s) in the Buyback on the basis of their shareholding as on the Record Date and the Buyback Entitlement. Eligible Shareholder(s) who intend to participate in the Buyback using the 'plain paper' option as mentioned in this paragraph are advised to confirm their Entitlement from the Registrar to the Buyback Offer, before participating in the Buyback.

The participation of the Eligible Shareholders in the Buyback is entirely at the discretion of the Eligible Shareholders. The Company does not accept any responsibility for the decision of any Eligible Shareholder to either participate or to not participate in the Buyback. The Company will not be responsible in any manner for any loss of share certificate(s) and other documents during transit and the Eligible Shareholders are advised to adequately safeguard their interest in this regard.

#### 20.29 Acceptance of Orders

The Registrar to the Buyback shall provide details of order Acceptance to the Clearing Corporation within specified timelines.

#### 20.30 Method of Settlement

Upon finalization of the basis of Acceptance as per Buyback Regulations:

- 20.30.1 The settlement of trades shall be carried out in the manner similar to settlement of trades in the secondary market and as intimated by the Clearing Corporation from time to time, and in compliance with the SEBI Circulars.
- 20.30.2 The Company will pay the consideration to the Company's Broker who will transfer the funds pertaining to the Buyback to the Clearing Corporation's bank

accounts as per the prescribed schedule. For Equity Shares accepted under the Buyback, the Clearing Corporation will make direct funds payout to respective Eligible Shareholders. For Eligible Shareholders holding Equity Shares in dematerialized form, if the Eligible Shareholders' bank account details are not available or if the funds transfer instruction is rejected by RBI/bank, due to any reason, then such funds will be transferred to the concerned Seller Member's settlement bank account for onward transfer to such Eligible Shareholders.

- 20.30.3 For the Eligible Shareholders holding Equity Shares in physical form, the funds pay-out would be given to their respective Seller Member's settlement accounts for releasing the same to the respective Eligible Shareholder's account.
- 20.30.4 In case of certain client types viz. Non-Resident Shareholders (where there are specific RBI and other regulatory requirements pertaining to funds pay-out) who do not opt to settle through custodians, the funds pay-out would be given to their respective Seller Member's settlement accounts for releasing the same to the respective Eligible Shareholder's account. For this purpose, the client type details would be collected from the Depositories, whereas funds payout pertaining to the bids settled through custodians will be transferred to the settlement bank account of the custodian, each in accordance with the applicable mechanism prescribed by BSE and the Clearing Corporation from time to time.
- 20.30.5 Details in respect of Eligible Shareholder's Entitlement for Tender Offer process will be provided to the Clearing Corporation by the Company or Registrar to the Buyback. On receipt of the same, Clearing Corporation will cancel the excess or unaccepted blocked Equity Shares in the demat account of the Eligible Shareholder. On settlement date, all blocked Equity Shares mentioned in the accepted bid will be transferred to the Clearing Corporation.
- 20.30.6 In the case of inter Depository, Clearing Corporation will cancel the excess or unaccepted shares in target Depository. Source Depository will not be able to release the lien without a release of IDT message from target Depository. Further, release of IDT message shall be sent by target Depository either based on cancellation request received from Clearing Corporation or automatically generated after matching with bid accepted detail as received from the Company or the Registrar to the Buyback. Post receiving the IDT message from target Depository, source Depository will cancel/ release excess or unaccepted block shares in the demat account of the shareholder. Post completion of tendering period and receiving the requisite details viz., demat account details and accepted bid quantity, source Depository shall debit the securities as per the communication/ message received from target Depository to the extent of accepted bid shares from shareholder's demat account and credit it to Clearing Corporation settlement account in target Depository on settlement date.
- 20.30.7 In relation to Equity Shares held in physical form: (a) If Equity Shares held in physical form tendered by Eligible Shareholders are not Accepted, then the Equity Share certificate would be returned to such Eligible Shareholders by registered post or by ordinary post or courier at the Eligible Shareholders' sole risk. The Company also encourages Eligible Shareholders holding Equity Shares in physical form to dematerialize them. (b) If however, only a portion of the Equity Shares held in physical form by an Eligible Shareholder is Accepted in the Buyback then the Company shall instead of issuing a split share certificate towards the unaccepted Equity Shares, issue a Letter of Confirmation ("LOC") in accordance with SEBI Master Circular No. SEBI/HO/MIRSD/POD1/P/CIR/2023/70 dated May 17, 2023. The LOC shall be dispatched to the address registered with

the Company. The Company shall retain the original Equity Share certificates and deface such certificates with a stamp "Letter of Confirmation Issued" on the face / reverse of the certificate to the extent of the excess Equity Shares in physical form. The LOC shall be valid for a period of 120 days from the date of its issuance, within which the Eligible Shareholder shall be required to make a request to their depository participant for dematerializing the Equity Shares. In case the Eligible Shareholder fails to submit the demat request within the aforementioned period, the RTA shall arrange to credit the Equity Shares to a separate demat account of the Company opened for the said purpose.

- 20.30.8 The Equity Shares bought back in dematerialized form would be transferred directly to the demat escrow account of the Company opened for the Buyback ("Company Demat Escrow Account") provided it is indicated by the Company's Broker or it will be transferred by the Company's Broker to the Company Demat Escrow Account on receipt of the Equity Shares from the clearing and settlement mechanism of BSE.
- 20.30.9 Eligible Shareholders who intend to participate in the Buyback should consult their respective Seller Member(s) for details of any cost, applicable taxes, charges and expenses (including brokerage) etc., that may be levied by the Seller Member(s) upon the selling shareholders for tendering Equity Shares in the Buyback (secondary market transaction). The Buyback consideration received by the Eligible Shareholders in respect of accepted Equity Shares could be net of such costs, applicable taxes, charges and expenses (including brokerage) and the Manager to the Buyback and Company accepts no responsibility to bear or pay such additional cost, charges and expenses (including brokerage) incurred solely by the Eligible Shareholders.
- 20.30.10 The Seller Member(s) would issue contract note and pay the consideration for the Equity Shares accepted under the Buyback and return the balance unaccepted Equity Shares to their respective clients/ will unblock the excess unaccepted Equity Shares. The Company's Broker would also issue a contract note to the Company for the Equity Shares accepted under the Buyback.
- 20.30.11 The Equity Shares accepted, bought and lying to the credit of the Company Demat Escrow Account will be extinguished in the manner and following the procedure prescribed in the Buyback Regulations.

#### 20.31 Rejection Criteria

The Equity Shares tendered by Eligible Shareholders would be liable to be rejected on the following grounds:

- 20.31.1 For Eligible Shareholders holding Equity Shares in dematerialized form:
  - (i) If the Shareholder is not an Eligible Shareholder of the Company as on the Record Date;
  - (ii) If there is a name mismatch in demat account of the Shareholder and PAN: or
  - (iii) There exists any restraint order of a court/any other competent authority for transfer/disposal/ sale or where loss of share certificates has been notified to the Company or where the title to the Equity Shares is under dispute or otherwise not clear or where any other restraint subsists.

#### 20.31.2 For Eligible Shareholders holding Equity Shares in physical form:

- (i) If the documents mentioned in the Tender Form for Eligible Shareholders holding Equity Shares in physical form are not received by the Registrar on or before the Buyback Closing Date i.e., Friday, August 09, 2024 by 5:00 pm (IST);
- (ii) If there is any other company's share certificate enclosed with the Tender Form instead of the share certificate of the Company;
- (iii) If the transmission of Equity Shares is not completed, and the Equity Shares are not in the name of the Eligible Shareholders;
- (iv) If the Eligible Shareholders bid the Equity Shares but the Registrar does not receive the physical share certificate;
- (v) If the PAN cards (self-attested) of the shareholder and all the joint holders, are not submitted with the form;
- (vi) In the event the signature in the Tender Form and Form SH-4 do not match as per the specimen signature recorded with Company or Registrar;
- (vii) If the shareholder is not an Eligible Shareholder of the Company on the Record Date;
- (viii) If there is a name mismatch in the share certificate of the shareholder;
- (ix) If the Eligible Shareholder has made a duplicate bid; or
- (x) Where there exists any restraint order of a court/ any other competent authority for transfer/ disposal/ sale or where loss of share certificates has been notified to the Company or where the title to the Equity Shares is under dispute or otherwise not clear or where any other restraint subsists.

#### 21. NOTE ON TAXATION

THE SUMMARY OF THE TAX CONSIDERATIONS IN THIS SECTION ARE BASED ON THE CURRENT PROVISIONS OF THE INCOME TAX LAWS OF INDIA AND THE REGULATIONS THEREUNDER, THE JUDICIAL AND THE ADMINISTRATIVE INTERPRETATIONS THEREOF, WHICH ARE SUBJECT TO CHANGE OR MODIFICATION BY SUBSEQUENT LEGISLATIVE, REGULATORY, ADMINISTRATIVE OR JUDICIAL DECISIONS. ANY SUCH CHANGES COULD HAVE DIFFERENT TAX IMPLICATIONS ON THESE TAX CONSIDERATIONS.

IN VIEW OF THE PARTICULARIZED NATURE OF TAX CONSEQUENCES, SHAREHOLDERS ARE REQUIRED TO CONSULT THEIR TAX ADVISORS FOR THE APPLICABLE TAX PROVISIONS INCLUDING THE TREATMENT THAT MAY BE GIVEN BY THEIR RESPECTIVE TAX OFFICERS IN THEIR CASE, AND THE APPROPRIATE COURSE OF ACTION THAT THEY SHOULD TAKE.

THE COMPANY DOES NOT ACCEPT ANY RESPONSIBILITY FOR THE ACCURACY OR OTHERWISE OF THIS TAX SUMMARY AND THERE CAN BE NO LIABILITY ON THE COMPANY IF ANY ACTION IS TAKEN BY THE SHAREHOLDER SOLELY BASED ON THIS TAX SUMMARY. THEREFORE, SHAREHOLDERS CANNOT RELY ON THIS ADVICE AND THE SUMMARY TAX IMPLICATIONS RELATING TO THE TREATMENT OF INCOME TAX IN THE CASE OF BUYBACK OF EQUITY SHARES LISTED ON THE STOCK EXCHANGE SET OUT BELOW SHOULD BE TREATED AS INDICATIVE AND FOR GUIDANCE PURPOSES ONLY.

#### 21.1 **GENERAL**

The Indian tax year runs from April 1 to March 31. The basis of charge of Indian income-tax depends upon the residential status of the taxpayer during a tax year. A person who is a tax resident of India is liable to taxation in India on his worldwide income, subject to certain prescribed tax exemptions provided under the Income Tax Act, 1961 ("IT Act").

A person who is treated as a non-resident for Indian tax purposes is generally liable to tax in India only on his / her Indian sourced income or income received by such person in India.

In case of shares of a company, the source of income from shares would depend on the "situs" of the shares. As per the IT Act and Judicial precedents, generally the "situs" of the shares is where company is "incorporated" and where its shares can be transferred. Accordingly, since the Company is incorporated in India, the shares of the Company would be "situated" in India and any gains arising to a non-resident on transfer of such shares should be taxable in India under the IT Act subject to any specific exemption in this regard. Further, the non-resident can avail the beneficial tax treatment prescribed under the Double Taxation Avoidance Agreement ("DTAA"), as modified by the Multilateral Instrument ("MLI"), if the same is applicable to the relevant DTAA between India and the respective country of which the said shareholder is tax resident.

The above benefit may be available subject to satisfying relevant conditions prescribed under the IT Act including but not limited to availability of Tax Residency Certificate, non-applicability of General Anti-Avoidance Rule ("GAAR") and providing and maintaining necessary information and documents as prescribed under the IT Act as well as satisfying the relevant conditions under the respective DTAA including anti-abuse measures under the MLI, if applicable.

#### 21.2 CLASSIFICATION OF SHAREHOLDERS

Section 6 of the IT Act determines the residential status of an assessee. Accordingly, shareholders can be classified broadly in two categories as below:

#### 21.2.1 Resident Shareholders being:

- (i) Individuals, Hindu Undivided Family ("HUF"), Association of Persons ("AOP"), Body of Individuals ("BOI"), Firm and Limited Liability Partnership ("LLP")
- (ii) Others (corporate bodies):
  - Company
  - Other than Company

#### 21.2.2 Non-Resident Shareholders being:

- (i) Non-Resident Indians (NRIs)
- (ii) Foreign Institutional Investors (FIIs) / Foreign Portfolio Investors (FPIs)
- (iii) Others:
  - Foreign Company
  - Foreign non-corporate shareholders Other than Company

## 21.3 INCOME TAX PROVISIONS IN RESPECT OF BUYBACK OF EQUITY SHARES LISTED ON RECOGNISED STOCK EXCHANGE

Section 115QA of the IT Act introduced by the Finance Act, 2013 w.e.f. June 1, 2013 contains provisions for taxation of a domestic company in respect of buyback of shares (within the meaning of Section 68 of the Companies Act, 2013). The Section provides for the levy of additional income-tax at the rate of twenty per cent (as increased by surcharge and health and education cess, as applicable) of the distributed income as defined under the said section on account of buyback of shares of all domestic Indian companies including listed companies, i.e. companies whose shares are listed on a recognized stock exchange.

Distributed Income is defined under section 115QA of the IT Act to mean the consideration paid by the company on buyback of shares as reduced by the amount which was received

by the company on issue of such shares, determined in the manner specified under rule 40BB of the Income Tax Rules, 1962 ("the Rules").

It would be noted that Section 115QA of the IT Act start with "notwithstanding anything contained in any other provisions of this Act". Thus, this section overrules all other provisions of the IT Act and has overriding effect on all other provisions of the IT Act.

### 21.3.1 Taxability in the hands of the Company

The tax on the Distributed Income by the company shall be treated as the final payment of tax in respect of the said income and no further credit thereof shall be claimed by the company or by any other person in respect of the amount of tax so paid.

No deduction under any other provision of this Act shall be allowed to the company or a shareholder in respect of the income which has been charged to tax.

#### 21.3.2 Taxability in the hands of the Shareholder

As additional income-tax has been levied on the company under Section 115QA of the IT Act, the consequential income arising in the hands of shareholders has been exempted from tax under section 10(34A) of the IT Act. Accordingly, any income arising in the hands of shareholder (whether resident or non-resident) on account of buyback of shares shall be exempt from any subsequent tax in India irrespective of the characterization of the shares, i.e. whether long term or short term or held as investment or stock-in-trade.

Thus, the tax implications to the following categories of shareholders are as under:

#### Resident Shareholders or Deemed Resident Shareholders

Income arising to the shareholder on account of buyback of shares as referred to in section 115QA of the IT Act is exempt from tax under the provisions of the amended section 10(34A) of the IT Act with effect from July 5, 2019.

#### Non-Resident Shareholders

While the income arising to the shareholder on account of buyback of shares as referred to in section 115QA of the IT Act is exempt from tax under the provisions of the amended section 10(34A) with effect from July 5, 2019 in the hands of a Non-resident as well, the same may be subject to tax in the country of residence of the shareholder as per the provisions of the tax laws of that country. The credit of tax may or may not be allowed to such Non-resident shareholder to be claimed in the country of residence in respect of the buyback tax paid by the company in view of Section 115QA (4) and (5) of the IT Act. The Non-resident shareholders need to consult their tax advisors with regard to availability of such a tax credit.

#### 21.4 TAX DEDUCTION AT SOURCE

The Company is not required to deduct tax at source on the consideration payable to shareholder (whether resident or non-resident) pursuant to the Buyback.

#### 21.5 **SECURITIES TRANSACTION TAX**

Since the Buyback of shares shall take place through the settlement mechanism of the Stock Exchange, Securities Transaction Tax will be applicable at the applicable rate.

#### 21.6 NON-APPLICABILITY OF RECENT AMENDMENTS IN THE FINANCE (NO.2) BILL, 2024

It may be noted that the Finance (no. 2) Bill, 2024 which is placed in parliament on July 23, 2024 has proposed the following amendments with respect to buy back of shares and the extract of the amendments is given below:

- Clause (22) of the Section 2 provides the definition of dividend which, inter alia, does
  not include any payment made by a company on purchase of its own shares from a
  shareholder in accordance with the provisions of section 77A of the Companies Act,
  1956.
  - It is proposed to amend the said clause so as to insert sub-clause (f) therein and omit item (iv) to provide that dividend, inter alia, include any payment by a company on purchase of its own shares from a shareholder in accordance with the provisions of section 68 of the Companies Act, 2013.
- In section 46A of the Income-tax Act, the following proviso shall be inserted before the Explanation, with effect from the 1st day of October, 2024, namely:— "Provided that where the shareholder receives any consideration of the nature referred to in subclause (f) of clause (22) of section 2 from any company, in respect of any buy-back of shares, that takes place on or after the 1st day of October, 2024, then for the purposes of this section, the value of consideration received by the shareholder shall be deemed to be nil."
- Clause (34) of the Section 10 of the Income Tax Act, provides exemption to any income arising to an assessee, being a shareholder, on account of buy back of shares by the company as referred to in section 115QA.
  - It is also proposed to insert a new proviso to clause (34) of the said section so as to provide that this clause shall not apply with respect to any buy back of shares by a company on or after the 1st day of October, 2024.

These amendments will take effect from October 1, 2024 and do not have any income tax implication on the proposed Buyback transaction being undertaken by the Company.

#### **CAVEAT:**

THE SUMMARY OF THE TAX CONSIDERATIONS AS ABOVE IS BASED ON THE CURRENT PROVISIONS OF THE TAX LAWS OF INDIA, WHICH ARE SUBJECT TO CHANGE OR MODIFICATION BY SUBSEQUENT LEGISLATIVE, REGULATORY, ADMINISTRATIVE OR JUDICIAL DECISIONS.

IN VIEW OF THE SPECIFIC NATURE OF TAX CONSEQUENCES, SHAREHOLDERS WHO ARE NOT TAX RESIDENTS OF INDIA ARE REQUIRED TO CONSULT THEIR TAX ADVISORS FOR THE APPLICABLE TAX AND THE APPROPRIATE COURSE OF ACTION THAT THEY SHOULD TAKE CONSIDERING THE PROVISIONS OF THE RELEVANT COUNTRY OR STATE TAX LAW AND PROVISIONS OF DTAA WHERE APPLICABLE.

#### 22. DECLARATION FROM THE BOARD OF DIRECTORS

Declaration as required by clause (ix) and clause (x) of Schedule I of the Buyback Regulations:

22.1 The Board confirms that there are no defaults (either in the past or subsisting) in the

repayment of any deposits (including interest payable thereon), redemption of debentures or preference shares, payment of dividend or repayment of any term loans to any financial institution or banks (including interest payable thereon), as the case may be, and in case of defaults which have ceased to subsist, if any, a period of more than 3 (three) years has lapsed.

As required by Clause (x) of Schedule I of the Buyback Regulations, the Board has confirmed that it has made full enquiry into the affairs and prospects of the Company and has formed an opinion, that:

- (i) immediately following the date of the Board Meeting, i.e., Thursday, July 18, 2024, approving the Buyback, there will be no grounds on which the Company could be found unable to pay its debts, if any;
- (ii) as regards the Company's prospects for the year immediately following the date of Board Meeting, and having regard to the Board's intention with respect to the management of the Company's business during that year and to the amount and character of the financial resources, which will, in the Board's view, be available to the Company during that year, the Company will be able to meet its liabilities as and when they fall due and will not be rendered insolvent within a period of 1 (One) year from the date of the Board Meeting; and
- (iii) in forming its opinion aforesaid, the Board has taken into account the liabilities (including prospective and contingent liabilities) as if the Company were being wound up under the provisions of the Companies Act, or the Insolvency and Bankruptcy Code, 2016, as applicable.

This declaration is made and issued under the authority of the Board of Directors in terms of the resolution passed at the meeting held on Thursday, July 18, 2024.

For and on behalf of the Board of Directors

Sd/- Sd/-

K. Nityananda Reddy Managing Director **DIN**: 01284195

Mettu Madan Mohan Reddy Whole-time Director **DIN**: 01284266

#### 23. STATUTORY AUDITOR'S REPORT

The text of the report dated Thursday, July 18, 2024, of M/s. Deloitte Haskins & Sells, Chartered Accountants, the statutory auditors of the Company, addressed to the Board of the Company is reproduced below:

### **Quote**

To, Board of Directors, Aurobindo Pharma Limited Plot No 2, Maithrivihar, Ameerpet, Hyderabad, Telangana India, – 500038 Re: Statutory Auditor's Report in respect of proposed buyback of equity shares by Aurobindo Pharma Limited (the "Company") in terms of Clause (xi) of Schedule I of the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended ("the Buyback Regulations")

- 1. This Report is issued in accordance with the terms of our engagement letter July 03, 2024.
- 2. The Board of Directors of the Company have approved a proposal for buyback of Equity Shares by the Company at its meeting held on July 18, 2024, in pursuance of the provisions of Sections 68, 69 and 70 of the Companies Act, 2013, as amended (the "Act") and the Buyback Regulations.
- 3. We have been requested by the Management of the Company to provide a report on the accompanying "Statement of Permissible Capital Payment as at March 31, 2024" ('Annexure A') (hereinafter referred to as the "Statement"). This Statement has been prepared by the Management, which we have stamped for the purposes of identification only.

# Management's Responsibility:

4. The preparation of the Statement in compliance with the proviso to Section 68(2)(b) of the Act and the proviso to Regulation 5(i)(b) of the Buyback Regulations and compliance with the Buyback Regulations, is the responsibility of the Management of the Company, including the computation of the amount of the permissible capital payment, the preparation and maintenance of all accounting and other relevant supporting records and documents. This responsibility includes the design, implementation and maintenance of internal controls relevant to the preparation and presentation of the Statement and applying an appropriate basis of preparation; and making estimates that are reasonable in the circumstances.

As the Buyback Regulations and the Act do not define the term "insolvent", the Company has applied the guidance provided in paragraphs 25 and 26 of Ind AS 1, Presentation of Financial Statements, which relate to the assessment of the Company's ability to continue as a going concern for a period of one year from July 18, 2024 (date of passing of the Board Meeting resolution).

# **Auditor's Responsibility:**

- 5. Pursuant to the requirements of the Buyback Regulations, it is our responsibility to provide a reasonable assurance that:
  - i. we have inquired into the state of affairs of the Company in relation to the annual audited standalone and consolidated financial statements as at March 31, 2024 which were approved by the Board of Directors of the Company at their meeting held on May 25, 2024, and yet to be adopted by the shareholders of the Company in the ensuing Annual General Meeting.
  - ii. the amount of permissible capital payment as stated in Annexure A, has been properly determined considering the annual audited standalone and consolidated financial statements as at March 31, 2024 in accordance with the proviso to Section 68(2)(b) of the Act and the proviso to Regulation 5(i)(b) of the Buyback Regulations; and
  - iii. the Board of Directors of the Company, in their Meeting held on July 18, 2024 have formed the opinion as specified in Clause (x) of Schedule I to the Buyback Regulations, on reasonable grounds and that the Company will not, having regard to its state of affairs, be rendered insolvent (as defined in management responsibility above) within a period of one year from the aforesaid date with regard to the proposed buyback is approved at

# Board meeting.

- 6. The annual standalone and consolidated financial statements referred to in paragraph 5 above, have been audited by us, on which we have issued an unmodified audit opinion in our report dated May 25, 2024. We conducted our audit of the annual standalone and consolidated financial statements in accordance with the Standards on Auditing specified under Section 143(10) of the Act and other applicable authoritative pronouncements issued by the Institute of Chartered Accountants of India. Those Standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. Our audit was not planned and performed in connection with any transactions to identify matters that may be of potential interest to third parties.
- 7. We conducted our examination of the Statement in accordance with the Guidance Note on Audit Reports and Certificates for Special Purposes (Revised 2016), issued by the Institute of Chartered Accountants of India (the "Guidance Note") and Standards on Auditing specified under Section 143(10) of the Companies Act, 2013, in so far as applicable for the purpose of this report. The Guidance Note requires that we comply with the ethical requirements of the Code of Ethics issued by the Institute of Chartered Accountants of India.
- 8. We have complied with the relevant applicable requirements of the Standard on Quality Control (SQC) 1, Quality Control for Firms that Perform Audits and Reviews of Historical Financial Information, and Other Assurance and Related Services Engagements. Further our examination did not extend to any other parts and aspects of a legal or proprietary nature in the aforesaid Buyback.

# **Opinion**

- 9. Based on inquiries conducted and our examination as above, we report that:
  - i. We have inquired into the state of affairs of the Company in relation to its annual audited standalone and consolidated financial statements as at March 31, 2024, which have been approved by the Board of Directors of the Company in their meeting held on May 25, 2024.
  - ii. The amount of permissible capital payment towards the proposed buy back of equity shares as computed in the Statement attached herewith, as Annexure A, in our view has been properly determined in accordance with the proviso to Section 68(2)(b) of the Act and the proviso to Regulation 5(i)(b) of the Buyback Regulations.
  - iii. The Board of Directors of the Company, at their meeting held on July 18, 2024 have formed their opinion as specified in clause (x) of Schedule I to the Buyback Regulations, on reasonable grounds and that the Company having regard to its state of affairs, will not be rendered insolvent (as defined in management responsibility above) within a period of one year from the date of passing the Board Resolution dated July 18, 2024.

# Restriction on use

10. This report has been issued at the request of the Company solely for use of the Company (i) in connection with the proposed buyback of equity shares of the Company as mentioned in paragraph 2 above, (ii) to enable the Board of Directors of the Company to include in the Letter of offer and other documents pertaining to buyback to be filed with (a) the Registrar of Companies, Securities and Exchange Board of India, stock exchanges, and any other regulatory authority as per applicable law; and (b) the Central Depository Services (India) Limited, National Securities Depository Limited and (c) can be shared with the Manager to Buyback offer in connection with the proposed buyback of equity shares of the Company for onward submission to relevant authorities in pursuance to the provisions of Section 68 and other applicable

provisions of the Act and the Buyback Regulations, and may not be suitable for any other purpose. This report should not be used for any other purpose without our prior written consent. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this report is shown or into whose hands it may come without our prior consent in writing.

For **Deloitte Haskins & Sells**Chartered Accountants
(Firm's Registration No.008072S)

Sd/-C Manish Muralidhar

(Partner) (Membership No. 213649)

(UDIN: 24213649BKCJHT3883)

Place: Hyderabad Date: July 18, 2024

## Annexure A - Statement of Permissible Capital Payment as at March 31, 2024:

Computation of amount of permissible capital payment towards buyback of equity shares in accordance with the proviso to Section 68(2)(b) of the Companies Act, 2013 ("the Act") and read with proviso to Regulation 5(i)(b) of Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended, based on annual audited standalone and consolidated financial statements as at and for the year ended March 31, 2024.

(Amount in ₹ millions)

Particulars		Amount - Standalone	Amount - Consolidated
Paid up Equity Share Capital as on March 31, 2024 (585,938,609 fully paid-up Equity Shares of ₹ 1 each)	(A)	585.9	585.9
Free Reserves as on March 31, 2024			
Securities Premium		3,427.9	4,178.9
General Reserve		7,888.4	8,131.6
Retained Earnings		1,83,488.7	2,68,014.2
Total Free Reserves	(B)	1,94,805.0	2,80,324.7
Total	C=(A+B)	1,95,390.9	2,80,910.6
Maximum amount permissible towards buyback of equity shares in accordance with the proviso to Section 68(2)(b) of the Companies Act, 2013 and read with proviso to Regulation 5(i)(b) of Buyback Regulations (10% of the total Paid-up equity capital and free reserves of standalone and consolidated financial statements)		19,539.1	28,091.1
Maximum amount permissible for buyback lower of Standalone and Consolidated amounts			19,539.1

# Notes:

1) The amount of paid-up equity share capital and free reserves as at March 31, 2024 have been extracted from the annual audited standalone and consolidated financial statements of the Company as at and for the year ended March 31, 2024.

2) As the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended and the Act do not define the term "insolvent", the Company has applied the guidance provided in paragraphs 25 and 26 of Ind AS 1, Presentation of Financial Statements, which relate to the assessment of the Company's ability to continue as a going concern for a period of one year from July 18, 2024 as well as for a period of one year immediately following the date of passing of the Board Meeting resolution.

For and on behalf of Board of Directors of Aurobindo Pharma Limited

Sd/-

K. Nityananda Reddy Vice Chairman & Managing Director

Date: July 18, 2024

# **Unquote**

#### 24. DOCUMENTS FOR INSPECTION

Copies of the following documents will be available for inspection at the registered office of the Company Plot No. 2, Maithrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India from Monday to Friday between 10:00 am (IST) to 5:00 pm (IST) on all working days except public holidays during the Buyback Period:

- 24.1 Copies of the certificate of incorporation, memorandum and articles of association of the Company;
- 24.2 Copies of the annual reports of the Company for the financial years ended March 31, 2024, March 31, 2023 and March 31, 2022;
- 24.3 Copy of the resolution passed by the Board of Directors at the meeting held on Thursday, July 18, 2024 approving proposal for Buyback;
- 24.4 Copy of the report dated Thursday, July 18, 2024 of M/s. Deloitte Haskins & Sells, Chartered Accountants, the Statutory Auditors of the Company, in terms of clause (xi) of Schedule I of the Buyback Regulations;
- 24.5 Copy of the Public Announcement dated Friday, July 19, 2024 and published in the newspapers on Monday, July 22, 2024 regarding the Buyback;
- 24.6 Copy of declaration of solvency as prescribed under Section 68(6) of the Companies Act;
- 24.7 Copy of Escrow Agreement dated Thursday, July 18, 2024 between the Company, the Escrow Agent and the Manager to the Buyback;
- 24.8 Letter from Escrow Bank dated Monday, July 22, 2024 that the Escrow Account in the name of "Aurobindo Pharma Limited Buyback Escrow Account" has been opened and confirming deposit of funds;
- 24.9 Certificate dated Friday, July 19, 2024 of G Pavan Kumar Reddy (Membership No. 229495), partner at G P M & Associates, Chartered Accountants (Firm Registration No. 015343S), confirming that the Company has firm and adequate financial arrangements to fulfil the obligations under the Buyback; and
- 24.10 Note on taxation, dated Wednesday, July 31, 2024, obtained by the Company from G P M & Associates, Chartered Accountants.

### 25. DETAILS OF THE COMPLIANCE OFFICER

The Company has designated the following as the Compliance Officer for the Buyback:

Name: Mr B Adi Reddy

**Designation**: Company Secretary and Compliance Officer

Address: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad

Knowledge City, Raidurg Panmaktha, Ranga Reddy District,

Hyderabad - 500 032, Telangana, India.

**Tel no.**: +91 40 6672 5333 **Email**: cs@aurobindo.com

In case of any clarifications or to address investor grievance, the shareholders may contact the Compliance Officer, from Monday to Friday between 10:00 am (IST) to 5:00 pm (IST) on all working days except public holidays, at the above-mentioned address.

# 26. DETAILS OF REMEDIES AVAILABLE TO SHAREHOLDERS/ BENEFICIAL OWNERS

- 26.1 In case of any grievances relating to the Buyback (including non-receipt of the Buyback consideration, share certificate, demat credit, etc.), the Eligible Shareholders can approach the Compliance Officer and/or Manager to the Buyback and/or Registrar to the Buyback for redressal.
- 26.2 If the Company makes any default in complying with the requirements under the Companies Act or any rules made thereunder as may be applicable to the Buyback, the Company or any officer of the Company who is in default shall be liable in terms of the Companies Act.
- 26.3 The address of the concerned office of the Registrar of Companies is as follows:

# Registrar of Companies, Telangana at Hyderabad

9HCQ+GG2, GSI Post, Tattiannaram, Corporate Bhawan Rd, Bandlaguda, Nagole, Hyderabad, Telangana 500068, India

Tel. no.: +91 40 2980 5427

# 27. DETAILS OF THE INVESTOR SERVICE CENTRE

In case of any query, the Eligible Shareholders may also contact the Registrar to the Buyback appointed as the Investor Service Centre for the purposes of the Buyback, from Monday to Friday between 10:00 am (IST) to 5:00 pm (IST) on all working days except public holidays, at the address at the following address:



# **KFin Technologies Limited**

**Address:** Selenium Tower- B, Plot No 31 & 32 Gachibowli, Financial District Nanakramguda,

Serilingampally, Hyderabad, Telangana - 500032

Tel. no.: +91 40 6716 2222 Fax no.: +91 40 6716 1563 Tollfree number: 18003094001 Contact person: M Murali Krishna

Email: aurobindo.buyback@kfintech.com

Website: www.kfintech.com

Investor Grievance mail: einward.ris@kfintech.com

SEBI Registration Number: INR000000221

Validity: Permanent

CIN: L72400TG2017PLC117649

### 28. DETAILS OF THE MANAGER TO THE BUYBACK

The Company has appointed the following as Manager to the Buyback:



# **AXIS CAPITAL LIMITED**

1st Floor, Axis House

C-2 Wadia International Centre, P. B. Marg, Worli

Mumbai - 400 025, Maharashtra, India

**Tel**.: +91 22 4325 2183 **Fax**: +91 22 4325 3000

Contact Person: Harish Patel/Simran Gadh

Email: apl.buyback@axiscap.in Website: www.axiscapital.co.in

**SEBI Registration Number**: INM000012029

# 29. DECLARATION BY THE DIRECTORS

In terms of Regulation 24(i)(a) of the Buyback Regulations, the Board accepts full responsibility for all the information contained in this Letter of Offer and confirms that this Letter of Offer contains and will contain true, factual and material information and does not contain any misleading information. This Letter of Offer is issued under the authority of the Board and in terms of the resolution passed by the Board on Thursday, July 18, 2024.

For and on behalf of the Board of Directors of Aurobindo Pharma Limited

Sd/- Sd/- Sd/-

Mettu Madan Mohan

K. Nityananda Reddy
Managing Director

lanaging Director Reddy
DIN: 01284195 Whole-time Director
DIN: 01284266

B. Adi Reddy
Company Secretary and Compliance
Officer
Membership No.: ACS 13709

**Date**: August 01, 2024 **Place**: Hyderabad

### TENDER FORM

# FORM OF ACCEPTANCE-CUM-ACKNOWLEDGEMENT (FOR ELIGIBLE SHAREHOLDERS HOLDING EQUITY SHARES IN DEMATERIALIZED FORM)

Bid Number:			BU	BACK OPENS	ON	MOND	AY, AUGUST	05, 2024		
Date:			BU	BACK CLOSES	ON	FRIDA	, AUGUST 09	, 2024		
							For Regist	rar use		
			II	nward No.	1	Da	te			Stamp
					1	Status	(please tick o	appropriate	box)	
				Individual			FII/FPI		T	Insurance Co
				Foreign Co	).		NRI/OCB			FVCI
				Body Corp	orate		Bank/FI			Pension/PF
				VCF			Partnershi	o/LLP		Mutual Fund
_				Others (Sp		<u> </u>			<u> </u>	
To,				1	India Tax	Reside	ncy Status: P	lease tick a	ppropri	ate box
The Board of Directors,										
AUROBINDO PHARMA LIMITED C/o. KFin Technologies Limited										Resident of
Selenium Tower- B, Plot No 31 & 32 Gacl	hibowli.			Resident in	n India		Non-Resid	ent in		
Financial District Nanakramguda,	,						India			(Shareholder to fill
Serilingampally, Hyderabad, Telangana –	500032									country of residence)
Tel. no.: +91 40 6716 2222										
				1			estment (For			•
				Portfolio I	nvestment	Schem	e	Foreign	Investn	nent Scheme
ear Sir/ Madam,		in valation to district		1 20 000 (=:6:	. 0	Thir	City The sec	Nim - II	dua -1	Fight, Ch t-A.F. 11 Cl
ub: Letter of Offer dated Thursday, Augu f Aurobindo Pharma Limited (hereinafte										
f Aurobindo Pharma Limited (nereinafte ayable in cash (the "Buyback")	r reterred a	is "the Company") at a	price of ₹ 1,46	ou/- (Rupees (	one inous	and Fo	ur Hunarea a	na Sixty on	iy) per i	equity Share ("Buyback Price"
. I / We (having read and understood t	the Letter c	f Offer dated Thursday	v. August 01. 2	024 issued by	the Comr	anv) he	ereby tender	/ offer my	/ our Ec	uity Shares in response to the
Buyback on the terms and conditions			_			,,		,,	,	, ,
. I / We authorize the Company to buyl				ove) and to iss	ue instruct	tion(s) t	o the Registr	ar to the Bu	ıyback to	extinguish the Equity Shares.
. I / We hereby affirm that the Equity S	hares comp	rised in this Tender Off	fer are offered	for Buyback b	y me / us f	ree fro	m all liens, ec	uitable inte	erest, ch	arges and encumbrance.
. I/We declare that there are no restr		•		•	which lim	its / res	tricts in any i	manner my	/ our ri	ght to tender Equity Shares fo
Buyback and that I / we am / are legal	-				C -l					: d
<ul> <li>I / We agree that the Company will pa mechanism.</li> </ul>	y the Buyba	ack Price only after due	verification of	the validity of	r documen	its and i	that the cons	deration w	ш ве ра	id as per the secondary marke
. The Eligible Shareholders will have to e	ensure that	they keen the DP Accou	ınt active and ı	inblocked to r	eceive cre	dit in ca	se of return o	f Fauity Sha	ares due	to rejection or due to prorate
Buyback decided by the Company. Fu										-
credit remittance due to acceptance of	_			, ,						
. I / We agree that the consideration fo	r the accep	ted Equity Shares will b	e paid to the E	ligible Shareh	older as pe	er the p	rovisions of E	uyback Reg	gulations	s and circulars issued by SEBI.
. I / We agree to return to the Company										
· · · · · · · · · · · · · · · · · · ·	I / We undertake to execute any further documents and give any further assurances that may be required or expedient to give effect to my / our tender / offer and agree to abide by									
any decision that may be taken by the	Company to	o effect the Buyback in	accordance wi	th the Compa	nies Act, Bi	uyback	Regulations,	the extant a	ipplicabl	le foreign exchange regulation
and any other applicable laws.  O. I / We acknowledge that the responsi	hility to dis	charge the tax due on a	any gains arisin	g on huvback	is on me/i	ıs I/W	le agree to co	mnute gai	ns on th	is transaction and immediately
=		-					-	mpate gan	13 011 011	is transaction and immediater
pay applicable taxes in India and file tax return in consultation with our custodians/ authorized dealers/ tax advisors appropriately.  I/ We undertake to indemnify the Company if any tax demand is raised on the Company on account of gains arising to me / us on buyback of shares. I/ We also undertake to provide										
the Company, the relevant details in r	espect of th	ne taxability / non-taxal	bility of the pro	ceeds arising	on buybad	k of sh	ares by the Co	ompany, co	py of ta:	x return filed in India, evidence
of the tax paid etc., whenever called f										
2. Non-Resident Shareholders (including										
Shares to be transferred, the name of										
transferred i.e., "Price determined in a power of attorney.	accordance	with the Buyback Regu	liations" duly s	igned by the S	narenoide	r or nis	its duly appo	inted agen	t and in	the latter case, also enclose tr
<ol><li>Details of Equity Shares held and tend</li></ol>	lered / offer	red for Buyback:								
Particulars		<u> </u>	gures					In Words		
Number of Equity Shares held as on	Record Daf		-							
(Tuesday, July 30, 2024)										
Number of Equity Shares Entitled	for Buyba	ck								
(Buyback Entitlement)										
Number of Equity Shares offered	tor Buyba	ck								
(Including Additional Shares, if any)	or Fauit Cl	ares over and shalls be	c / har Dimbar-	k Entitlor	Number -	f E~:+-	Charac!:-!	lu tanda	l hy a=:	Eligible Chareholder += +1-
<b>Note</b> : An Eligible Shareholder may tende Buyback Entitlement of such Eligible Sha										
of such Eligible Shareholder shall be acco							-			
Eligible Shareholder over and above the	•		•	-	_					
14. I / We agree that the Clearing Corp	-		_					-		÷ •
				•						
	,	ACKNOWLEDGMENT SI								
		(To be filled by	tne Eligible Sho		oject to vei	rıfıcatio	n)			
DP ID				Client ID						
Received from Mr./Ms./Mrs.										
Form of Acceptance-cum-Acknowledge		inal TRS along with:								
No. of Equity Shares offered for Buybac	k (In	1	in words)							
Figures)			wolusj							
Please quote Client ID No. & DP ID No.	for all futur	e correspondence		Stamp of Sto	ck Broker					

15. Details of Account with Depository Participant (DP):		
Name of the Depository (tick whichever is applicable)	NSDL	CDSL

Name of the Depository Participant

DP ID No.

Client ID No. with the DP

6. Equity Shareholders Details:

Particulars	First/Sole Holder	Joint Hol	der 1	Joint Holder 2	Joint Holder 3
Full Name(s) Of the Holder					
Signature(s)*					
PAN					
Address of the Sole/First Equity Shareholder					•
Telephone No. of Sole/First Equity Shareholder			Email ID of Sole/First Equity Shareholder		

<sup>\*</sup> Non-individual Shareholders must affix rubber stamp and sign under valid authority. The relevant authorization should be enclosed with the application form submitted.

- 17. Applicable for all Non-Resident Shareholders only:
  - I / We undertake to pay income taxes in India on any income arising on such Buyback accordance with prevailing income tax laws in India. I / We also undertake to indemnify the Company against any income tax liability on any income earned on such Buyback of shares by me / us. I / We undertake to return to the Company any consideration in respect of the Buyback that may be wrongfully received by me/us.
  - I / We, being a Non-Resident Shareholder, agree to obtain and submit all necessary approvals, if any, and to the extent required from the concerned authorities including approvals from the Reserve Bank of India ("RBI") under Foreign Exchange Management Act, 1999, as amended ("FEMA") and the rules and regulations framed there under, for tendering Equity Shares in the Buyback, and also undertake to comply with the reporting requirements, if applicable, under the FEMA and any other rules, regulations and guidelines, in regard to remittance of funds outside India.

#### INSTRUCTIONS

#### This Tender Form has to be read along with the Letter of Offer and is subject to the terms and conditions mentioned in the Letter of Offer and this Tender Form

- 1. This Buyback will open on Monday, August 05, 2024 and close on Friday, August 09, 2024.
- 2. Eligible Shareholders who desire to tender their Equity Shares in dematerialized form under the Buyback would have to do so through their respective Seller Member by indicating the details of Equity Shares they intend to tender under the Buyback offer. For further details, please see the procedure as specified in the section entitled "Procedure for Tendering Shares and Settlement" in paragraph 20 on page no. 56 of the Letter of Offer.
- 3. Eligible-Shareholders may submit their duly filled Tender Form to the office of Registrar to the Buyback Offer (as mentioned in paragraph 20 (*Procedure for Tendering Shares and Settlement*) of the Letter of Offer) only post placing the bid via the Seller Member.
- 4. In case any registered entity that has merged with another entity and the merger has been approved and has come into effect but the process of getting the successor company as the registered Shareholder is still incomplete, then such entity along with the Tender Form should file a copy of the following documents: (i) Approval from the appropriate authority for such merger; (ii) The scheme of merger; and (iii) The requisite form filed with MCA intimating the merger.
- 5. The Buyback shall be rejected for Shareholders in case of receipt of the completed Tender Form and other documents, but non-receipt of Shares in the special account of the Clearing Corporation or a non-receipt of valid bid in the exchange bidding system.
- 6. The shares in the Offer would be liable to be rejected if (i) the tenderer is not an Eligible Shareholder of the Company as on the Record Date (ii) if there is a name and PAN mismatch in the demat account of the Eligible Shareholder (iii) in the event of non-receipt of the completed Tender Form and other documents from the Eligible Shareholders who were holding shares in physical form as on the Record Date and have placed their bid in dematerialized form.
- 7. The Eligible Shareholders will have to ensure that they keep the DP Account active and unblocked to receive credit in case of return of Equity Shares due to rejection or due to prorated Buyback as may be decided by the Company / Registrar to the Buyback, in accordance with the Buyback Regulations.
- 8. Eligible Shareholders to whom the Offer is made are free to tender shares to the extent of their Entitlement in whole or in part or in excess of their Entitlement, but not exceeding their holding as on Record Date.
- 9. All documents sent by Eligible Shareholders will be at their own risk. Eligible Shareholders are advised to safeguard adequately their interests in this regard.
- 10. By agreeing to participate in the Buyback, each Eligible Shareholder (including the Non-Resident Shareholder) undertakes to complete all relevant regulatory / statutory filings and compliances to be made by it under applicable law, including filing of Form FC-TRS. Further, by agreeing to participate in the Buyback, each Eligible Shareholder hereby (a) authorises the Company to take all necessary action, solely to the extent required, and if necessary, to be undertaken by the Company, for making any regulatory / statutory filings and compliances on behalf of such Shareholder; and (b) undertakes to provide the requisite assistance to the Company for making any such regulatory / statutory filings and compliances.
- 11. Non-Resident Shareholders must obtain and submit all necessary approvals, if any and to the extent required from the concerned authorities including approvals from the RBI under FEMA and the rules and regulations framed there under, for tendering Equity Shares in the Buyback, and also undertake to comply with the reporting requirements, if applicable, under the FEMA and any other rules, regulations and guidelines, in regard to remittance of funds outside India.
- 12. In case of non-receipt of the Letter of Offer, Eligible Shareholders holding Equity Shares may participate in the Buyback by providing their application in plain paper in writing signed by all Eligible Shareholders (in case of joint holding), stating name and address of the Eligible Shareholder(s), number of Equity Shares held as on the Record Date, Client ID number, DP Name, DP ID, beneficiary account number and number of Equity Shares tendered for the Buyback.
- 13. Eligible Sellers have to fill up the EVENT number issued by Depositary in the column for settlement details along with the market type as "Buyback", ISIN, Quantity of shares and CM BP ID of broker and execution date in the Delivery Instruction Slips (DIS) so that Equity Shares can be tendered for Buyback Offer
- 14. For the Eligible Shareholders holding Equity Shares in dematerialised form, the Tender Form and TRS is not required to be submitted to the Company, Manager or the Registrar. After the receipt of the Equity Shares in dematerialized form by the Clearing Corporation and a valid bid in the exchange bidding system, the Buyback shall be deemed to have been accepted for the Eligible Shareholders holding Equity Shares in dematerialized form.

All capitalised items not defined herein shall have the meaning ascribed to them in the Letter of Off	fer.
---	------

Tear along this line
ALL FUTURE CORRESPONDENCE IN CONNECTION WITH THIS BUYBACK, IF ANY, SHOULD BE ADDRESSED TO REGISTRAR TO THE BUYBACK AT THE FOLLOWING ADDRESS QUOTING
YOUR CLIENT ID AND DP ID:

Investor Service Centre: Aurobindo Pharma Limited - Buyback offer KFin Technologies Limited

#### TENDER FORM

# FORM OF ACCEPTANCE-CUM-ACKNOWLEDGEMENT (FOR ELIGIBLE SHAREHOLDERS HOLDING EQUITY SHARES IN PHYSICAL FORM)

Eligible Shareholders holding Equity Shares in physical form are requested to refer to paragraph 20.26 of the Letter of Offer titled 'Procedure to be followed by Eligible Shareholders

BUYBACK CLOSES ON FRIDAY, AUGUST 09, 2024  FOR Registrar use  Inward No.  Status (please tick appropriate box)  Individual FII/FPI Insurance Co Foreign Co. NRI/OCB FVCI Body Corporate Bank/FI Pension/PF VCF Partnership/LLP Mutual fund  Others (Specify)  Others (Specify)  India Tax Residency Status: Please tick appropriate box  India Tax Residency Status: Please tick appropriate box  Resident in India  Resident in India  Non-Resident in India  Resident of Investment (For NR Shareholders only)  Portfolio Investment Scheme  Foreign Investment Scheme  Foreign Investment Scheme	Bid Number:	d Securities Transfer Form with respect to Equity Shares held in physical form.  BUYBACK OPENS ON MONDAY, AUGUST 05, 2024						
Individual   Fil/Fel   Insurance Co   India Tax Residency Status: Please tick appropriate box   India Tax Residency Status: Please tick of India Tax Residency Status: Please tick appropriate box   India Tax Residency Status: Please ti								
Individual   Fil/FP    Insurance Co   Foreign Co.   NRIJOCB   FVC			HER CLOSES ON			•		
Stotus (please tick appropriate box)  Individual   BHJFP    Insurance Co   Foreign Co.   RNI/OCB   Shoty Corporate   Bank/FI   Pension/PF   Pension/PF   VCF   Dothers (Specify)   Pension/PF   VCF   VCF   Pension/PF   VCF   VCF   Pension/PF   VCF   VCF   Pension/PF   VCF   VCF   VCF   Pension/PF   VCF   VC			Inward No.				Stamp	
Individual   Fil/Pol   Insurance Co   Foreign Co.   NRI/OCD   NRI/OCD   Pertnership/L.P   Mutual fund   Muse Co.   NRI/OCD								
Individual   Fil/Pol   Insurance Co   Foreign Co.   NRI/OCD   NRI/OCD   Pertnership/L.P   Mutual fund   Muse Co.   NRI/OCD								
Foreign Co.   NRI/OCB   FVC    Partnership/LP   Mutual fund   Non-Resident in India   (Shareholder to fill country of residence)   Resident in India   Non-Resident in India   (Shareholder to fill country of residence)   Resident in India   Non-Resident in India   (Shareholder to fill country of residence)   Resident in India   Non-Resident in India   (Shareholder to fill country of residence)   Resident in India   Non-Resident in India   (Shareholder to fill country of residence)   Resident in India   Non-Resident in India   (Shareholder to fill country of residence)   Resident in India   (Shareholder to fill country of residence)   Resident in India   Non-Resident in India   (Shareholder to fill country of residence)   Resident in India   (Shareholder to fill country of residence)   Resident in India   (Shareholder to fill country of residence)   Resident in India   (Shareholder to fill country of residence)   Resident in India   (Shareholder to fill country of residence)   Resident in India   (Shareholder to fill country of residence)   Resident in India   (Shareholder to fill country of residence)   Resident in India   (Shareholder to fill country of residence)   Resident in India   (Shareholder to fill country of residence)   Resident in India   (Shareholder to fill country of residence)   Resident in India   (Shareholder to fill country of residence)   Resident in India   (Shareholder to fill country of residence)   Resident in India   (Shareholder to fill country of residence)   Resident in India   (Shareholder to fill country of residence)   Resident in India   (Shareholder to fill country of residence)   Resident in India   (Shareholder to fill country of residence)   Resident in India   (Shareholder to fill country of residence)   Resident in India				Statu		propriate box	•	
Body Corporate Bank/FI Pentenship/LIP Mutual fund  Tothers (Specify)  Resident in India  Resident in India  Tothers (Specify)					<u> </u>			
VCF   Partnership/LIP   Mutual fund					+ · · · · · · · · · · · · · · · · · · ·			
The Board of Directors,  WINDOBINDO PHARMA LIMITED  Jo. KFin Technologies Limited  Resident of Directors,  WINDOBINDO PHARMA LIMITED  Jo. KFin Technologies Limited  Resident of Directors,  Windoal Director Manakcampuda,  Berlingampally, Hyderabad, Telangana – 500032  Lel. no.: 491 40 6716 2222  Route of Investment (For NR Shareholders only)  Portfolio Investment Scheme  Toreign investment Scheme  Toreign investment Scheme  Portfolio Investment Scheme  Toreign investment Scheme  Portfolio Investment Scheme  Toreign investment Sch					· · · · · · · · · · · · · · · · · · ·	B	·	
India Tax Residency Status: Please tick appropriate box  WROSINDO PHARMA LIMITED  Jo. KFin Technologies Limited  Besident in India  Resident in India  Non-Resident in India  Non-Resident in India  Resident in India  Non-Resident in India  Resident of Issurance and Iss					Partnership/Li	_P	Mutuai iund	
MRS BOAT OF Directors, MURDINDO PARMA LIMITED C/o. KFin Technologies Limited Selenium Tower- B, Plot No 31, 8:32 Gachibowli, imancial District Nanakranguda, enlingampally, Hyderabad, Telangana – 500032 ele. no.: +91:40 6716 2222  Route of Investment (For NR Shareholders only) Portfolio Investment Scheme   Portfolio Investment Scheme   Foreign Investment Scheme   F	To.			ia Tay Posis	doney Status: Blo	aco tick appro	pariata hay	
AUROBINDO PHARMA LIMITED  To, KFIn Technologies Limited  Resident in India  Resident in I	,	-	IIIu	ia rax nesic	lency Status. Fie	ase tick appir	риасе вох	
Resident in India  Resident in I								
Resident in India    Resident in India   Non-Resident in India   Non-Resident in India   (Shareholder to fill country of residence)							Resident of	
Country of residence	John III recimologico Elimeca						Resident of	
Country of residence	Selenium Tower- B. Plot No 31 & 32 Gachibowli.		Resident in India		Non-Resident	in India	(Shareholder to fill	
Route of Investment (For NR Shareholders only)  Portfolio Investment (For NR Shareholders only)  Roughcek Price (Papashle in case (the "Buyback")  1. // We without the terms and conditions set out below and in the Letter of Offer.  2. // We authorize the Company to Buyback the Equity Shares offered (as mentioned above) and to issue instruction(s) to the Registrar to the Buyback to extinguish the Equity Shares.  3. // We hereby affirm that the Equity Shares offered (as mentioned above) and to issue instruction(s) to the Registrar to the Buyback to extinguish the Equity Shares.  3. // We agree that the Equity Shares offered (as mentioned above) and to issue instruction(s) to the Registrar to the Buyback to extinguish the Equity Shares.  3. // We hereby affirm that the Equity Shares offered (as mentioned above) and to issue instruction(s) to the Registrar to the Buyback to extinguish the Equity Shares.  3. // We agree that the Consideration for the accepted Equity Shares for Buyback and that i./ we am / are legally entitled to tender the Equity Shares for Buyback.  3. // We agree that the Company is not obliged to accept any Equity Shares offered for Buyback where loss of share certificates has been notified to the Company.  3. // We agree that the Company will pay the Buyback Price only after due verification of the validity of the documents and that the consideration will be paid as per secondary market mechanism to first ramed Eligible Shareholder.  3. // We agree to return to the Company any Buyback consideration that may be wron							, ,	
Dear Sir/ Madam,  Dear Sir/ Ma	Serilingampally, Hyderabad, Telangana – 500032							
Dear Sir / Madam, Sub: Letter of Offer dated Thursday, August 01, 2024 in relation to the buyback of up to 51,36,986 (Fifty One Lakh Thirty Six Thousand Nine Hundred and Eighty Six only) Equity shares of Aurobindo Pharma Limited (hereinafter referred as "the Company") at a price of ₹ 1,460/- (Rupees One Thousand Four Hundred and Sixty only) per Equity Share "Rubyback Price" payable in case hithe "Buyback")  1. I / We (having read and understood the Letter of Offer dated Thursday, August 01, 2024 issued by the Company) hereby tender / offer my / our Equity Shares in response to the Buyback on the terms and conditions set out below and in the Letter of Offer.  2. I / We authorize the Company to Buyback the Equity Shares offered (as mentioned above) and to issue instruction(s) to the Registrar to the Buyback to extinguish the Equity Shares.  3. I / We hereby affirm that the Equity Shares comprised in this Tender Offer are offered for Buyback by me / us free from all liens, equitable interest, charges and encumbrance.  4. I / We declare that there are no restraints / injunctions or other covenants of any nature which limits / restricts in any manner my/ our right to tender Equity Shares for Buyback and that I / we am / are legally entitled to tender the Equity Shares for Buyback.  5. I / We agree that the consideration for the accepted Equity Shares will be paid to the Eligible Shareholder as per the provisions of Buyback Regulations and circulars issued by SEBI.  5. I / We agree that the Company is not obliged to accept any Equity Shares offered for Buyback where loss of share certificates has been notified to the Company.  7. I / We agree that the Company will pay the Buyback Price only after due verification of the validity of the documents and that the consideration will be paid as per secondary market mechanism to first named Eligible Shareholder.  5. I / We agree to return to the Company any Buyback consideration that may be wrongfully received by me / us.  6. I / We agree to return to the Company any Buyback	Tel. no.: +91 40 6716 2222							
Dear Sir / Madam, sub: Letter of Offer dated Thursday, August 01, 2024 in relation to the buyback of up to 51,36,986 (Fifty One Lakh Thirty Six Thousand Nine Hundred and Eighty Six only) Equity Shares of Aurobindo Pharma Limited (hereinafter referred as "the Company") at a price of ₹ 1,460/ (Rupees One Thousand Four Hundred and Sixty only) per Equity Shares davobindo Pharma Limited (hereinafter referred as "the Company") at a price of ₹ 1,460/ (Rupees One Thousand Four Hundred and Sixty only) per Equity Shares (Buyback Price") payable in cash (the "Suyback").  I // We (aurity Fig. 2014) and continues and conditions set out below and in the Letter of Offer.  I // We authorize the Company to Buyback the Equity Shares offered (as mentioned above) and to issue instruction(s) to the Registrar to the Buyback to extinguish the Equity Shares.  I // We declare that there are no restraints / injunctions or other covenants of any nature which limits / restricts in any manner my/ our right to tender Equity Shares for Buyback.  I // We declare that there are no restraints / injunctions or other covenants of any nature which limits / restricts in any manner my/ our right to tender Equity Shares for Buyback.  I // We agree that the consideration for the accepted Equity Shares for Buyback.  I // We agree that the consideration for the accepted Equity Shares offered for Buyback where loss of share certificates has been notified to the Company.  I // We agree that the Company will pay the Buyback Price only after due verification of the validity of the documents and that the consideration will be paid as per secondary market mechanism to first named Eligible Shareholder.  I // We agree that the Company to Issue a Letter of Confirmation ("LOC") for the unaccepted Equity shares in case only a portion of the physical shares held by me is accepted in the Buyback.  I // We agree to return to the Company any Buyback consideration that may be required or expedient to give effect to my / our tender / offer and agree to abide by any deci				Route of In	vestment (For N	R Shareholder	rs only)	
Sub: Letter of Offer dated Thursday, August 01, 2024 in relation to the buyback of up to 51,36,986 (Fifty One Lakh Thirty Six Thousand Nine Hundred and Eighty Six only) Equity Shares of Aurobindo Pharma Limited (hereinafter referred as "the Company") at a price of ₹ 1,460/- (Rupees One Thousand Four Hundred and Sixty only) per Equity Shares "Buyback Price") payable in cash (the "Buyback")  1.   / We (having read and understood the Letter of Offer dated Thursday, August 01, 2024 issued by the Company) hereby tender / offer my / our Equity Shares in response to the Buyback on the terms and conditions set out below and in the Letter of Offer.  2.   / We having read and understood the Letter of Offer are offered for Buyback by the Company) hereby tender / offer my / our Equity Shares in response to the Buyback on the terms and conditions set out below and in the Letter of Offer.  2.   / We authorize the Company to Buyback the Equity Shares offered (as mentioned above) and to issue instruction(s) to the Registrar to the Buyback to extinguish the Equity Shares.  3.   / We hereby affirm that the Equity Shares comprised in this Tender Offer are offered for Buyback by me / us free from all liens, equitable interest, charges and encumbrance.  4.   / We declare that there are no restraints / injunctions or other covenants of any nature which limits / restricts in any manner my/ our right to tender Equity Shares for Buyback and that 1 / we am / are legally entitled to tender the Equity Shares for Buyback.  3.   / We agree that the Company is not obliged to accept any Equity Shares offered for Buyback where loss of share certificates has been notified to the Company.  4.   / We agree that the Company will pay the Buyback Price only after due verification of the validity of the documents and that the consideration will be paid as per secondary market mechanism to first named Eligible Shareholder.  3.   / We agree that the Company is not obliged to accept any Equity Shares offered for Buyback where loss of share only a portio			Portfolio Investme	nt Scheme		Foreign Inve	estment Scheme	
Shares of Aurobindo Pharma Limited (hereinafter referred as "the Company") at a price of ₹ 1,460/- (Rupees One Thousand Four Hundred and Sixty only) per Equity Share' "Buyback Price") payable in cash (the "Buyback")  1. I/ We (having read and understood the Letter of Offer dated Thursday, August 01, 2024 issued by the Company) hereby tender / offer my / our Equity Shares in response to the Buyback on the terms and conditions set out below and in the Letter of Offer.  2. I/ We authorize the Company to Buyback the Equity Shares offered (as mentioned above) and to issue instruction(s) to the Registrar to the Buyback to extinguish the Equity Shares.  3. I/ We hereby affirm that the Equity Shares comprised in this Tender Offer are offered for Buyback by me / us free from all liens, equitable interest, charges and encumbrance.  3. I/ We hereby affirm that the Equity Shares comprised in this Tender Offer are offered for Buyback by me / us free from all liens, equitable interest, charges and encumbrance.  4. I/ We declare that there are no restraints / injunctions or other covenants of any nature which limits / restricts in any manner my/ our right to tender Equity Shares for Buyback.  5. I/ We agree that the consideration for the accepted Equity Shares for Buyback.  5. I/ We agree that the company is not obliged to accept any Equity Shares offered for Buyback where loss of share certificates has been notified to the Company.  5. I/ We agree that the Company will pay the Buyback Price only after due verification of the validity of the documents and that the consideration will be paid as per secondary market mechanism to first named Eligible Shareholder.  5. I/ We agree to return to the Company any Buyback consideration that may be wrongfully received by me / us.  6. I/ We authorize the Company to issue a Letter of Confirmation ("LOC") for the unaccepted Equity shares in case only a portion of the physical shares held by me is accepted in the Buyback.  6. I/ We authorize the Company to issue a Letter of Confirmation ("	Dear Sir/ Madam,							
13. Details of Equity Shares held and tendered / offered for Buyback:  Particulars  Number of Equity Shares held as on Record Date (Tuesday, July 30, 2024)  Number of Equity Shares Entitled for Buyback (Buyback Entitlement)  Number of Equity Shares offered for Buyback (including Additional Shares, if any)  Note: An Eligible Shareholder may tender Equity Shares over and above his / her Buyback Entitlement. Number of Equity Shares validly tendered by any Eligible Shareholder up to the	Buyback on the terms and conditions set out below and in the Letter of 2. I / We authorize the Company to Buyback the Equity Shares offered (a Shares.  I / We hereby affirm that the Equity Shares comprised in this Tender Of 1. I / We declare that there are no restraints / injunctions or other covena and that I / we am / are legally entitled to tender the Equity Shares for 1. I / We agree that the consideration for the accepted Equity Shares will SEBI.  I / We agree that the Company is not obliged to accept any Equity Shares vill we agree that the Company will pay the Buyback Price only after dimarket mechanism to first named Eligible Shareholder.  I / We agree to return to the Company any Buyback consideration that I / We authorize the Company to issue a Letter of Confirmation ("LOC" the Buyback.  I / We undertake to execute any further documents and give any further abide by any decision that may be taken by the Company to effect the exchange regulations and any other applicable laws.  I / We acknowledge that the responsibility to discharge the tax due on any pay applicable taxes in India and file tax return in consultation with our 12. I / We undertake to indemnify the Company if any tax demand is raised provide the Company, the relevant details in respect of the taxability /	f Offer. as mentione ffer are offer ints of any r Buyback. I be paid to es offered f ue verificat may be wro ) for the un her assuran he Buyback ny gains aris custodians d on the Co	ed above) and to is ered for Buyback by nature which limits the Eligible Sharel for Buyback where ion of the validity congfully received b accepted Equity shaces that may be re- in accordance with sing on buyback is co- sid authorized deale- empany on account	ssue instruct  y me / us fre  / restricts in  nolder as pe  loss of share  of the docum  y me / us.  nares in case  equired or e  th the Comp  on me/us. I /  rs/ tax advis  of gains ari	ee from all liens, in any manner my er the provisions e certificates has ments and that the e only a portion of expedient to give panies Act, Buyb We agree to comsors appropriatelising to me / us of the end of	gistrar to the lequitable intervious of Buyback Resulation of the physical effect to my plack Regulation on buyback of buyback of the physical effect to my plack Regulation on buyback of buyback of	Buyback to extinguish the Equity rest, charges and encumbrance. tender Equity Shares for Buyback egulations and circulars issued by to the Company. ion will be paid as per secondary shares held by me is accepted in / our tender / offer and agree to ns, the extant applicable foreign this transaction and immediately shares. I / We also undertake to	
Particulars  Number of Equity Shares held as on Record Date (Tuesday, July 30, 2024)  Number of Equity Shares Entitled for Buyback (Buyback Entitlement)  Number of Equity Shares offered for Buyback (including Additional Shares, if any)  Note: An Eligible Shareholder may tender Equity Shares over and above his / her Buyback Entitlement. Number of Equity Shares validly tendered by any Eligible Shareholder up to the	· · · · · · · · · · · · · · · · · · ·							
Number of Equity Shares held as on Record Date (Tuesday, July 30, 2024)  Number of Equity Shares Entitled for Buyback (Buyback Entitlement)  Number of Equity Shares offered for Buyback (including Additional Shares, if any)  Note: An Eligible Shareholder may tender Equity Shares over and above his / her Buyback Entitlement. Number of Equity Shares validly tendered by any Eligible Shareholder up to the		1	In Figure .			In 1411		
Number of Equity Shares Entitled for Buyback (Buyback Entitlement)  Number of Equity Shares offered for Buyback (including Additional Shares, if any)  Note: An Eligible Shareholder may tender Equity Shares over and above his / her Buyback Entitlement. Number of Equity Shares validly tendered by any Eligible Shareholder up to the			In Figures			in Words		
Number of Equity Shares offered for Buyback (including Additional Shares, if any)  Note: An Eligible Shareholder may tender Equity Shares over and above his / her Buyback Entitlement. Number of Equity Shares validly tendered by any Eligible Shareholder up to the								
Note: An Eligible Shareholder may tender Equity Shares over and above his / her Buyback Entitlement. Number of Equity Shares validly tendered by any Eligible Shareholder up to the	1 / / /	if any						
			ole Entitlement Al	mhor of F	uitu Charas!: -!!	u tandarad bii	any Eliaible Charabalder to the	
	, , ,					•		

Particulars	In Figures	In Words
Number of Equity Shares held as on Record Date (Tuesday, July 30, 2024)		
Number of Equity Shares Entitled for Buyback (Buyback Entitlement)		
Number of Equity Shares offered for Buyback (including Additional Shares, if any)		
**	1 15	

of such Eligible Shareholder shall be accepted in accordance with paragraph 20 (Procedure for Tendering Shares and Settlement) of the Letter of Offer. Equity Shares tendered be Eligible Shareholder as on the Record Date shall not be considered for the purpose of Acceptance.

14. Details of Share Certificate(s) enclosed: Total No. of Share Certificates Submitted:

Sr. No.	Folio No.	Share Certificate No.	Distinctive	e No(s)	No. of Shares
			From	То	
Total					

|--|

-----Tear along this line-----

(To be filled by the Equity Shareholder) (Subject to verification)

Folio No.		
Received from Mr./ Ms./Mrs.		
Form of Acceptance-cum-Acknowledgement, Original TRS along with:		
No. of Equity Shares offered for Buyback (In figures)	(in words)	
Please quote Folio No. for all future correspondence		Stamp of Broker
		-

15. Details of the bank account of the sole or first Eligible Shareholder to be incorporated in the consideration warrant (to be mandatorily filled):

Name of the Bank	Name of the Bank Branch and City		Account Number (indicate type of account)

16. Details of other Documents (Please V as appropriate, if applicable) enclosed:

Power of Attorney	Previous RBI approvals for acquiring the Equity Shares hereby tendered in the Buyback	
Death Certificate	Succession Certificate	
Self-attested copy of PAN	Corporate authorisations	
TRS	Others (please specify)	

17. Equity Shareholders Details:

Particulars	First/Sole Holder	Joint Holde	er 1	Joint Holder 2		Joint Holder 3
Full Name(s) Of the Holder						
Signature(s)*						
PAN						
Address of the Sole/First Equity Shareholder						
Telephone No. of Sole/First Equity Shareholder			Email ID of Sole/Firs	st		
relephone No. of Sole/First Equity shareholder			<b>Equity Shareholder</b>			

<sup>\*</sup> Non-individual Shareholders must affix rubber stamp and sign. The relevant authorisation should be enclosed with the application form submitted.

18. Applicable for all Non-Resident Shareholders

- I / We undertake to pay income taxes in India on any income arising on such Buyback and taxable in accordance with prevailing income tax laws in India within 7th day of the succeeding months in which the Shares are bought back by the Company. I / We also undertake to indemnify the Company against any income tax liability on any income earned on such Buyback of shares by me / us. I / We undertake to return to the Company any consideration in respect of the Buyback that may be wrongfully received by me/us.
- I / We, being a Non-Resident Shareholder, agree to obtain and submit all necessary approvals, if any, and to the extent required from the concerned authorities including approvals from the Reserve Bank of India ("RBI") under Foreign Exchange Management Act, 1999, as amended ("FEMA") and the rules and regulations framed there under, for tendering Equity Shares in the Buyback, and also undertake to comply with the reporting requirements, if applicable, under the FEMA and any other rules, regulations and guidelines, in regard to remittance of funds outside India.

#### INSTRUCTIONS

#### This Tender Form has to be read along with the Letter of Offer and is subject to the terms and conditions mentioned in the Letter of Offer and this Tender Form

- 1. This Buyback will open on Monday, August 05, 2024 and close on Friday, August 09, 2024.
- 2. Eligible Shareholders who wish to tender their Equity Shares in response to this Buyback Offer should submit the following documents to their Seller Member, who in turn would deliver the said documents along with the Transaction Registration Slip (TRS) to the Registrar; the documents should be sent to the Registrar only after the placement of a valid bid; non-submission of the below mentioned documents directly to the Registrar shall result in the rejection of the tendered Equity Shares: (i) The Tender Form duly signed (by all Equity Shareholders in case shares are in joint names) the same order in which they hold the shares. (ii) Original share certificates (iii) Valid share transfer form(s) (SH-4) duly filled and signed by the transferors (i.e., by all registered Shareholders in same order and as per the specimen signatures registered with the Company / Registrar) and duly witnessed at the appropriate place authorizing the transfer in favour of the Company (iv) Self-attested copy of the Permanent Account Number (PAN) Card (by all Eligible Shareholders in case shares are in joint names). (v) Any other relevant documents such as (but not limited to): Duly attested Power of Attorney if any person other than the Equity Shareholder has signed the relevant Tender Form, Notarized copy of death certificate and succession certificate or probated will, as applicable, if the original Shareholder has deceased, necessary corporate authorisations, such as board resolutions etc., in case of companies. (vi) In addition to the above, if the address of the Shareholder has undergone a change from the address registered in the Register of Members of the Company, the Shareholder would be required to submit a self-attested copy of address proof consisting of any one of the following documents: valid Aadhar Card, Voter Identity Card or Passport.
- 3. In case any registered entity that has merged with another entity and the merger has been approved and has come into effect but the process of getting the successor company as the registered Shareholder is still incomplete, then such entity along with the Tender Form file a copy of the following documents: (i) Approval from the appropriate authority for such merger; (ii) the scheme of merger and (iii) the requisite form filed with MCA intimating the merger.
- 4. Eligible Shareholders whom the Buyback Offer is made are free to tender Equity Shares to the extent of their Entitlement in whole or in part or in excess of their Entitlement, but not exceeding the number of Shares held by them as on Record Date.
- 5. All documents / remittances sent by or to Eligible Shareholders will be at their own risk and the Eligible Shareholders are advised to adequately safeguard their interests in this regard.
- 6. In case of non-receipt of the Letter of Offer, Eligible Shareholders holding Equity Shares may participate in the offer by providing their application in plain paper in writing signed by all Eligible Shareholders (in case of joint holding), stating name, address, folio number, number of Equity Shares held, Equity Share certificate number, number of Equity Shares tendered for the Buyback and the distinctive numbers thereof, enclosing the original Equity Share certificate(s), copy of Eligible Shareholder's PAN card(s) and executed share transfer form in favour of the Company. Eligible Shareholders must ensure that the Tender Form, along with the TRS and requisite documents, reach the Registrar to the Buyback on or before the Buyback Closing Date, i.e., Friday, August 09, 2024 by 5:00 pm (IST).
- 7. For procedure followed by Eligible Shareholders for tendering shares in the buyback offer, please refer to paragraph 20 (*Procedure for Tendering Shares and Settlement*) of the Letter of Offer.
- 8. All documents as mentioned above shall be enclosed with the valid Tender Form otherwise the shares will be liable for rejection. The shares shall be liable for rejection on the following grounds amongst others: (a) If any other company share certificates are enclosed with the Tender Form instead of the share certificate of the Company; (b) Non-submission of Notarized copy of death certificate and succession certificate / probated / Will, as applicable in case any Eligible Shareholder has deceased; (c) If the Eligible Shareholder(s) bid the shares but the Registrar does not receive the physical share certificate; or (d) In case the signature in the Tender Form and Form SH-4 doesn't match as per the specimen signature recorded with Company / Registrar; (e) If necessary corporate authorizations under official stamp are not accompanied with Tender Form; (f) If the transmission of Equity Shares is not completed, and the Equity Shares are not in the name of the Eligible Shareholders; (g) the Form SH-4 is not witnessed
- 9. The Equity Shares tendered in the buyback shall be rejected if (i) the Shareholder is not a Eligible Shareholder of the Company on the Record Date; or (ii) if there is a name mismatch in the share certificate of the Shareholder; or (iii) where there exists any restraint order of a Court/ any other competent authority for transfer / disposal/ sale; or (iv) or where the title to the Equity Shares is under dispute or otherwise not clear or where any other restraint subsists; or (v) the documents mentioned in the Tender Form for Eligible Shareholders holding Equity Shares in physical form are not received by the Registrar on or before the close of business hours of Friday, August 09, 2024 by 5:00 pm (IST).
- 10. By agreeing to participate in the Buyback, each Eligible Shareholder (including each Non-Resident Shareholder) undertakes to complete all relevant regulatory / statutory filings and compliances to be made by it under applicable law, including filing of Form FC-TRS. Further, by agreeing to participate in the Buyback, each Eligible Shareholder hereby (a) authorises the Company to take all necessary action, solely to the extent required, and if necessary, to be undertaken by the Company, for making any regulatory / statutory filings and compliances on behalf of such Shareholder; and (b) undertakes to provide the requisite assistance to the Company for making any such regulatory / statutory filings and compliances.
- 11. Non-Resident Shareholders must obtain and submit all necessary approvals, if any and to the extent required from the concerned authorities including approvals from the Reserve Bank of India ("RBI") under Foreign Exchange Management Act, 1999, as amended ("FEMA") and the rules and regulations framed there under, for tendering Equity Shares in the Buyback, and also undertake to comply with the reporting requirements, if applicable, under the FEMA and any other rules, regulations and guidelines, in regard to remittance of funds outside India.

 $\textit{All capitalised items not defined herein shall have the meaning ascribed to them in the \textit{Letter of Offer}.}$ 

-----Tear along this line----

ALL FUTURE CORRESPONDENCE IN CONNECTION WITH THIS BUYBACK, IF ANY, SHOULD BE ADDRESSED TO REGISTRAR TO THE BUYBACK AT THIS ADDRESS:

Investor Service Centre: Aurobindo Pharma Limited - Buyback offer

**KFin Technologies Limited** 

Selenium Tower- B, Plot No 31 & 32 Gachibowli, Financial District Nanakramguda, Serilingampally, Hyderabad, Telangana – 500032

Contact Person: M Murali Krishna; Tel. no.: +91 40 6716 2222; Fax no.: +91 40 6716 1563; Toll free No.:18003094001

E-mail: <a href="mailto:aurobindo.buyback@kfintech.com">aurobindo.buyback@kfintech.com</a>; Website: <a href="mailto:www.kfintech.com">www.kfintech.com</a>; Investor Grievance Email: <a href="mailto:einward.ris@kfintech.com">einward.ris@kfintech.com</a>

SEBI Registration Number: INR000000221; CIN: L72400TG2017PLC117649

Pursuant to Section	n 56 of the Co	Form N Impanies Act, 2013 and			Transfer Form 11 of the Companies	(Share Cap	ital and Deben	tures) Rules 2014
			Ι	Date o	f execution:	/	/	2024
FOR THE CONSIDERA specified below subjective hereby agree to accept	ect to the co	onditions on which th	he said securi	ities a	re now held by th			
CIN: L 2 4	2 3 9 T	G 1 9 8 6 F	P L C 0	1 5	1 9 0			
Name of the compan	y (in full):				Aurobind	o Pharma	Limited	
Name of the Stock Ex listed, (if any):	change whe	ere the company is	В	SE Lir	nited and Nationa	l Stock Ex	change of Inc	lia Limited
DESCRIPTION OF SECU	URITIES							
Kind/ class of sec (1)	curities	Nominal value of each unit of security (2)		Am	Amount called up per unit of security (3)		Amount paid up per unit of security (4)	
Equity Shar	e	₹ 1/-			₹ 1/-			₹ 1/-
No	. of Securiti	es being Transferred			C	Considera	tion received	(₹)
In Figures		In words		In words		In Figures		
Distinctive Number	From To							
Corresponding Certificate Nos.								
			Transferor's	s Parti	culars			
Registered Folio Num	nber							
Name(s) in full and PAN (attach copy of pan card)  1.						Seller Signature(s)		
2. 3.								
I hereby confirm that Signature of the Witr		•						
Name of the Witness	:	•						
Address of the Witne	ess :	:						

# Transferee's Particulars

	Transiere	e s raiticulais			
Name in full (1)	Father's/Mothe	r's /Spouse Name (2)	Address & E-mail id (3)		
Aurobindo Pharma Limit	ed Not A	Applicable	Address: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India		
			Email: info@aurobindo.com		
Occupation (4)	Existing Fol	lio No., if any (5)	Signature (6)		
Business					
Folio	No. of Transferee	1.	Specimen Signature of Transferee(s)		
Value of stamp affixed: _₹		2			
3. Copy of PAN Card of all the Tr 4. Others, specify,  For Office Use Only  Checked by  Signature Tallied by  Entered in the Register of Transfe					
Approval Date	vide Transfer no				
Power of attorney / Probate / De	ath Certificate / Letter of Admi	inistration			
Registered on		at			
No					
On the reverse page of the certific	cate				
Name of the Transferor	Name of the Transferee	No. of shares	Date of Transfer		

Signature of the authorized signatory